European Society for Medical Oncology Congress 2023

Description

+ Include: 1268 videos + 1050 pdfs, size: 385 GB

+ Target Audience: oncologist

+ Sample video: contact me for sample video

+ Information:

+ Topics:

A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass Discussion.mp4
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass How to guide treatment with PET.mp4
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass How to guide treatment with PET.pdf
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass How to select the chemotherapy.mp4
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass How to select the chemotherapy.pdf
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass Presentation of case condition.mp4
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass Presentation of case condition.pdf
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass Preserving fertility in female patients.mp4
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass Preserving fertility in female patients.pdf
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass When or when not to irradiate.mp4
A young female with limited stage classic Hodgkin’s lymphoma and large mediastinal mass When or when not to irradiate.pdf
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Current standard of care in adjuvant neoadjuvant therapy of operable NSCLC.mp4
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Current standard of care in adjuvant neoadjuvant therapy of operable NSCLC.pdf
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Discussion.mp4
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Discussion.pdf
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Management of relapse on after perioperative IO.mp4
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Management of relapse on after perioperative IO.pdf
Adjuvant neoadjuvant therapy of operable NSCLC in 2023 Predictive biomarkers for adjuvant neoadjuvant IO.mp4
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Adjuvant only.mp4
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Adjuvant only.pdf
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC First voting.mp4
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC First voting.pdf
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Neo adjuvant follow by adjuvant.mp4
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Neo adjuvant follow by adjuvant.pdf
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Neo adjuvant only.mp4
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Neo adjuvant only.pdf
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Perspective from the Chair.mp4
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Perspective from the Chair.pdf
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Second voting.mp4
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Second voting.pdf
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Welcome and set the scene.mp4
Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC Welcome and set the scene.pdf
Adrenocortical carcinoma Discussion led by Chair.mp4
Adrenocortical carcinoma Presentation by Expert.mp4
Adrenocortical carcinoma Presentation by Expert.pdf
Advances in our understanding of paraganglioma pheochromocytoma Conclusions and perspectives.mp4
Advances in our understanding of paraganglioma pheochromocytoma Discussion.mp4
Advances in our understanding of paraganglioma pheochromocytoma Discussion.pdf
Advances in our understanding of paraganglioma pheochromocytoma Introduction and scientific background.mp4
Advances in our understanding of paraganglioma pheochromocytoma Introduction and scientific background.pdf
Advances in our understanding of paraganglioma pheochromocytoma Perioperative considerations and management of localised disease.mp4
Advances in our understanding of paraganglioma pheochromocytoma Perioperative considerations and management of localised disease.pdf
Advances in our understanding of paraganglioma pheochromocytoma Targeted radionuclide therapy for advanced disease theranostics.mp4
Advances in our understanding of paraganglioma pheochromocytoma Targeted radionuclide therapy for advanced disease theranostics.pdf
Advances in our understanding of paraganglioma pheochromocytoma The genetics of paraganglioma (PPGL) and implications for testing and screening.mp4
Advances in our understanding of paraganglioma pheochromocytoma The genetics of paraganglioma (PPGL) and implications for testing and screening.pdf
Advances in our understanding of paraganglioma pheochromocytoma The treatment landscape for metastatic PPGL- Are we making progress.mp4
Advances in our understanding of paraganglioma pheochromocytoma The treatment landscape for metastatic PPGL- Are we making progress.pdf
Advances in the management of locally advanced NPC How to transfer results from endemic to non-endemic settings.mp4
Advances in the management of locally advanced NPC How to transfer results from endemic to non-endemic settings.pdf
Advances in the management of locally advanced NPC Induction versus adjuvant chemotherapy in LA-NPC- Deciphering the latest evidence for the practicing oncologist.mp4
Advances in the management of locally advanced NPC Induction versus adjuvant chemotherapy in LA-NPC- Deciphering the latest evidence for the practicing oncologist.pdf
Advances in the management of locally advanced NPC Navigating the undulating landscape of radiotherapy escalation de-escalation in the treatment of LA-NPC.mp4
Advances in the management of locally advanced NPC Navigating the undulating landscape of radiotherapy escalation de-escalation in the treatment of LA-NPC.pdf
Advances in the management of locally advanced NPC Q&A and Discussion.mp4
Advances in the management of locally advanced NPC Q&A and Discussion.pdf
Advances in the management of locally advanced NPC Recent advances in the clinical application of plasma EBV DNA in individualizing treatment of LA-NPC.mp4
Advances in the management of locally advanced NPC Recent advances in the clinical application of plasma EBV DNA in individualizing treatment of LA-NPC.pdf
Advancing strategies for cancer immunotherapy Activation of innate cells through Treg targeting.mp4
Advancing strategies for cancer immunotherapy Activation of innate cells through Treg targeting.pdf
Advancing strategies for cancer immunotherapy CAR-T and TCR-T approaches for solid cancers.mp4
Advancing strategies for cancer immunotherapy CAR-T and TCR-T approaches for solid cancers.pdf
Advancing strategies for cancer immunotherapy Conclusions and perspectives.mp4
Advancing strategies for cancer immunotherapy Conclusions and perspectives.pdf
Advancing strategies for cancer immunotherapy Discussion.mp4
Advancing strategies for cancer immunotherapy Discussion.pdf
Advancing strategies for cancer immunotherapy Intra-tumoural immunotherapy.mp4
Advancing strategies for cancer immunotherapy Intra-tumoural immunotherapy.pdf
Advancing strategies for cancer immunotherapy Introduction and scientific background.mp4
Advancing strategies for cancer immunotherapy Introduction and scientific background.pdf
Advancing strategies for cancer immunotherapy New approaches in cancer vaccines.mp4
Advancing strategies for cancer immunotherapy New approaches in cancer vaccines.pdf
Alcohol consumption and cancer risk- The sobering facts about alcohol and cancer Discussion led by Chair.mp4
Alcohol consumption and cancer risk- The sobering facts about alcohol and cancer Discussion led by Chair.pdf
Alcohol consumption and cancer risk- The sobering facts about alcohol and cancer Presentation by Expert.mp4
Alcohol consumption and cancer risk- The sobering facts about alcohol and cancer Presentation by Expert.pdf
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy First voting.mp4
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy First voting.pdf
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy No.mp4
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy No.pdf
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Perspective from the Chair.mp4
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Perspective from the Chair.pdf
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Second voting.mp4
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Second voting.pdf
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Welcome and set the scene.mp4
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Welcome and set the scene.pdf
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Yes.mp4
All patients with resected stage IIB IIC should be treated with adjuvant anti-PD1 therapy Yes.pdf
All you want to know about advanced prostate cancer as we finally enter the era of biomarker-triggered treatment Discussion led by Chair.mp4
All you want to know about advanced prostate cancer as we finally enter the era of biomarker-triggered treatment Discussion led by Chair.pdf
All you want to know about advanced prostate cancer as we finally enter the era of biomarker-triggered treatment Presentation by Expert.mp4
All you want to know about advanced prostate cancer as we finally enter the era of biomarker-triggered treatment Presentation by Expert.pdf
Antibody drug conjugates- Current data and future role in drug development Discussion led by Chair.mp4
Antibody drug conjugates- Current data and future role in drug development Presentation by Expert.mp4
Antibody drug conjugates- Current data and future role in drug development Presentation by Expert.pdf
Artificial Intelligence in prognostication AI for breast cancer prognostication.mp4
Artificial Intelligence in prognostication AI for breast cancer prognostication.pdf
Artificial Intelligence in prognostication Biomarkers of response to drugs and radiotherapy.mp4
Artificial Intelligence in prognostication Biomarkers of response to drugs and radiotherapy.pdf
Artificial Intelligence in prognostication Digital pathology for immuno-oncology.mp4
Artificial Intelligence in prognostication Digital pathology for immuno-oncology.pdf
Artificial Intelligence in prognostication Q&A and Discussion.mp4
Artificial Intelligence in prognostication Q&A and Discussion.pdf
Astellas Pharma Europe Ltd – Putting the patient first Closing remarks.mp4
Astellas Pharma Europe Ltd – Putting the patient first Maximising quality of life- Holistic approaches in the management of patients with mHSPC.mp4
Astellas Pharma Europe Ltd – Putting the patient first Reinforcing standard of care- The benefits of early treatment intensification in patients with mHSPC.mp4
Astellas Pharma Europe Ltd – Putting the patient first The importance of first-line treatment choice in patients with mHSPC.mp4
Astellas Pharma Europe Ltd – Putting the patient first Welcome and introduction.mp4
Astellas Pharma Europe Ltd – The evolving treatment landscape in LA mUC Clinical experiences with first-line treatment of LA_mUC.mp4
Astellas Pharma Europe Ltd – The evolving treatment landscape in LA mUC First-line therapy for patients with LA_mUC- The transformation.mp4
Astellas Pharma Europe Ltd – The evolving treatment landscape in LA mUC Housekeeping and introductions.mp4
Astellas Pharma Europe Ltd – The evolving treatment landscape in LA mUC Overview of current trials investigating first-line treatment of LA_mUC.mp4
Astellas Pharma Europe Ltd – The evolving treatment landscape in LA mUC Panel discussion.mp4
Astellas Pharma Europe Ltd – The evolving treatment landscape in LA mUC Summary and close.mp4
AstraZeneca – Evolving Paradigms in Hormone Receptor-Positive Breast Cancer Antibody-Drug Conjugates for HR-Positive Breast Cancer- Where Are We Today-.mp4
AstraZeneca – Evolving Paradigms in Hormone Receptor-Positive Breast Cancer Audience Q&A.mp4
AstraZeneca – Evolving Paradigms in Hormone Receptor-Positive Breast Cancer Concluding Remarks.mp4
AstraZeneca – Evolving Paradigms in Hormone Receptor-Positive Breast Cancer New Antibody-Drug Conjugates on the Horizon.mp4
AstraZeneca – Evolving Paradigms in Hormone Receptor-Positive Breast Cancer Next-Generation Antibody-Drug Conjugates in Practice- A Case-Based Discussion.mp4
AstraZeneca – Evolving Paradigms in Hormone Receptor-Positive Breast Cancer Welcome and Introduction.mp4
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives Closing Remarks.mp4
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives Impact From Within- Patient Advocacy and the Voices That Bring Progress.mp4
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives Making It Stick- Implementing the Advances in Precision Oncology into Clinical Practice.mp4
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives Open Panel Audience Q&A.mp4
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives The Big Bang of Precision Oncology- Creating Milestones in Medicine.mp4
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives The Voice That Matters – A Patient Perspective.mp4
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives Theory to Reality- Overcoming Challenges and Raising the Value of Precision Oncology.mp4
Bayer – Delivering on the Promise of Precision Oncology- From the Big Bang to Tangible Impact on Patients’ Lives Welcome.mp4
Biomarkers in metastatic colorectal cancer Biomarkers in 2023- What, how and when to test.mp4
Biomarkers in metastatic colorectal cancer Biomarkers in 2023- What, how and when to test.pdf
Biomarkers in metastatic colorectal cancer Biomarkers in the near future- What to expect.mp4
Biomarkers in metastatic colorectal cancer Biomarkers in the near future- What to expect.pdf
Biomarkers in metastatic colorectal cancer Clinical data of genomic subtypes of mCRC (MSI, BRAF V600, HER2, KRAS G12C, NTRK).mp4
Biomarkers in metastatic colorectal cancer Clinical data of genomic subtypes of mCRC (MSI, BRAF V600, HER2, KRAS G12C, NTRK).pdf
Biomarkers in metastatic colorectal cancer Q&A and Discussion.mp4
Biomarkers in metastatic colorectal cancer Q&A and Discussion.pdf
Bladder preservation strategies Discussion.mp4
Bladder preservation strategies Discussion.pdf
Bladder preservation strategies Organ preservation for refractory NMIBC- A surgeon’s perspective.mp4
Bladder preservation strategies Organ preservation for refractory NMIBC- A surgeon’s perspective.pdf
Bladder preservation strategies Presentation of case condition- Non-muscle invasive bladder cancer (NMIBC) progressing to MIBC.mp4
Bladder preservation strategies Presentation of case condition- Non-muscle invasive bladder cancer (NMIBC) progressing to MIBC.pdf
Bladder preservation strategies Radiotherapy in bladder preservation.mp4
Bladder preservation strategies Radiotherapy in bladder preservation.pdf
Bladder preservation strategies The role of systemic therapy in bladder preservation.mp4
Bladder preservation strategies The role of systemic therapy in bladder preservation.pdf
Boehringer Ingelheim – Rethinking Cancer Therapies Improving HER2 Targeting in NSCLC with Selective TKI.mp4
Boehringer Ingelheim – Rethinking Cancer Therapies Panel Discussion and Audience Q&A, Key Takeaways and Closing Remarks.mp4
Boehringer Ingelheim – Rethinking Cancer Therapies Restoring p53 by Antagonizing MDM2-p53 in Soft Tissue Sarcoma.mp4
Boehringer Ingelheim – Rethinking Cancer Therapies T-cell Engagers- Fighting Solid Tumors from Within.mp4
Boehringer Ingelheim – Rethinking Cancer Therapies Welcome and Introduction of Agenda and Speakers.mp4
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Discussion.mp4
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Discussion.pdf
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies How often and to which extent does the E-E gap seriously affect treatment outcome in daily practice.mp4
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies How often and to which extent does the E-E gap seriously affect treatment outcome in daily practice.pdf
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Should effectiveness data be taken into consideration for drug appraisal by regulatory authorities.mp4
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Should effectiveness data be taken into consideration for drug appraisal by regulatory authorities.pdf
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Under which circumstances could effectiveness data be used for clinical guidelines.mp4
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Under which circumstances could effectiveness data be used for clinical guidelines.pdf
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Which adaptations in trials and daily practice could bridge the E-E gap.mp4
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Which adaptations in trials and daily practice could bridge the E-E gap.pdf
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Which factors can cause an E-E gap.mp4
Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies Which factors can cause an E-E gap.pdf
Bringing together thyroid cancer and neuroendocrine tumours Discussion.mp4
Bringing together thyroid cancer and neuroendocrine tumours Discussion.pdf
Bringing together thyroid cancer and neuroendocrine tumours Future directions on targeted agents and beyond in thyroid and neuroendocrine tumours.mp4
Bringing together thyroid cancer and neuroendocrine tumours Future directions on targeted agents and beyond in thyroid and neuroendocrine tumours.pdf
Bringing together thyroid cancer and neuroendocrine tumours State-of-the-art in the treatment of advanced neuroendocrine tumours .pdf
Bringing together thyroid cancer and neuroendocrine tumours State-of-the-art in the treatment of advanced neuroendocrine tumours.mp4
Bringing together thyroid cancer and neuroendocrine tumours State-of-the-art in the treatment of advanced thyroid cancer.mp4
Bringing together thyroid cancer and neuroendocrine tumours State-of-the-art in the treatment of advanced thyroid cancer.pdf
Bringing together thyroid cancer and neuroendocrine tumours What we could learn from each tumour type to improve the management of both.mp4
Bringing together thyroid cancer and neuroendocrine tumours What we could learn from each tumour type to improve the management of both.pdf
Bristol Myers Squibb – Immuno-Oncology Landscape for GI Cancers Advances in Immuno-Oncology for the Treatment of Colorectal Cancer.mp4
Bristol Myers Squibb – Immuno-Oncology Landscape for GI Cancers Immuno-Oncology Landscape for GI Cancers- Perspectives on Current Practices and Recent Advances.mp4
Bristol Myers Squibb – Immuno-Oncology Landscape for GI Cancers Immunotherapeutic Advances in the Treatment of Esophageal Cancer.mp4
Bristol Myers Squibb – Immuno-Oncology Landscape for GI Cancers Roundtable Case Discussion, Q&A.mp4
Bristol Myers Squibb – Immuno-Oncology Landscape for GI Cancers Update on Immuno-Oncology for the Treatment of Gastric Cancer.mp4
Bristol Myers Squibb – The Changing Paradigm of Melanoma Treatment Current and Emerging Neoadjuvant Treatment Options for Resectable Melanoma.mp4
Bristol Myers Squibb – The Changing Paradigm of Melanoma Treatment Evidence-Based Considerations for the First-Line Treatment of Metastatic Melanoma.mp4
Bristol Myers Squibb – The Changing Paradigm of Melanoma Treatment Navigating the Adjuvant Setting- Who, When, and What-.mp4
Bristol Myers Squibb – The Changing Paradigm of Melanoma Treatment Panel Discussion- Factors Impacting Treatment Selection for Resectable Melanoma.mp4
Bristol Myers Squibb – The Changing Paradigm of Melanoma Treatment Summary and Close.mp4
Bristol Myers Squibb – The Changing Paradigm of Melanoma Treatment Welcome and Introduction.mp4
Building an academic cell therapy programme Clinical requirements.mp4
Building an academic cell therapy programme Clinical requirements.pdf
Building an academic cell therapy programme Lab requirements and translational opportunities.mp4
Building an academic cell therapy programme Lab requirements and translational opportunities.pdf
Building an academic cell therapy programme Presentation of case condition.mp4
Building an academic cell therapy programme Presentation of case condition.pdf
Building an academic cell therapy programme Q&A and Discussion.mp4
Building an academic cell therapy programme Q&A and Discussion.pdf
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients First voting.mp4
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients First voting.pdf
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients No.mp4
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients No.pdf
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Perspective from the Chair.mp4
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Perspective from the Chair.pdf
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Second voting.mp4
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Second voting.pdf
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Welcome and set the scene.mp4
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Welcome and set the scene.pdf
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Yes.mp4
Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients Yes.pdf
Cancer-related central and peripheral neuropathy Conclusions and perspectives.mp4
Cancer-related central and peripheral neuropathy Conclusions and perspectives.pdf
Cancer-related central and peripheral neuropathy Discussion.mp4
Cancer-related central and peripheral neuropathy Discussion.pdf
Cancer-related central and peripheral neuropathy Introduction and scientific background.mp4
Cancer-related central and peripheral neuropathy Introduction and scientific background.pdf
Cancer-related central and peripheral neuropathy Preventive strategies for chemotherapy-induced peripheral neuropathy (CIPN).mp4
Cancer-related central and peripheral neuropathy Preventive strategies for chemotherapy-induced peripheral neuropathy (CIPN).pdf
Cancer-related central and peripheral neuropathy Unmet needs.mp4
Cancer-related central and peripheral neuropathy Unmet needs.pdf
Challenges in the management of Waldenstr”m’s macroglobulinemia Discussion led by Chair.mp4
Challenges in the management of Waldenstr”m’s macroglobulinemia Presentation by Expert.mp4
Challenges in the management of Waldenstr”m’s macroglobulinemia Presentation by Expert.pdf
Challenging common problems in neuro-oncology Discussion.mp4
Challenging common problems in neuro-oncology Presentation of case- Low-grade glioma.mp4
Challenging common problems in neuro-oncology Presentation of case- Low-grade glioma.pdf
Challenging common problems in neuro-oncology Radiotherapy for low grade gliomas with and without mutations- Wait or treat.mp4
Challenging common problems in neuro-oncology Radiotherapy for low grade gliomas with and without mutations- Wait or treat.pdf
Challenging common problems in neuro-oncology The optimal radiochemotherapeutic combination for low grade gliomas- Lessons from trials.mp4
Challenging common problems in neuro-oncology Upfront and salvage surgery for low grade gliomas.mp4
Challenging common problems in neuro-oncology Upfront and salvage surgery for low grade gliomas.pdf
Challenging the status quo of early phase clinical trial design- Project Optimus Conclusions and perspectives.mp4
Challenging the status quo of early phase clinical trial design- Project Optimus Discussion.mp4
Challenging the status quo of early phase clinical trial design- Project Optimus Discussion.pdf
Challenging the status quo of early phase clinical trial design- Project Optimus Introduction and scientific background.mp4
Challenging the status quo of early phase clinical trial design- Project Optimus Introduction and scientific background.pdf
Challenging the status quo of early phase clinical trial design- Project Optimus Investigator perspective.mp4
Challenging the status quo of early phase clinical trial design- Project Optimus Investigator perspective.pdf
Challenging the status quo of early phase clinical trial design- Project Optimus Patient advocacy perspective.mp4
Challenging the status quo of early phase clinical trial design- Project Optimus Patient advocacy perspective.pdf
Challenging the status quo of early phase clinical trial design- Project Optimus Pharmaceutical industry perspective.mp4
Challenging the status quo of early phase clinical trial design- Project Optimus Pharmaceutical industry perspective.pdf
Challenging the status quo of early phase clinical trial design- Project Optimus Project Optimus update.mp4
Challenging the status quo of early phase clinical trial design- Project Optimus Project Optimus update.pdf
Challenging the status quo of early phase clinical trial design- Project Optimus Regulatory perspective- FDA.mp4
Challenging the status quo of early phase clinical trial design- Project Optimus Regulatory perspective- FDA.pdf
Checkpoint inhibition and beyond- New approaches in advanced gastric oesophageal cancer Discussion led by Chair.mp4
Checkpoint inhibition and beyond- New approaches in advanced gastric oesophageal cancer Presentation by Expert.mp4
Checkpoint inhibition and beyond- New approaches in advanced gastric oesophageal cancer Presentation by Expert.pdf
Circulating tumour DNA A perfect fit Conclusions and perspectives.mp4
Circulating tumour DNA A perfect fit Conclusions and perspectives.pdf
Circulating tumour DNA A perfect fit ctDNA assessment- How and when.mp4
Circulating tumour DNA A perfect fit ctDNA assessment- How and when.pdf
Circulating tumour DNA A perfect fit ctDNA clearance- Surrogacy for cure and organ-sparing approaches.mp4
Circulating tumour DNA A perfect fit ctDNA clearance- Surrogacy for cure and organ-sparing approaches.pdf
Circulating tumour DNA A perfect fit ctDNA in early-stage CRC- Tailoring the adjuvant therapy.mp4
Circulating tumour DNA A perfect fit ctDNA in early-stage CRC- Tailoring the adjuvant therapy.pdf
Circulating tumour DNA A perfect fit ctDNA in mCRC- Monitoring response and guiding treatment.mp4
Circulating tumour DNA A perfect fit ctDNA in mCRC- Monitoring response and guiding treatment.pdf
Circulating tumour DNA A perfect fit Discussion.mp4
Circulating tumour DNA A perfect fit Discussion.pdf
Circulating tumour DNA A perfect fit Introduction and scientific background.mp4
Circulating tumour DNA A perfect fit Introduction and scientific background.pdf
Climate Change Task Force – How to build more sustainable and environment-friendly oncology care Rationale drug prescribing to reduce environmental impact.pdf
Controversies in early stage triple negative breast cancer Conclusions and perspectives.mp4
Controversies in early stage triple negative breast cancer Discussion.mp4
Controversies in early stage triple negative breast cancer Discussion.pdf
Controversies in early stage triple negative breast cancer Individualisation of adjuvant therapy in TNBC- Who gets what.mp4
Controversies in early stage triple negative breast cancer Individualisation of adjuvant therapy in TNBC- Who gets what.pdf
Controversies in early stage triple negative breast cancer Introduction and scientific background.mp4
Controversies in early stage triple negative breast cancer Introduction and scientific background.pdf
Controversies in early stage triple negative breast cancer Optimal neo-adjuvant therapy in TNBC- Does one size fit all.mp4
Controversies in early stage triple negative breast cancer Optimal neo-adjuvant therapy in TNBC- Does one size fit all.pdf
Controversies in early stage triple negative breast cancer Role of biomarkers ctDNA monitoring in therapy decisions.mp4
Controversies in early stage triple negative breast cancer Role of biomarkers ctDNA monitoring in therapy decisions.pdf
Controversies in early stage triple negative breast cancer What to do with stage 1 TNBC- Can we deescalate systemic therapy.mp4
Controversies in early stage triple negative breast cancer What to do with stage 1 TNBC- Can we deescalate systemic therapy.pdf
Current issues in primary prevention and screening to block the onset or development of cancer Commercial drivers of cancer medicines and non-pharmaceutical technologies in cancer care.mp4
Current issues in primary prevention and screening to block the onset or development of cancer Commercial drivers of cancer medicines and non-pharmaceutical technologies in cancer care.pdf
Current issues in primary prevention and screening to block the onset or development of cancer False dichotomies and going beyond screening.mp4
Current issues in primary prevention and screening to block the onset or development of cancer False dichotomies and going beyond screening.pdf
Current issues in primary prevention and screening to block the onset or development of cancer Processed meat, sugar, exercise- Prevention opportunities for oncologists.mp4
Current issues in primary prevention and screening to block the onset or development of cancer Processed meat, sugar, exercise- Prevention opportunities for oncologists.pdf
Current issues in primary prevention and screening to block the onset or development of cancer Q&A and Discussion.mp4
Current issues in primary prevention and screening to block the onset or development of cancer Q&A and Discussion.pdf
Current issues in primary prevention and screening to block the onset or development of cancer Structural and behavioural interventions.mp4
Current issues in primary prevention and screening to block the onset or development of cancer Structural and behavioural interventions.pdf
Cutting edge diagnostics and innovation in the treatment of brain tumours Conclusions and perspectives.mp4
Cutting edge diagnostics and innovation in the treatment of brain tumours Discussion.mp4
Cutting edge diagnostics and innovation in the treatment of brain tumours Discussion.pdf
Cutting edge diagnostics and innovation in the treatment of brain tumours Immunotherapy.mp4
Cutting edge diagnostics and innovation in the treatment of brain tumours Immunotherapy.pdf
Cutting edge diagnostics and innovation in the treatment of brain tumours Introduction and scientific background.mp4
Cutting edge diagnostics and innovation in the treatment of brain tumours Introduction and scientific background.pdf
Cutting edge diagnostics and innovation in the treatment of brain tumours Methylation profiling- Hype or progress.mp4
Cutting edge diagnostics and innovation in the treatment of brain tumours Methylation profiling- Hype or progress.pdf
Cutting edge diagnostics and innovation in the treatment of brain tumours New treatment targets- From bench to bedside.mp4
Cutting edge diagnostics and innovation in the treatment of brain tumours New treatment targets- From bench to bedside.pdf
Cutting edge diagnostics and innovation in the treatment of brain tumours Opening the blood-brain barrier (BBB).mp4
Cutting edge diagnostics and innovation in the treatment of brain tumours Opening the blood-brain barrier (BBB).pdf
Diffuse large B-cell lymphoma First-line therapy.mp4
Diffuse large B-cell lymphoma First-line therapy.pdf
Diffuse large B-cell lymphoma Molecular classification.mp4
Diffuse large B-cell lymphoma Molecular classification.pdf
Diffuse large B-cell lymphoma Q&A and Discussion.mp4
Diffuse large B-cell lymphoma Q&A and Discussion.pdf
Diffuse large B-cell lymphoma Therapy at relapse.mp4
Diffuse large B-cell lymphoma Therapy at relapse.pdf
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Discussion.mp4
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Discussion.pdf
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Evidence from trials- Summary of a fantastic decade.mp4
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Evidence from trials- Summary of a fantastic decade.pdf
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit How to best integrate biology.mp4
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit How to best integrate biology.pdf
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Next generation imaging- How does it change the evidence seen in trials.mp4
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Next generation imaging- How does it change the evidence seen in trials.pdf
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Tolerance and long-term side-effects.mp4
Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit Tolerance and long-term side-effects.pdf
Do we enter a new era of oncology AI-based therapeutic algorithms in oncology.mp4
Do we enter a new era of oncology AI-based therapeutic algorithms in oncology.pdf
Do we enter a new era of oncology Q&A and Discussion.mp4
Do we enter a new era of oncology Q&A and Discussion.pdf
Do we enter a new era of oncology Wearable medical devices in oncology.mp4
Do we enter a new era of oncology Wearable medical devices in oncology.pdf
Do we enter a new era of oncology What will the European Health Data Space bring us.mp4
Do we enter a new era of oncology What will the European Health Data Space bring us.pdf
Do we enter a new era of oncology Where are we in Oncology in relation to developments in digital health, big data, artificial intelligence.mp4
Do we enter a new era of oncology Where are we in Oncology in relation to developments in digital health, big data, artificial intelligence.pdf
Early-stage (II III) melanoma- Risk stratification and treatment decisions A dermatologist’s perspective- Secondary prevention and risk stratifications strategies.mp4
Early-stage (II III) melanoma- Risk stratification and treatment decisions A dermatologist’s perspective- Secondary prevention and risk stratifications strategies.pdf
Early-stage (II III) melanoma- Risk stratification and treatment decisions A pathologist’s perspective- What to look for and how to report it.mp4
Early-stage (II III) melanoma- Risk stratification and treatment decisions A pathologist’s perspective- What to look for and how to report it.pdf
Early-stage (II III) melanoma- Risk stratification and treatment decisions Discussion.mp4
Early-stage (II III) melanoma- Risk stratification and treatment decisions Discussion.pdf
Early-stage (II III) melanoma- Risk stratification and treatment decisions Further development of the clinical case- A medical oncologist’s perspective.mp4
Early-stage (II III) melanoma- Risk stratification and treatment decisions Further development of the clinical case- A medical oncologist’s perspective.pdf
Early-stage (II III) melanoma- Risk stratification and treatment decisions Further development of the clinical case- A surgeon’s perspective.mp4
Early-stage (II III) melanoma- Risk stratification and treatment decisions Further development of the clinical case- A surgeon’s perspective.pdf
Early-stage (II III) melanoma- Risk stratification and treatment decisions Presentation of case condition.mp4
Early-stage (II III) melanoma- Risk stratification and treatment decisions Presentation of case condition.pdf
East meets West in the management of head and neck cancer- Learning from each other Discussion led by Chair.mp4
East meets West in the management of head and neck cancer- Learning from each other Presentation by Expert.mp4
East meets West in the management of head and neck cancer- Learning from each other Presentation by Expert.pdf
Elucidating cancer biology, and transforming cancer care, through academic drug development Elucidating cancer biology, and transforming cancer care, through academic drug development.mp4
Elucidating cancer biology, and transforming cancer care, through academic drug development Elucidating cancer biology, and transforming cancer care, through academic drug development.pdf
Elucidating cancer biology, and transforming cancer care, through academic drug development Introduction by the Chair.mp4
Elucidating cancer biology, and transforming cancer care, through academic drug development Introduction by the Chair.pdf
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases AYA oncology- The importance of research, with a focus on patients with melanoma.mp4
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases AYA oncology- The importance of research, with a focus on patients with melanoma.pdf
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Discussion.mp4
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Discussion.pdf
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Introduction.mp4
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Introduction.pdf
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Setting priorities for AYA patients with sarcoma.mp4
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Setting priorities for AYA patients with sarcoma.pdf
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Short- and long-term side effects in AYA patients, with a focus on patients with breast cancer.mp4
Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases Short- and long-term side effects in AYA patients, with a focus on patients with breast cancer.pdf
ESMO ASCO Global Curriculum Medical oncology Training Development and update of the ESMO ASCO Global Curriculum- Why and how.mp4
ESMO ASCO Global Curriculum Medical oncology Training Development and update of the ESMO ASCO Global Curriculum- Why and how.pdf
ESMO ASCO Global Curriculum Medical oncology Training Discussion and Q&A.mp4
ESMO ASCO Global Curriculum Medical oncology Training Discussion and Q&A.pdf
ESMO ASCO Global Curriculum Medical oncology Training Integrating global standards in medical oncology training- The perspective of the trainee.mp4
ESMO ASCO Global Curriculum Medical oncology Training Integrating global standards in medical oncology training- The perspective of the trainee.pdf
ESMO ASCO Global Curriculum Medical oncology Training Introduction.mp4
ESMO ASCO Global Curriculum Medical oncology Training Introduction.pdf
ESMO ASCO Global Curriculum Medical oncology Training Optimizing learning in a fast-paced training environment- The perspective of the trainee.mp4
ESMO ASCO Global Curriculum Medical oncology Training Optimizing learning in a fast-paced training environment- The perspective of the trainee.pdf
ESMO ASCO Global Curriculum Medical oncology Training The role of the Global Curriculum in the era of digital health and artificial intelligence.mp4
ESMO ASCO Global Curriculum Medical oncology Training The role of the Global Curriculum in the era of digital health and artificial intelligence.pdf
ESMO ASCO Global Curriculum Medical oncology Training Using the ESMO ASCO Global Curriculum and Log Book to improve educational content.mp4
ESMO ASCO Global Curriculum Medical oncology Training Using the ESMO ASCO Global Curriculum and Log Book to improve educational content.pdf
ESMO Clinical Practice Guidelines 1 Advanced pancreatic cancer case presentation.mp4
ESMO Clinical Practice Guidelines 1 Advanced pancreatic cancer case presentation.pdf
ESMO Clinical Practice Guidelines 1 Advanced pancreatic cancer discussion.mp4
ESMO Clinical Practice Guidelines 1 Advanced pancreatic cancer discussion.pdf
ESMO Clinical Practice Guidelines 1 Early breast cancer case discussion.mp4
ESMO Clinical Practice Guidelines 1 Early breast cancer case discussion.pdf
ESMO Clinical Practice Guidelines 1 Early breast cancer case presentation.mp4
ESMO Clinical Practice Guidelines 1 Early breast cancer case presentation.pdf
ESMO Clinical Practice Guidelines 1 Oncogene-addicted metastatic NSCLC case presentation.mp4
ESMO Clinical Practice Guidelines 1 Oncogene-addicted metastatic NSCLC case presentation.pdf
ESMO Clinical Practice Guidelines 1 Oncogene-addicted metastatic NSCLC discussion.mp4
ESMO Clinical Practice Guidelines 1 Oncogene-addicted metastatic NSCLC discussion.pdf
ESMO Clinical Practice Guidelines 1 Q&A 1.mp4
ESMO Clinical Practice Guidelines 1 Q&A 1.pdf
ESMO Clinical Practice Guidelines 1 Q&A 2.mp4
ESMO Clinical Practice Guidelines 1 Q&A 2.pdf
ESMO Clinical Practice Guidelines 1 Q&A and Discussion.mp4
ESMO Clinical Practice Guidelines 1 Q&A and Discussion.pdf
ESMO Clinical Practice Guidelines 2 Non-oncogene-addicted metastatic NSCLC case presentation.mp4
ESMO Clinical Practice Guidelines 2 Non-oncogene-addicted metastatic NSCLC case presentation.pdf
ESMO Clinical Practice Guidelines 2 Non-oncogene-addicted metastatic NSCLC discussion.mp4
ESMO Clinical Practice Guidelines 2 Non-oncogene-addicted metastatic NSCLC discussion.pdf
ESMO Clinical Practice Guidelines 2 Prostate cancer case presentation.mp4
ESMO Clinical Practice Guidelines 2 Prostate cancer case presentation.pdf
ESMO Clinical Practice Guidelines 2 Prostate cancer discussion.mp4
ESMO Clinical Practice Guidelines 2 Prostate cancer discussion.pdf
ESMO Clinical Practice Guidelines 2 Q&A 1.mp4
ESMO Clinical Practice Guidelines 2 Q&A 1.pdf
ESMO Clinical Practice Guidelines 2 Q&A 2.mp4
ESMO Clinical Practice Guidelines 2 Q&A 2.pdf
ESMO Clinical Practice Guidelines 2 Q&A and Discussion.mp4
ESMO Clinical Practice Guidelines 2 Q&A and Discussion.pdf
ESMO Clinical Practice Guidelines 2 Recurrent metastatic squamous cell carcinoma of the head and neck case presentation.mp4
ESMO Clinical Practice Guidelines 2 Recurrent metastatic squamous cell carcinoma of the head and neck case presentation.pdf
ESMO Clinical Practice Guidelines 2 Recurrent metastatic squamous cell carcinoma of the head and neck discussion.mp4
ESMO Clinical Practice Guidelines 2 Recurrent metastatic squamous cell carcinoma of the head and neck discussion.pdf
ESMO Colloquium supported by Daiichi Sankyo Antibody-drug conjugates- Novel combinations with precision therapeutics and the quest for biomarkers.mp4
ESMO Colloquium supported by Daiichi Sankyo Concluding remarks.mp4
ESMO Colloquium supported by Daiichi Sankyo Emerging data on the role of ADCs in the clinical care pathways for advanced NSCLC patients.mp4
ESMO Colloquium supported by Daiichi Sankyo Improving the safety profiles of ADCs- Early detection and optimal management of toxicities.mp4
ESMO Colloquium supported by Daiichi Sankyo Q&A and discussion.mp4
ESMO Colloquium supported by Daiichi Sankyo Welcome and introduction.mp4
ESMO Colloquium supported by Eisai Europe Ltd Concluding remarks.mp4
ESMO Colloquium supported by Eisai Europe Ltd Current and emerging clinicopathologic and molecular prognostic schemes for patients with advanced renal cell carcinoma.mp4
ESMO Colloquium supported by Eisai Europe Ltd Do all patients need combination therapy- De-escalation and patient selection.mp4
ESMO Colloquium supported by Eisai Europe Ltd Q&A and discussion.mp4
ESMO Colloquium supported by Eisai Europe Ltd Research insights in enhancing treatment efficacy- Escalation, sequencing and prediction.mp4
ESMO Colloquium supported by Eisai Europe Ltd State-of-the-art combination therapies for patients with advanced RCC.mp4
ESMO Colloquium supported by Eisai Europe Ltd Welcome and introduction.mp4
ESMO Colloquium supported by Eli Lilly and Company Concluding remarks.mp4
ESMO Colloquium supported by Eli Lilly and Company Q&A and discussion.mp4
ESMO Colloquium supported by Eli Lilly and Company Targeting molecular aberrations beyond EGFR, ALK- Clinical evidence for efficacy and ongoing research.mp4
ESMO Colloquium supported by Eli Lilly and Company The availability of molecular testing in Europe and its implications for state-of-the-art care for patients with lung cancer.mp4
ESMO Colloquium supported by Eli Lilly and Company The importance of next-generation sequencing (NGS) testing in non-small cell lung cancer- Science, implementation and timing.mp4
ESMO Colloquium supported by Eli Lilly and Company Welcome and introduction.mp4
ESMO Designated Centres Conclusion and next steps.mp4
ESMO Designated Centres Conclusion and next steps.pdf
ESMO Designated Centres Designated Centres Awards.mp4
ESMO Designated Centres Designated Centres Awards.pdf
ESMO Designated Centres Designated centres virtual visits pilot.mp4
ESMO Designated Centres Designated centres virtual visits pilot.pdf
ESMO Designated Centres Importance of integration of palliative care into mainstream oncology.mp4
ESMO Designated Centres Importance of integration of palliative care into mainstream oncology.pdf
ESMO Designated Centres Introduction.mp4
ESMO Designated Centres Introduction.pdf
ESMO Designated Centres MyPath update and introduction to the JANE network.mp4
ESMO Designated Centres MyPath update and introduction to the JANE network.pdf
ESMO Designated Centres Q&A.mp4
ESMO Designated Centres Q&A.pdf
ESMO Designated Centres Symptom screening with Targeted Early Palliative care (STEP) intervention.mp4
ESMO Designated Centres Symptom screening with Targeted Early Palliative care (STEP) intervention.pdf
ESMO Guideline updates on supportive and palliative care Anxiety, depression and insomnia.mp4
ESMO Guideline updates on supportive and palliative care Anxiety, depression and insomnia.pdf
ESMO Guideline updates on supportive and palliative care Prognostication in advanced cancer- Navigating the uncertainty.mp4
ESMO Guideline updates on supportive and palliative care Prognostication in advanced cancer- Navigating the uncertainty.pdf
ESMO Guideline updates on supportive and palliative care Q&A and Discussion.mp4
ESMO Guideline updates on supportive and palliative care Q&A and Discussion.pdf
ESMO-MCBS 2023 revolution A guide through the new ESMO-MCBS v2.0.mp4
ESMO-MCBS 2023 revolution A guide through the new ESMO-MCBS v2.0.pdf
ESMO-MCBS 2023 revolution Conclusions and perspectives, discussion and Q&A.mp4
ESMO-MCBS 2023 revolution Conclusions and perspectives, discussion and Q&A.pdf
ESMO-MCBS 2023 revolution ESMO-Magnitude of Clinical Scale for Haematological Malignancies (ESMO-MCBS-H).mp4
ESMO-MCBS 2023 revolution ESMO-Magnitude of Clinical Scale for Haematological Malignancies (ESMO-MCBS-H).pdf
ESMO-MCBS 2023 revolution Introduction.mp4
ESMO-MCBS 2023 revolution Introduction.pdf
ESMO-MCBS 2023 revolution Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints (SISAQOL-IMI).mp4
ESMO-MCBS 2023 revolution Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints (SISAQOL-IMI).pdf
ESMO-WHO review of innovation in cancer therapeutics Evaluating innovative products in breast cancer Characteristics, impact and market share.mp4
ESMO-WHO review of innovation in cancer therapeutics Evaluating innovative products in breast cancer Characteristics, impact and market share.pdf
ESMO-WHO review of innovation in cancer therapeutics Horizon scanning of emerging therapeutics in the next decade What does the future hold.mp4
ESMO-WHO review of innovation in cancer therapeutics Horizon scanning of emerging therapeutics in the next decade What does the future hold.pdf
ESMO-WHO review of innovation in cancer therapeutics Innovation in the EU Cancer Mission Delivering solutions.mp4
ESMO-WHO review of innovation in cancer therapeutics Innovation in the EU Cancer Mission Delivering solutions.pdf
ESMO-WHO review of innovation in cancer therapeutics Introduction.mp4
ESMO-WHO review of innovation in cancer therapeutics Introduction.pdf
ESMO-WHO review of innovation in cancer therapeutics Panel Discussion.mp4
ESMO-WHO review of innovation in cancer therapeutics Q&A and closing remarks.mp4
ESMO-WHO review of innovation in cancer therapeutics Q&A and closing remarks.pdf
Fight the enemy as soon as possible Current systemic treatment of locally advanced colon cancer.mp4
Fight the enemy as soon as possible Current systemic treatment of locally advanced colon cancer.pdf
Fight the enemy as soon as possible Future directions neoadjuvant versus adjuvant.mp4
Fight the enemy as soon as possible Future directions neoadjuvant versus adjuvant.pdf
Fight the enemy as soon as possible How do we optimise imaging.mp4
Fight the enemy as soon as possible How do we optimise imaging.pdf
Fight the enemy as soon as possible Q&A and Discussion.mp4
Fight the enemy as soon as possible Q&A and Discussion.pdf
Fight the enemy as soon as possible Screening programmes 20 years later Lessons learned and how to move on.mp4
Fight the enemy as soon as possible Screening programmes 20 years later Lessons learned and how to move on.pdf
final_programme_esmo2023.pdf
Finding the positive in triple negative breast cancer Conclusions and perspectives.mp4
Finding the positive in triple negative breast cancer Conclusions and perspectives.pdf
Finding the positive in triple negative breast cancer Discussion.mp4
Finding the positive in triple negative breast cancer Discussion.pdf
Finding the positive in triple negative breast cancer Emerging targets in TNBC.mp4
Finding the positive in triple negative breast cancer Emerging targets in TNBC.pdf
Finding the positive in triple negative breast cancer Integrative multiomics analysis to dissect TNBC.mp4
Finding the positive in triple negative breast cancer Integrative multiomics analysis to dissect TNBC.pdf
Finding the positive in triple negative breast cancer Introduction and scientific background.mp4
Finding the positive in triple negative breast cancer Introduction and scientific background.pdf
Finding the positive in triple negative breast cancer Predicting response or resistance to IO.mp4
Finding the positive in triple negative breast cancer Predicting response or resistance to IO.pdf
Finding the positive in triple negative breast cancer Targeting DNA damage response.mp4
Finding the positive in triple negative breast cancer Targeting DNA damage response.pdf
First-line therapy in advanced melanoma- What is my preferred choice I prefer the combination of anti-PD-1 and anti-LAG-3, and these are the reasons why.mp4
First-line therapy in advanced melanoma- What is my preferred choice I prefer the combination of anti-PD-1 and anti-LAG-3, and these are the reasons why.pdf
First-line therapy in advanced melanoma- What is my preferred choice My preferred choice is combined immunotherapy with PD1+CTLA-4, and these are the reasons why.mp4
First-line therapy in advanced melanoma- What is my preferred choice My preferred choice is combined immunotherapy with PD1+CTLA-4, and these are the reasons why.pdf
First-line therapy in advanced melanoma- What is my preferred choice My preferred choice is PD-1 monotherapy, and these are the reasons why.mp4
First-line therapy in advanced melanoma- What is my preferred choice My preferred choice is PD-1 monotherapy, and these are the reasons why.pdf
First-line therapy in advanced melanoma- What is my preferred choice Q&A and Discussion.mp4
First-line therapy in advanced melanoma- What is my preferred choice Q&A and Discussion.pdf
First-line treatment of oncogene-addicted mutated NSCLC- Choosing between many options Discussion led by Chair.mp4
First-line treatment of oncogene-addicted mutated NSCLC- Choosing between many options Discussion led by Chair.pdf
First-line treatment of oncogene-addicted mutated NSCLC- Choosing between many options Presentation by Expert ALK.mp4
First-line treatment of oncogene-addicted mutated NSCLC- Choosing between many options Presentation by Expert ALK.pdf
First-line treatment of oncogene-addicted mutated NSCLC- Choosing between many options Presentation by Expert EGFR.mp4
First-line treatment of oncogene-addicted mutated NSCLC- Choosing between many options Presentation by Expert EGFR.pdf
Genetic predisposition in patients with sarcoma Discussion.mp4
Genetic predisposition in patients with sarcoma Discussion.pdf
Genetic predisposition in patients with sarcoma How to treat bone, soft tissue and GIST patients with a hereditary predisposition- A medical oncologist’s perspective.mp4
Genetic predisposition in patients with sarcoma How to treat bone, soft tissue and GIST patients with a hereditary predisposition- A medical oncologist’s perspective.pdf
Genetic predisposition in patients with sarcoma How to treat bone, soft tissue and GIST patients with a hereditary predisposition- A surgeon’s perspective.mp4
Genetic predisposition in patients with sarcoma How to treat bone, soft tissue and GIST patients with a hereditary predisposition- A surgeon’s perspective.pdf
Genetic predisposition in patients with sarcoma How to treat sarcoma patients with a hereditary predisposition- A radiation oncologist’s perspective.mp4
Genetic predisposition in patients with sarcoma How to treat sarcoma patients with a hereditary predisposition- A radiation oncologist’s perspective.pdf
Genetic predisposition in patients with sarcoma How to use radiology in patients with hereditary syndromes.mp4
Genetic predisposition in patients with sarcoma How to use radiology in patients with hereditary syndromes.pdf
Genetic predisposition in patients with sarcoma When and why to test a patient with sarcoma for hereditary predisposition.mp4
Genetic predisposition in patients with sarcoma When and why to test a patient with sarcoma for hereditary predisposition.pdf
Gilead Sciences Europe Ltd – Lines of progress Audience Q&A.mp4
Gilead Sciences Europe Ltd – Lines of progress Expanding possibilities in HR+_HER2- mBC.mp4
Gilead Sciences Europe Ltd – Lines of progress Improving outcomes for patients with metastatic TNBC.mp4
Gilead Sciences Europe Ltd – Lines of progress Metastatic Breast Cancer- A journey of progress through innovations.mp4
Gilead Sciences Europe Ltd – MILLIONS OF LIVES. ONE MISSION Expanding opportunities in patients with metastatic NSCLC.mp4
Gilead Sciences Europe Ltd – MILLIONS OF LIVES. ONE MISSION Improving the lives of patients with triple-negative and HR+_HER2- metastatic breast cancer.mp4
Gilead Sciences Europe Ltd – MILLIONS OF LIVES. ONE MISSION Q&A and closing remarks.mp4
Gilead Sciences Europe Ltd – MILLIONS OF LIVES. ONE MISSION Unlocking the potential for the treatment of metastatic urothelial cancer.mp4
Gilead Sciences Europe Ltd – MILLIONS OF LIVES. ONE MISSION Welcome and introduction- ADCs – A journey across time.mp4
GSK – The breakthrough era in endometrial cancer treatment Anti-PD-(L)1s plus chemotherapies continue to evolve- Updates from 2023 congresses.mp4
GSK – The breakthrough era in endometrial cancer treatment Full discussion_Q&A.mp4
GSK – The breakthrough era in endometrial cancer treatment Surge in molecular-based targets brings new hope for EC treatment.mp4
GSK – The breakthrough era in endometrial cancer treatment Synergy- Is it more than a buzzword for IO plus PARPi or TKI-.mp4
GSK – The breakthrough era in endometrial cancer treatment Three ways EC management is changing.mp4
GSK – The Need for Better Patient Outcomes Locally Advanced dMMR_MSI-H Colon Cancer- New Approaches Under Investigation.mp4
GSK – The Need for Better Patient Outcomes Locally Advanced dMMR_MSI-H Rectal Cancer- New Approaches Under Investigation.mp4
GSK – The Need for Better Patient Outcomes Q&A – Panel Discussion.mp4
GSK – The Need for Better Patient Outcomes The Multidisciplinary Approach to Locally Advanced dMMR_MSI-H CRC- Reducing the Patient Burden.mp4
GSK – The Need for Better Patient Outcomes The Need for New Approaches in Locally Advanced dMMR_MSI-H CRC.mp4
Harnessing innate immunity to fight cancer Are Gamma Delta T cells the protagonists of cancer attack by the innate immune system.mp4
Harnessing innate immunity to fight cancer Are Gamma Delta T cells the protagonists of cancer attack by the innate immune system.pdf
Harnessing innate immunity to fight cancer Cytokine cis-targeting to selectively activate tumor-specific immunity.mp4
Harnessing innate immunity to fight cancer Q&A and Discussion.mp4
Harnessing innate immunity to fight cancer The Type 2 immune axis in the marrow directs pro-tumorigenic myelopoiesis.mp4
Harnessing innate immunity to fight cancer The Type 2 immune axis in the marrow directs pro-tumorigenic myelopoiesis.pdf
Healthcare in times of crises Healthcare in times of crises.mp4
Healthcare in times of crises Healthcare in times of crises.pdf
Healthcare in times of crises Introduction by the Chair.mp4
Healthcare in times of crises Introduction by the Chair.pdf
HER2 positive gastroesophageal cancer Conclusions and perspectives.mp4
HER2 positive gastroesophageal cancer Discussion.mp4
HER2 positive gastroesophageal cancer Discussion.pdf
HER2 positive gastroesophageal cancer HER2 and beyond- What’s next.mp4
HER2 positive gastroesophageal cancer HER2 and beyond- What’s next.pdf
HER2 positive gastroesophageal cancer Introduction and scientific background.mp4
HER2 positive gastroesophageal cancer Lessons from the biology of HER2 positive gastroesophageal cancer.mp4
HER2 positive gastroesophageal cancer Lessons from the biology of HER2 positive gastroesophageal cancer.pdf
HER2 positive gastroesophageal cancer Novel therapies in HER2 in advanced gastroesophageal cancer.mp4
HER2 positive gastroesophageal cancer Novel therapies in HER2 in advanced gastroesophageal cancer.pdf
HER2 positive gastroesophageal cancer Targeting HER2 in operable gastroesophageal cancer.mp4
HER2 positive gastroesophageal cancer Targeting HER2 in operable gastroesophageal cancer.pdf
How do we best monitor patients during follow-up Discussion.mp4
How do we best monitor patients during follow-up Discussion.pdf
How do we best monitor patients during follow-up Introduction.mp4
How do we best monitor patients during follow-up Introduction.pdf
How do we best monitor patients during follow-up It is not just survival- Rehabilitation, quality of life and late toxicities.mp4
How do we best monitor patients during follow-up It is not just survival- Rehabilitation, quality of life and late toxicities.pdf
How do we best monitor patients during follow-up Liquid biopsy may improve a tailored follow up.mp4
How do we best monitor patients during follow-up Liquid biopsy may improve a tailored follow up.pdf
How do we best monitor patients during follow-up Minimalist or maximalist- From literature to real-world data.mp4
How do we best monitor patients during follow-up Minimalist or maximalist- From literature to real-world data.pdf
How do we best monitor patients during follow-up Radiological imaging vs clinical examination- When less is more.mp4
How do we best monitor patients during follow-up Radiological imaging vs clinical examination- When less is more.pdf
How do we best monitor patients during follow-up The patient’s perspective and expectations.mp4
How do we best monitor patients during follow-up The patient’s perspective and expectations.pdf
How do we manage patients with complicated toxicity to immunotherapy Discussion led by Chair.mp4
How do we manage patients with complicated toxicity to immunotherapy Discussion led by Chair.pdf
How do we manage patients with complicated toxicity to immunotherapy Presentation by Expert.mp4
How do we manage patients with complicated toxicity to immunotherapy Presentation by Expert.pdf
How does digitalisation help personalised care throughout the patient journey Discussion.mp4
How does digitalisation help personalised care throughout the patient journey Discussion.pdf
How does digitalisation help personalised care throughout the patient journey New solutions for cancer patients.mp4
How does digitalisation help personalised care throughout the patient journey New solutions for cancer patients.pdf
How does digitalisation help personalised care throughout the patient journey New technologies in hospitals, improving patient experience.mp4
How does digitalisation help personalised care throughout the patient journey New technologies in hospitals, improving patient experience.pdf
How does digitalisation help personalised care throughout the patient journey Patients at the centre of the new digital solutions- HealthDay and personalised care.mp4
How does digitalisation help personalised care throughout the patient journey Patients at the centre of the new digital solutions- HealthDay and personalised care.pdf
How does digitalisation help personalised care throughout the patient journey Saving life trough tracking symptoms and early detection of cancer recurrence- The importance of collecting data in registries.mp4
How does digitalisation help personalised care throughout the patient journey Saving life trough tracking symptoms and early detection of cancer recurrence- The importance of collecting data in registries.pdf
How does digitalisation help personalised care throughout the patient journey Virtual nursing services- Data for healthier patient lives.mp4
How does digitalisation help personalised care throughout the patient journey Virtual nursing services- Data for healthier patient lives.pdf
How to improve access to medicines through patient engagement A gap analysis on access to modern medicines and treatments.mp4
How to improve access to medicines through patient engagement A gap analysis on access to modern medicines and treatments.pdf
How to improve access to medicines through patient engagement Discussion.mp4
How to improve access to medicines through patient engagement Incorporating patient organizations’ expertise into the healthcare legislation.mp4
How to improve access to medicines through patient engagement Incorporating patient organizations’ expertise into the healthcare legislation.pdf
How to improve access to medicines through patient engagement Leukaemia care and the collaboration with NICE.mp4
How to improve access to medicines through patient engagement Leukaemia care and the collaboration with NICE.pdf
How to improve access to medicines through patient engagement Patient engagement and collaboration with national regulatory agencies.mp4
How to improve access to medicines through patient engagement Patient engagement and collaboration with national regulatory agencies.pdf
How to improve access to medicines through patient engagement The improvement of the regulatory process through the consideration of patients.mp4
How to improve access to medicines through patient engagement The improvement of the regulatory process through the consideration of patients.pdf
How to navigate the different treatment options for hepatobiliary cancers Immunotherapy for biliary cancer.mp4
How to navigate the different treatment options for hepatobiliary cancers Immunotherapy for biliary cancer.pdf
How to navigate the different treatment options for hepatobiliary cancers Immunotherapy for liver cancer.mp4
How to navigate the different treatment options for hepatobiliary cancers Immunotherapy for liver cancer.pdf
How to navigate the different treatment options for hepatobiliary cancers Personalised medicine and targeted agents for biliary tract cancer.mp4
How to navigate the different treatment options for hepatobiliary cancers Personalised medicine and targeted agents for biliary tract cancer.pdf
How to navigate the different treatment options for hepatobiliary cancers Personalised treatment for HCC- Where are we now.mp4
How to navigate the different treatment options for hepatobiliary cancers Personalised treatment for HCC- Where are we now.pdf
How to navigate the different treatment options for hepatobiliary cancers Q&A and Discussion.mp4
How to navigate the different treatment options for hepatobiliary cancers Q&A and Discussion.pdf
Immunotherapy for head and neck cancer What, when and how long Conclusions and perspectives.mp4
Immunotherapy for head and neck cancer What, when and how long Conclusions and perspectives.pdf
Immunotherapy for head and neck cancer What, when and how long Discussion.mp4
Immunotherapy for head and neck cancer What, when and how long Discussion.pdf
Immunotherapy for head and neck cancer What, when and how long Incorporating immunotherapy into the approach to locally advanced HNSCC.mp4
Immunotherapy for head and neck cancer What, when and how long Incorporating immunotherapy into the approach to locally advanced HNSCC.pdf
Immunotherapy for head and neck cancer What, when and how long Introduction and scientific background.mp4
Immunotherapy for head and neck cancer What, when and how long Introduction and scientific background.pdf
Immunotherapy for head and neck cancer What, when and how long Novel combinations in the non-curative HNSCC setting.mp4
Immunotherapy for head and neck cancer What, when and how long Novel combinations in the non-curative HNSCC setting.pdf
Immunotherapy for head and neck cancer What, when and how long Patient selection is crucial to improve immunotherapy effectiveness.mp4
Immunotherapy for head and neck cancer What, when and how long Patient selection is crucial to improve immunotherapy effectiveness.pdf
Immunotherapy for head and neck cancer What, when and how long Perioperative immunotherapy for head and neck squamous cell carcinoma (HNSCC).mp4
Immunotherapy for head and neck cancer What, when and how long Perioperative immunotherapy for head and neck squamous cell carcinoma (HNSCC).pdf
Immunotherapy in colorectal cancer Where do we stand and what do we expect Discussion led by Chair.mp4
Immunotherapy in colorectal cancer Where do we stand and what do we expect Discussion led by Chair.pdf
Immunotherapy in colorectal cancer Where do we stand and what do we expect Presentation by Expert.mp4
Immunotherapy in colorectal cancer Where do we stand and what do we expect Presentation by Expert.pdf
Immunotherapy in dMMR MSI-H recurrent metastatic endometrial cancer Monotherapy or combination Discussion led by Chair.mp4
Immunotherapy in dMMR MSI-H recurrent metastatic endometrial cancer Monotherapy or combination Discussion led by Chair.pdf
Immunotherapy in dMMR MSI-H recurrent metastatic endometrial cancer Monotherapy or combination Presentation by Expert.mp4
Immunotherapy in dMMR MSI-H recurrent metastatic endometrial cancer Monotherapy or combination Presentation by Expert.pdf
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Discussion.mp4
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Discussion.pdf
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Geriatric assessment It is primetime now.mp4
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Geriatric assessment It is primetime now.pdf
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Optimizing oncologic care in older patients with advanced breast cancer.mp4
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Optimizing oncologic care in older patients with advanced breast cancer.pdf
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Optimizing oncologic care in older patients with advanced colorectal cancer.mp4
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Optimizing oncologic care in older patients with advanced colorectal cancer.pdf
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Optimizing oncologic care in older patients with advanced lung cancer.mp4
In collaboration with SIOG Fundamentals in geriatric oncology in clinical practice Optimizing oncologic care in older patients with advanced lung cancer.pdf
In collaboration with the IARC – Cancer prevention Discussion.mp4
In collaboration with the IARC – Cancer prevention Discussion.pdf
In collaboration with the IARC – Cancer prevention IARC’s European Code Against Cancer- The EONS-ESMO campaign.mp4
In collaboration with the IARC – Cancer prevention IARC’s European Code Against Cancer- The EONS-ESMO campaign.pdf
In collaboration with the IARC – Cancer prevention Introduction.mp4
In collaboration with the IARC – Cancer prevention Introduction.pdf
In collaboration with the IARC – Cancer prevention Presentation of the IARC-ESMO survey results on the educational needs of medical oncologists on cancer.mp4
In collaboration with the IARC – Cancer prevention Presentation of the IARC-ESMO survey results on the educational needs of medical oncologists on cancer.pdf
In collaboration with the IARC – Cancer prevention The IARC World Cancer Report Updates Learning Platform – Supported by ESMO.mp4
In collaboration with the IARC – Cancer prevention The IARC World Cancer Report Updates Learning Platform – Supported by ESMO.pdf
In collaboration with the IARC – Cancer prevention The present and future of lung cancer screening What does the scientific evidence show.mp4
In collaboration with the IARC – Cancer prevention The present and future of lung cancer screening What does the scientific evidence show.pdf
In collaboration with the IARC – Cancer prevention WHO’s cancer prevention policy resolutions, best buys, and framework convention on tobacco control.mp4
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Fatigue in health care professionals Another term for burnout.mp4
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Fatigue in health care professionals Another term for burnout.pdf
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Fatigue related to emerging targeted anticancer therapeutics.mp4
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Fatigue related to emerging targeted anticancer therapeutics.pdf
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Panel discussion Q&A.mp4
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Panel discussion Q&A.pdf
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Systemic anticancer therapy-related fatigue Causes and management.mp4
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem Systemic anticancer therapy-related fatigue Causes and management.pdf
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem The epidemiology, biology and aetiology of cancer-related fatigue.mp4
In collaboration with the MASCC The multiple faces of fatigue in the cancer ecosystem The epidemiology, biology and aetiology of cancer-related fatigue.pdf
Integrating immunotherapy into the standard of care for cervical cancer Discussion.mp4
Integrating immunotherapy into the standard of care for cervical cancer In metastatic and recurrence.mp4
Integrating immunotherapy into the standard of care for cervical cancer In metastatic and recurrence.pdf
Integrating immunotherapy into the standard of care for cervical cancer IO in combination with chemoradiation therapy in locally advanced cervical cancer.mp4
Integrating immunotherapy into the standard of care for cervical cancer IO in combination with chemoradiation therapy in locally advanced cervical cancer.pdf
Integrating immunotherapy into the standard of care for cervical cancer Treatment after progression on immunotherapy.mp4
Integrating immunotherapy into the standard of care for cervical cancer Treatment after progression on immunotherapy.pdf
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Beyond medical oncology in the management of metastatic disease.mp4
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Beyond medical oncology in the management of metastatic disease.pdf
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Discussion.mp4
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Discussion.pdf
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Integrating locoregional and systemic therapies for CNS metastatic disease.mp4
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Integrating locoregional and systemic therapies for CNS metastatic disease.pdf
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Integrating locoregional and systemic therapies for non-CNS metastatic disease.mp4
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Integrating locoregional and systemic therapies for non-CNS metastatic disease.pdf
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Presentation of case with CNS met condition.mp4
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Presentation of case with CNS met condition.pdf
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Presentation of case with extra cranial met condition.mp4
Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients Presentation of case with extra cranial met condition.pdf
Intensification vs descalation of therapy in H&N cancer When and for whom De-escalation in radiation and systemic therapy.mp4
Intensification vs descalation of therapy in H&N cancer When and for whom De-escalation in radiation and systemic therapy.pdf
Intensification vs descalation of therapy in H&N cancer When and for whom Novel strategies to de-escalate surgery.mp4
Intensification vs descalation of therapy in H&N cancer When and for whom Novel strategies to de-escalate surgery.pdf
Intensification vs descalation of therapy in H&N cancer When and for whom Q&A and Discussion.mp4
Intensification vs descalation of therapy in H&N cancer When and for whom Q&A and Discussion.pdf
Intensification vs descalation of therapy in H&N cancer When and for whom Which patients need more intensive treatment.mp4
Intensification vs descalation of therapy in H&N cancer When and for whom Which patients need more intensive treatment.pdf
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Presentation of case condition.mp4
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Presentation of case condition.pdf
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Q&A and Discussion.mp4
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Q&A and Discussion.pdf
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Role of locoregional and ablative therapies.mp4
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Role of locoregional and ablative therapies.pdf
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Role of surgery in advanced disease.mp4
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Role of surgery in advanced disease.pdf
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Role of systemic therapies in the control of hormone-release.mp4
Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Role of systemic therapies in the control of hormone-release.pdf
Ipsen aRCC and mCRPC is your decision-making up-to-date Closing Remarks.mp4
Ipsen aRCC and mCRPC is your decision-making up-to-date Direction of travel in mCRPC Description- A presentation reflecting on the similar rapid changes that are occurring in mCRPC and changes anticipated in the near-term, and considering th.mp4
Ipsen aRCC and mCRPC is your decision-making up-to-date Keeping pace in aRCC Description- A presentation highlighting the rapid advances in treatment landscape as well as biological understanding of aRCC, and what this means for patients in .mp4
Ipsen aRCC and mCRPC is your decision-making up-to-date Panel Discussion.mp4
Ipsen aRCC and mCRPC is your decision-making up-to-date Putting theory into practice Description- A simulated multi-disciplinary tumour board considering the first- and second-line treatment choices for a patient with aRCC.mp4
Ipsen aRCC and mCRPC is your decision-making up-to-date Spoilt for choice in 1L aRCC- Or not Really- Description- A presentation discussing the clinical endpoints that are considered when selecting first-line treatment for patients with aRCC.mp4
Ipsen aRCC and mCRPC is your decision-making up-to-date Welcome & introduction.mp4
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types How to personalise neoadjuvant immunotherapy.mp4
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types How to personalise neoadjuvant immunotherapy.pdf
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types Is chemotherapy plus immunotherapy equal to immunotherapy alone at the neoadjuvant stage.mp4
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types Is chemotherapy plus immunotherapy equal to immunotherapy alone at the neoadjuvant stage.pdf
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types Novel neoadjuvant combination immunotherapies.mp4
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types Novel neoadjuvant combination immunotherapies.pdf
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types Q&A and Discussion.mp4
Is neoadjuvant immunotherapy a therapeutic platform for all tumour types Q&A and Discussion.pdf
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC A radiation oncologist’s perspective.mp4
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC A radiation oncologist’s perspective.pdf
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC A surgeon’s perspective.mp4
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC A surgeon’s perspective.pdf
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC Characteristics and treatment outcomes of screening-detected early NSCLC.mp4
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC Characteristics and treatment outcomes of screening-detected early NSCLC.pdf
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC Discussion.mp4
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC Discussion.pdf
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC Opportunities for immunotherapy in stage I NSCLC.mp4
Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC Opportunities for immunotherapy in stage I NSCLC.pdf
Is there still a place for anthracyclines in early breast cancer Discussion led by Chair.mp4
Is there still a place for anthracyclines in early breast cancer Discussion led by Chair.pdf
Is there still a place for anthracyclines in early breast cancer Presentation by Expert.mp4
Is there still a place for anthracyclines in early breast cancer Presentation by Expert.pdf
Janssen Pharmaceutica N.V. Targeted therapy optimising the future of GU cancer care Closing remarks.mp4
Janssen Pharmaceutica N.V. Targeted therapy optimising the future of GU cancer care Germ line testing and genomic profiling – isn’t it time for personalised prostate cancer care-.mp4
Janssen Pharmaceutica N.V. Targeted therapy optimising the future of GU cancer care How can we balance efficacy and QoL in mHSPC treatment- Why it’s time to tailor treatments.mp4
Janssen Pharmaceutica N.V. Targeted therapy optimising the future of GU cancer care Interactive Q&A session.mp4
Janssen Pharmaceutica N.V. Targeted therapy optimising the future of GU cancer care Opening remarks & introduction.mp4
Janssen Pharmaceutica N.V. Targeted therapy optimising the future of GU cancer care Revolutionising urothelial carcinoma care- Discovering the value of targeted therapy.mp4
Janssen Pharmaceutica N.V. Transforming treatment approaches for patients with EGFR-mutant NSCLC Current and future directions for EGFR exon 20 insertion mutations in NSCLC.mp4
Janssen Pharmaceutica N.V. Transforming treatment approaches for patients with EGFR-mutant NSCLC Expanding our horizons- Novel frontline approaches in EGFR-mutant NSCLC.mp4
Janssen Pharmaceutica N.V. Transforming treatment approaches for patients with EGFR-mutant NSCLC Key learnings_closing remarks.mp4
Janssen Pharmaceutica N.V. Transforming treatment approaches for patients with EGFR-mutant NSCLC Strategies for overcoming EGFR resistance in NSCLC patient management.mp4
Janssen Pharmaceutica N.V. Transforming treatment approaches for patients with EGFR-mutant NSCLC Welcome and introductions.mp4
Liquid biopsies development and application Where do we stand Detection of HPV circulating tumour DNA.mp4
Liquid biopsies development and application Where do we stand Detection of HPV circulating tumour DNA.pdf
Liquid biopsies development and application Where do we stand Genome-wide cell-free DNA fragmentation in cancer.mp4
Liquid biopsies development and application Where do we stand Genome-wide cell-free DNA fragmentation in cancer.pdf
Liquid biopsies development and application Where do we stand Incorporating liquid biopsies into clinical trials.mp4
Liquid biopsies development and application Where do we stand Incorporating liquid biopsies into clinical trials.pdf
Liquid biopsies development and application Where do we stand Q&A and Discussion.mp4
Liquid biopsies development and application Where do we stand Q&A and Discussion.pdf
Liquid biopsies development and application Where do we stand Standardisation of liquid biopsy approaches.mp4
Liquid biopsies development and application Where do we stand Standardisation of liquid biopsy approaches.pdf
Living with and after cancer Behavioural changes in daily life- A cross-cutting approach for daily wellbeing.mp4
Living with and after cancer Behavioural changes in daily life- A cross-cutting approach for daily wellbeing.pdf
Living with and after cancer Conclusion.mp4
Living with and after cancer Conclusion.pdf
Living with and after cancer Discussion.mp4
Living with and after cancer Discussion.pdf
Living with and after cancer Palliative and supportive care.mp4
Living with and after cancer Palliative and supportive care.pdf
Living with and after cancer Quality of life and survivorship.mp4
Living with and after cancer Quality of life and survivorship.pdf
Living with and after cancer Reducing inequalities in Europe through robust national cancer control plans that include palliative care.mp4
Living with and after cancer Reducing inequalities in Europe through robust national cancer control plans that include palliative care.pdf
Living with and after cancer Resilience is key after diagnosis, during treatment, and after treatment.mp4
Living with and after cancer Resilience is key after diagnosis, during treatment, and after treatment.pdf
Long term survivors in the era of immunotherapy of cancer Cognitive defects in long term IO.mp4
Long term survivors in the era of immunotherapy of cancer Cognitive defects in long term IO.pdf
Long term survivors in the era of immunotherapy of cancer Discussion.mp4
Long term survivors in the era of immunotherapy of cancer Discussion.pdf
Long term survivors in the era of immunotherapy of cancer Ideal duration of IT- How to define it and what are the implications.mp4
Long term survivors in the era of immunotherapy of cancer Ideal duration of IT- How to define it and what are the implications.pdf
Long term survivors in the era of immunotherapy of cancer Long-term toxicity of immunotherapeutics.mp4
Long term survivors in the era of immunotherapy of cancer Long-term toxicity of immunotherapeutics.pdf
Long term survivors in the era of immunotherapy of cancer Quality of life in IO-treated long-term survivors.mp4
Long term survivors in the era of immunotherapy of cancer Quality of life in IO-treated long-term survivors.pdf
Looking ahead in SCLC From biology to clinical practice Discussion led by Chair.mp4
Looking ahead in SCLC From biology to clinical practice Discussion led by Chair.pdf
Looking ahead in SCLC From biology to clinical practice Presentation by Expert.mp4
Looking ahead in SCLC From biology to clinical practice Presentation by Expert.pdf
Making essential cancer drugs affordable Governmental policies to control cancer medicine prices.mp4
Making essential cancer drugs affordable Governmental policies to control cancer medicine prices.pdf
Making essential cancer drugs affordable India’s approach to advance access to cancer medicines.mp4
Making essential cancer drugs affordable India’s approach to advance access to cancer medicines.pdf
Making essential cancer drugs affordable Insights in essential medicine availability and accessibility from ESMO antineoplastic medicines study 2.0.mp4
Making essential cancer drugs affordable Insights in essential medicine availability and accessibility from ESMO antineoplastic medicines study 2.0.pdf
Making essential cancer drugs affordable Policy and intellectual property regulatory instruments as tools to enhance access to expensive essential cancer medicines.mp4
Making essential cancer drugs affordable Policy and intellectual property regulatory instruments as tools to enhance access to expensive essential cancer medicines.pdf
Making essential cancer drugs affordable Q&A and Discussion.mp4
Making essential cancer drugs affordable Q&A and Discussion.pdf
Management of (very) high-risk localised PCA Delineating staging pelvic LND before RT and positioning primary prostatectomy.mp4
Management of (very) high-risk localised PCA Delineating staging pelvic LND before RT and positioning primary prostatectomy.pdf
Management of (very) high-risk localised PCA Dose intensification and field expansion of EBRT.mp4
Management of (very) high-risk localised PCA Dose intensification and field expansion of EBRT.pdf
Management of (very) high-risk localised PCA How much systemic treatment is needed and how long.mp4
Management of (very) high-risk localised PCA How much systemic treatment is needed and how long.pdf
Management of (very) high-risk localised PCA Presentation of case condition.mp4
Management of (very) high-risk localised PCA Presentation of case condition.pdf
Management of (very) high-risk localised PCA Q&A and Discussion.mp4
Management of (very) high-risk localised PCA Q&A and Discussion.pdf
Management of (very) high-risk localised PCA Usefulness and limitations of PSMA imaging PET in high-risk localised disease.mp4
Management of (very) high-risk localised PCA Usefulness and limitations of PSMA imaging PET in high-risk localised disease.pdf
Management of IMDC favourable-risk patients in metastatic renal cell carcinoma (RCC) Discussion led by Chair.mp4
Management of IMDC favourable-risk patients in metastatic renal cell carcinoma (RCC) Presentation by Expert.mp4
Management of IMDC favourable-risk patients in metastatic renal cell carcinoma (RCC) Presentation by Expert.pdf
Management of novel treatments toxicities Discussion and Q&A.mp4
Management of novel treatments toxicities Discussion and Q&A.pdf
Management of novel treatments toxicities Management of antibody-drug conjugates toxicities.mp4
Management of novel treatments toxicities Management of antibody-drug conjugates toxicities.pdf
Management of novel treatments toxicities Toxicities of novel therapies Why is that important.mp4
Management of novel treatments toxicities Toxicities of novel therapies Why is that important.pdf
Management of novel treatments toxicities Toxicities of TILs, CAR-Ts and bispecific antibodies.mp4
Management of novel treatments toxicities Toxicities of TILs, CAR-Ts and bispecific antibodies.pdf
Management of novel treatments toxicities Toxicity of IO + targeted agents.mp4
Management of novel treatments toxicities Toxicity of IO + targeted agents.pdf
Management of oligometastatic disease in NSCLC Introduction and definition of oligometastatic disease(s) Case presentation.mp4
Management of oligometastatic disease in NSCLC Introduction and definition of oligometastatic disease(s) Case presentation.pdf
Management of oligometastatic disease in NSCLC Q&A and Discussion.mp4
Management of oligometastatic disease in NSCLC Q&A and Discussion.pdf
Management of oligometastatic disease in NSCLC The role of radiation therapy.mp4
Management of oligometastatic disease in NSCLC The role of radiation therapy.pdf
Management of oligometastatic disease in NSCLC The role of surgery.mp4
Management of oligometastatic disease in NSCLC The role of surgery.pdf
Management of oligometastatic disease in NSCLC The role of systemic therapy in patients with or without molecular alterations.mp4
Management of oligometastatic disease in NSCLC The role of systemic therapy in patients with or without molecular alterations.pdf
Management of retroperitoneal sarcoma A medical oncologist’s perspective.mp4
Management of retroperitoneal sarcoma A medical oncologist’s perspective.pdf
Management of retroperitoneal sarcoma A pathologist’s perspective.mp4
Management of retroperitoneal sarcoma A pathologist’s perspective.pdf
Management of retroperitoneal sarcoma A radiation oncologist’s perspective.mp4
Management of retroperitoneal sarcoma A radiation oncologist’s perspective.pdf
Management of retroperitoneal sarcoma A surgeon’s perspective.mp4
Management of retroperitoneal sarcoma A surgeon’s perspective.pdf
Management of retroperitoneal sarcoma Discussion.mp4
Management of retroperitoneal sarcoma Discussion.pdf
Management of retroperitoneal sarcoma Presentation of case condition.mp4
Management of retroperitoneal sarcoma Presentation of case condition.pdf
Managing disease progression in oncogene-driven lung cancer Detection From technology to clinical practice.mp4
Managing disease progression in oncogene-driven lung cancer Detection From technology to clinical practice.pdf
Managing disease progression in oncogene-driven lung cancer Discussion.mp4
Managing disease progression in oncogene-driven lung cancer Discussion.pdf
Managing disease progression in oncogene-driven lung cancer Managing progression after EGFR TKIs in EGFR-mutant lung cancer.mp4
Managing disease progression in oncogene-driven lung cancer Managing progression after EGFR TKIs in EGFR-mutant lung cancer.pdf
Managing disease progression in oncogene-driven lung cancer Managing progression after TKIs in oncogenic fusion-driven lung cancer.mp4
Managing disease progression in oncogene-driven lung cancer Managing progression after TKIs in oncogenic fusion-driven lung cancer.pdf
Managing disease progression in oncogene-driven lung cancer Mechanisms of resistance.mp4
Managing disease progression in oncogene-driven lung cancer Mechanisms of resistance.pdf
Managing stage III NSCLC in the era of IO IO after or with chemoradiotherapy For how long.mp4
Managing stage III NSCLC in the era of IO IO after or with chemoradiotherapy For how long.pdf
Managing stage III NSCLC in the era of IO IO and chemotherapy before or after surgery.mp4
Managing stage III NSCLC in the era of IO IO and chemotherapy before or after surgery.pdf
Managing stage III NSCLC in the era of IO Presentation of case condition.mp4
Managing stage III NSCLC in the era of IO Presentation of case condition.pdf
Managing stage III NSCLC in the era of IO Q&A and Discussion.mp4
Managing stage III NSCLC in the era of IO Q&A and Discussion.pdf
Managing stage III NSCLC in the era of IO Who should and shouldn’t get surgery.mp4
Managing stage III NSCLC in the era of IO Who should and shouldn’t get surgery.pdf
Mini oral session – Basic science & translational research A randomized phase III trial of site-specific therapy guided.mp4
Mini oral session – Basic science & translational research A randomized phase III trial of site-specific therapy guided.pdf
Mini oral session – Basic science & translational research BRCA-DIRECT- A randomised UK study evaluating a digital pathway.mp4
Mini oral session – Basic science & translational research BRCA-DIRECT- A randomised UK study evaluating a digital pathway.pdf
Mini oral session – Basic science & translational research CDC7 inhibition constrains lineage plasticity.mp4
Mini oral session – Basic science & translational research CDC7 inhibition constrains lineage plasticity.pdf
Mini oral session – Basic science & translational research Comparison of clinical and radiological features-based and radiomics features-based.mp4
Mini oral session – Basic science & translational research Comparison of clinical and radiological features-based and radiomics features-based.pdf
Mini oral session – Basic science & translational research Computer-aided HCC lesion detection based on deep learning and CT images.mp4
Mini oral session – Basic science & translational research Computer-aided HCC lesion detection based on deep learning and CT images.pdf
Mini oral session – Basic science & translational research CUP-ONE trial A prospective double-blind validation.mp4
Mini oral session – Basic science & translational research CUP-ONE trial A prospective double-blind validation.pdf
Mini oral session – Basic science & translational research Differentiation of malignant and benign lung nodules using epigenetically modified nucleosomes in plasma.mp4
Mini oral session – Basic science & translational research Differentiation of malignant and benign lung nodules using epigenetically modified nucleosomes in plasma.pdf
Mini oral session – Basic science & translational research Invited Discussant 1209MO and 1210MO.mp4
Mini oral session – Basic science & translational research Invited Discussant 1209MO and 1210MO.pdf
Mini oral session – Basic science & translational research Invited Discussant 132MO, LBA100, 1208MO and LBA101.mp4
Mini oral session – Basic science & translational research Invited Discussant 132MO, LBA100, 1208MO and LBA101.pdf
Mini oral session – Basic science & translational research Invited Discussant 2233MO and 133MO.mp4
Mini oral session – Basic science & translational research Invited Discussant 2233MO and 133MO.pdf
Mini oral session – Basic science & translational research olecular profiling of 991 prospectively recruited rare cancers patients in EUROPE.mp4
Mini oral session – Basic science & translational research olecular profiling of 991 prospectively recruited rare cancers patients in EUROPE.pdf
Mini oral session – Breast cancer, early stage A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine.mp4
Mini oral session – Breast cancer, early stage A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine.pdf
Mini oral session – Breast cancer, early stage Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS).mp4
Mini oral session – Breast cancer, early stage Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS).pdf
Mini oral session – Breast cancer, early stage Connected device and therapeutic patient education to promote physical.mp4
Mini oral session – Breast cancer, early stage Connected device and therapeutic patient education to promote physical.pdf
Mini oral session – Breast cancer, early stage Impact of body mass index and its change on survival outcomes in patients with early breast cancer.mp4
Mini oral session – Breast cancer, early stage Impact of body mass index and its change on survival outcomes in patients with early breast cancer.pdf
Mini oral session – Breast cancer, early stage Invasive disease-free survival (iDFS) across key subgroups from the phase III.mp4
Mini oral session – Breast cancer, early stage Invasive disease-free survival (iDFS) across key subgroups from the phase III.pdf
Mini oral session – Breast cancer, early stage Invited Discussant 238MO, LBA22 and 239MO.mp4
Mini oral session – Breast cancer, early stage Invited Discussant 238MO, LBA22 and 239MO.pdf
Mini oral session – Breast cancer, early stage Invited Discussant 240MO, LBA23, 241MO, 242MO and LBA24.mp4
Mini oral session – Breast cancer, early stage Invited Discussant 240MO, LBA23, 241MO, 242MO and LBA24.pdf
Mini oral session – Breast cancer, early stage Invited Discussant 243MO and 244MO.mp4
Mini oral session – Breast cancer, early stage Invited Discussant 243MO and 244MO.pdf
Mini oral session – Breast cancer, early stage Long-term residential and workplace exposure to air pollution and breast cancer risk.mp4
Mini oral session – Breast cancer, early stage Long-term residential and workplace exposure to air pollution and breast cancer risk.pdf
Mini oral session – Breast cancer, early stage Multiparametric prognostic score in early HR+.mp4
Mini oral session – Breast cancer, early stage Multiparametric prognostic score in early HR+.pdf
Mini oral session – Breast cancer, early stage Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer.mp4
Mini oral session – Breast cancer, early stage Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer.pdf
Mini oral session – Breast cancer, early stage Patient characteristics and real-world outcomes in HER2 negative.mp4
Mini oral session – Breast cancer, early stage Patient characteristics and real-world outcomes in HER2 negative.pdf
Mini oral session – Breast cancer, early stage Prognostic and predictive impact of estrogen progesterone receptor (ER PR).mp4
Mini oral session – Breast cancer, early stage Prognostic and predictive impact of estrogen progesterone receptor (ER PR).pdf
Mini oral session – Breast cancer, metastatic A multicenter, open-label, dose escalation and expansion study of DP303c.mp4
Mini oral session – Breast cancer, metastatic A multicenter, open-label, dose escalation and expansion study of DP303c.pdf
Mini oral session – Breast cancer, metastatic Datopotamab deruxtecan (Dato-DXd) durvalumab (D) as first-line (1L).mp4
Mini oral session – Breast cancer, metastatic Datopotamab deruxtecan (Dato-DXd) durvalumab (D) as first-line (1L).pdf
Mini oral session – Breast cancer, metastatic Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy.mp4
Mini oral session – Breast cancer, metastatic Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy.pdf
Mini oral session – Breast cancer, metastatic First results of the SOLTI-1903 HOPE’s patient-centric molecular screening program in advanced breast cancer.mp4
Mini oral session – Breast cancer, metastatic First results of the SOLTI-1903 HOPE’s patient-centric molecular screening program in advanced breast cancer.pdf
Mini oral session – Breast cancer, metastatic Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC).mp4
Mini oral session – Breast cancer, metastatic Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC).pdf
Mini oral session – Breast cancer, metastatic Invited Discussant 379MO and 380MO.mp4
Mini oral session – Breast cancer, metastatic Invited Discussant 379MO and 380MO.pdf
Mini oral session – Breast cancer, metastatic Invited Discussant 382MO, 383MO and 384MO.mp4
Mini oral session – Breast cancer, metastatic Invited Discussant 382MO, 383MO and 384MO.pdf
Mini oral session – Breast cancer, metastatic Invited Discussant 385MO, 386MO and 387MO.mp4
Mini oral session – Breast cancer, metastatic Invited Discussant 385MO, 386MO and 387MO.pdf
Mini oral session – Breast cancer, metastatic SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+).mp4
Mini oral session – Breast cancer, metastatic SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+).pdf
Mini oral session – Breast cancer, metastatic Trastuzumab duocarmazine versus physician’s choice therapy in pre-treated HER2-positive metastatic breast cancer.mp4
Mini oral session – Breast cancer, metastatic Trastuzumab duocarmazine versus physician’s choice therapy in pre-treated HER2-positive metastatic breast cancer.pdf
Mini oral session – Breast cancer, metastatic Updated results from the phase I II study of OP-1250, an oral complete estrogen receptor.mp4
Mini oral session – Breast cancer, metastatic Updated results from the phase I II study of OP-1250, an oral complete estrogen receptor.pdf
Mini oral session – Gastrointestinal tumours, lower digestive 554MO – Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients.mp4
Mini oral session – Gastrointestinal tumours, lower digestive 554MO – Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients.pdf
Mini oral session – Gastrointestinal tumours, lower digestive 555MO – Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS BRAF.mp4
Mini oral session – Gastrointestinal tumours, lower digestive 555MO – Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS BRAF.pdf
Mini oral session – Gastrointestinal tumours, lower digestive 556MO – A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab.mp4
Mini oral session – Gastrointestinal tumours, lower digestive 556MO – A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab.pdf
Mini oral session – Gastrointestinal tumours, lower digestive 557MO – Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients.mp4
Mini oral session – Gastrointestinal tumours, lower digestive 557MO – Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients.pdf
Mini oral session – Gastrointestinal tumours, lower digestive 558MO – Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC).mp4
Mini oral session – Gastrointestinal tumours, lower digestive 558MO – Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC).pdf
Mini oral session – Gastrointestinal tumours, lower digestive 559MO – Rechallenge with EGFR inhibitors in ctDNA RAS BRAF wild type refractory metastatic colorectal cancer.mp4
Mini oral session – Gastrointestinal tumours, lower digestive 559MO – Rechallenge with EGFR inhibitors in ctDNA RAS BRAF wild type refractory metastatic colorectal cancer.pdf
Mini oral session – Gastrointestinal tumours, lower digestive 560MO – Maintenance with 5FU LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept.mp4
Mini oral session – Gastrointestinal tumours, lower digestive 560MO – Maintenance with 5FU LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept.pdf
Mini oral session – Gastrointestinal tumours, lower digestive Invited Discussant 558MO, 559MO and 560MO.mp4
Mini oral session – Gastrointestinal tumours, lower digestive Invited Discussant 558MO, 559MO and 560MO.pdf
Mini oral session – Gastrointestinal tumours, lower digestive Invited Discussant LBA30, 554MO and 555MO.mp4
Mini oral session – Gastrointestinal tumours, lower digestive Invited Discussant LBA30, 554MO and 555MO.pdf
Mini oral session – Gastrointestinal tumours, lower digestive Invited Discussant LBA31, 556MO, LBA32 and 557MO.mp4
Mini oral session – Gastrointestinal tumours, lower digestive Invited Discussant LBA31, 556MO, LBA32 and 557MO.pdf
Mini oral session – Gastrointestinal tumours, lower digestive LBA30 – Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC).mp4
Mini oral session – Gastrointestinal tumours, lower digestive LBA30 – Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC).pdf
Mini oral session – Gastrointestinal tumours, lower digestive LBA31 – Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers.mp4
Mini oral session – Gastrointestinal tumours, lower digestive LBA31 – Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers.pdf
Mini oral session – Gastrointestinal tumours, lower digestive LBA32 – Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H) mismatch repair-deficient (dMMR).mp4
Mini oral session – Gastrointestinal tumours, lower digestive LBA32 – Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H) mismatch repair-deficient (dMMR).pdf
Mini oral session – Genitourinary tumours, non-prostate 1883MO – MEDI5752 (volrustomig), a novel PD-1 CTLA-4 bispecific antibody, in the first-line (1L).mp4
Mini oral session – Genitourinary tumours, non-prostate 1883MO – MEDI5752 (volrustomig), a novel PD-1 CTLA-4 bispecific antibody, in the first-line (1L).pdf
Mini oral session – Genitourinary tumours, non-prostate 1884MO – Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients.mp4
Mini oral session – Genitourinary tumours, non-prostate 1884MO – Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients.pdf
Mini oral session – Genitourinary tumours, non-prostate 2361MO – Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer.mp4
Mini oral session – Genitourinary tumours, non-prostate 2361MO – Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer.pdf
Mini oral session – Genitourinary tumours, non-prostate 2362MO – Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer.mp4
Mini oral session – Genitourinary tumours, non-prostate 2362MO – Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer.pdf
Mini oral session – Genitourinary tumours, non-prostate 2363MO – A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial.mp4
Mini oral session – Genitourinary tumours, non-prostate 2363MO – A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial.pdf
Mini oral session – Genitourinary tumours, non-prostate 2364MO – Durvalumab (D) +- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC).mp4
Mini oral session – Genitourinary tumours, non-prostate 2364MO – Durvalumab (D) +- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC).pdf
Mini oral session – Genitourinary tumours, non-prostate 2365MO – Study EV-103 cohort L Perioperative treatment w enfortumab vedotin (EV) monotherapy.mp4
Mini oral session – Genitourinary tumours, non-prostate 2365MO – Study EV-103 cohort L Perioperative treatment w enfortumab vedotin (EV) monotherapy.pdf
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant 1883MO and 1884MO.mp4
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant 1883MO and 1884MO.pdf
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant 2361MO and 2362MO.mp4
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant 2361MO and 2362MO.pdf
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant 2363MO, 2364MO and 2365MO.mp4
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant 2363MO, 2364MO and 2365MO.pdf
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant LBA104 and LBA105.mp4
Mini oral session – Genitourinary tumours, non-prostate Invited Discussant LBA104 and LBA105.pdf
Mini oral session – Genitourinary tumours, non-prostate LBA104 – First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system.mp4
Mini oral session – Genitourinary tumours, non-prostate LBA104 – First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system.pdf
Mini oral session – Genitourinary tumours, non-prostate LBA105 – Results from SunRISe-1 in patients (Pts) with bacillus Calmette-Gu‚rin (BCG)-unresponsive high-risk.mp4
Mini oral session – Genitourinary tumours, non-prostate LBA105 – Results from SunRISe-1 in patients (Pts) with bacillus Calmette-Gu‚rin (BCG)-unresponsive high-risk.pdf
Mini oral session – Genitourinary tumours, prostate 1766MO – Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer.mp4
Mini oral session – Genitourinary tumours, prostate 1766MO – Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer.pdf
Mini oral session – Genitourinary tumours, prostate 1767MO – External validation of a digital pathology-based multimodal artificial intelligence (MMAI).mp4
Mini oral session – Genitourinary tumours, prostate 1767MO – External validation of a digital pathology-based multimodal artificial intelligence (MMAI).pdf
Mini oral session – Genitourinary tumours, prostate 1768MO – Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic.mp4
Mini oral session – Genitourinary tumours, prostate 1768MO – Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic.pdf
Mini oral session – Genitourinary tumours, prostate 1771MO – Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration.mp4
Mini oral session – Genitourinary tumours, prostate 1771MO – Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration.pdf
Mini oral session – Genitourinary tumours, prostate 1772MO – Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT).mp4
Mini oral session – Genitourinary tumours, prostate 1772MO – Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT).pdf
Mini oral session – Genitourinary tumours, prostate Invited Discussant 1766MO, 1767MO and 1768MO.mp4
Mini oral session – Genitourinary tumours, prostate Invited Discussant 1766MO, 1767MO and 1768MO.pdf
Mini oral session – Genitourinary tumours, prostate Invited Discussant 1771MO, 1772MO, LBA85 and LBA86.mp4
Mini oral session – Genitourinary tumours, prostate Invited Discussant 1771MO, 1772MO, LBA85 and LBA86.pdf
Mini oral session – Genitourinary tumours, prostate LBA85 – Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients.mp4
Mini oral session – Genitourinary tumours, prostate LBA85 – Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients.pdf
Mini oral session – Genitourinary tumours, prostate LBA86 – Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration.mp4
Mini oral session – Genitourinary tumours, prostate LBA86 – Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration.pdf
Mini oral session – Gynaecological cancers 740MO – Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pArEC).mp4
Mini oral session – Gynaecological cancers 740MO – Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pArEC).pdf
Mini oral session – Gynaecological cancers 741MO – Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRà) antibody drug conjugate.mp4
Mini oral session – Gynaecological cancers 741MO – Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRà) antibody drug conjugate.pdf
Mini oral session – Gynaecological cancers 742MO – Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer.mp4
Mini oral session – Gynaecological cancers 742MO – Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer.pdf
Mini oral session – Gynaecological cancers 743MO – Efficacy and safety of QL1706 plus paclitaxel and cisplatin carboplatin +- bevacizumab (Bev).mp4
Mini oral session – Gynaecological cancers 743MO – Efficacy and safety of QL1706 plus paclitaxel and cisplatin carboplatin +- bevacizumab (Bev).pdf
Mini oral session – Gynaecological cancers 744MO – AdvanTIG-202- Phase II randomized, multicenter, open-label study of tislelizumab (TIS).mp4
Mini oral session – Gynaecological cancers 744MO – AdvanTIG-202- Phase II randomized, multicenter, open-label study of tislelizumab (TIS).pdf
Mini oral session – Gynaecological cancers 745MO – Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC).mp4
Mini oral session – Gynaecological cancers 745MO – Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC).pdf
Mini oral session – Gynaecological cancers 746MO – Randomized phase II trial of durvalumab in combination with olaparib and cediranib.mp4
Mini oral session – Gynaecological cancers 746MO – Randomized phase II trial of durvalumab in combination with olaparib and cediranib.pdf
Mini oral session – Gynaecological cancers 747MO – First results from the ENGOT-GYN2 GOG-3051 BOUQUET phase II biomarker-directed platform study.mp4
Mini oral session – Gynaecological cancers 747MO – First results from the ENGOT-GYN2 GOG-3051 BOUQUET phase II biomarker-directed platform study.pdf
Mini oral session – Gynaecological cancers Invited Discussant 743MO, 744MO and LBA44.mp4
Mini oral session – Gynaecological cancers Invited Discussant 743MO, 744MO and LBA44.pdf
Mini oral session – Gynaecological cancers Invited Discussant 745MO and 747MO.mp4
Mini oral session – Gynaecological cancers Invited Discussant 745MO and 747MO.pdf
Mini oral session – Gynaecological cancers Invited Discussant LBA43, 740MO, 742MO and 741MO.mp4
Mini oral session – Gynaecological cancers Invited Discussant LBA43, 740MO, 742MO and 741MO.pdf
Mini oral session – Gynaecological cancers Invited Discussant LBA45 and 746MO.mp4
Mini oral session – Gynaecological cancers Invited Discussant LBA45 and 746MO.pdf
Mini oral session – Gynaecological cancers LBA43 – Updated response data and analysis of progression free survival by mechanism of mismatch.mp4
Mini oral session – Gynaecological cancers LBA43 – Updated response data and analysis of progression free survival by mechanism of mismatch.pdf
Mini oral session – Gynaecological cancers LBA44 – Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice.mp4
Mini oral session – Gynaecological cancers LBA44 – Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice.pdf
Mini oral session – Gynaecological cancers LBA45 – Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib.mp4
Mini oral session – Gynaecological cancers LBA45 – Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib.pdf
Mini oral session – Head and neck cancer 855MO – Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma.mp4
Mini oral session – Head and neck cancer 855MO – Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma.pdf
Mini oral session – Head and neck cancer 856MO – A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT).mp4
Mini oral session – Head and neck cancer 856MO – A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT).pdf
Mini oral session – Head and neck cancer 859MO – Sacituzumab govitecan (SG) in patients (pts) with relapsed refractory (R R) advanced head and neck.mp4
Mini oral session – Head and neck cancer 859MO – Sacituzumab govitecan (SG) in patients (pts) with relapsed refractory (R R) advanced head and neck.pdf
Mini oral session – Head and neck cancer 860MO – MRG003- A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent metastatic nasopharyngeal carcinoma.mp4
Mini oral session – Head and neck cancer 860MO – MRG003- A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent metastatic nasopharyngeal carcinoma.pdf
Mini oral session – Head and neck cancer Invited Discussant 855MO, 856MO and LBA46.mp4
Mini oral session – Head and neck cancer Invited Discussant 855MO, 856MO and LBA46.pdf
Mini oral session – Head and neck cancer Invited Discussant 859MO, 860MO and LBA47.mp4
Mini oral session – Head and neck cancer Invited Discussant 859MO, 860MO and LBA47.pdf
Mini oral session – Head and neck cancer LBA46 – SAKK 11 16, a phase IIa trial evaluating overall survival (OS) for recurrent metastatic Head & neck.mp4
Mini oral session – Head and neck cancer LBA46 – SAKK 11 16, a phase IIa trial evaluating overall survival (OS) for recurrent metastatic Head & neck.pdf
Mini oral session – Head and neck cancer LBA47 – A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study).mp4
Mini oral session – Head and neck cancer LBA47 – A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study).pdf
Mini oral session – Investigational immunotherapy 1020MO – AdvanTIG-203- Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab.mp4
Mini oral session – Investigational immunotherapy 1020MO – AdvanTIG-203- Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab.pdf
Mini oral session – Investigational immunotherapy 1021MO – Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent advanced solid tumors.mp4
Mini oral session – Investigational immunotherapy 1021MO – Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent advanced solid tumors.pdf
Mini oral session – Investigational immunotherapy 1022MO – Predicting overall survival of patients with melanoma and NSCLC treated with immunotherapy.mp4
Mini oral session – Investigational immunotherapy 1022MO – Predicting overall survival of patients with melanoma and NSCLC treated with immunotherapy.pdf
Mini oral session – Investigational immunotherapy 1023MO – Decoding immunotherapy resistance A novel multiparametric magnetic resonance imaging approach to stratify cancer patient outcomes.mp4
Mini oral session – Investigational immunotherapy 1023MO – Decoding immunotherapy resistance A novel multiparametric magnetic resonance imaging approach to stratify cancer patient outcomes.pdf
Mini oral session – Investigational immunotherapy 1024MO – Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate.mp4
Mini oral session – Investigational immunotherapy 1024MO – Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate.pdf
Mini oral session – Investigational immunotherapy 1025MO – Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor.mp4
Mini oral session – Investigational immunotherapy 1025MO – Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor.pdf
Mini oral session – Investigational immunotherapy 1026MO – A phase Ib II study of SHR-1701 (a bifunctional anti-PD-L1 TGF-áRII agent) in combination.mp4
Mini oral session – Investigational immunotherapy 1026MO – A phase Ib II study of SHR-1701 (a bifunctional anti-PD-L1 TGF-áRII agent) in combination.pdf
Mini oral session – Investigational immunotherapy Invited Discussant 1020MO and 1021MO.mp4
Mini oral session – Investigational immunotherapy Invited Discussant 1020MO and 1021MO.pdf
Mini oral session – Investigational immunotherapy Invited Discussant 1022MO, 1023MO and 1024MO.mp4
Mini oral session – Investigational immunotherapy Invited Discussant 1022MO, 1023MO and 1024MO.pdf
Mini oral session – Investigational immunotherapy Invited Discussant 1025MO and 1026MO.mp4
Mini oral session – Investigational immunotherapy Invited Discussant 1025MO and 1026MO.pdf
Mini oral session – Melanoma and other skin tumours 1083MO – Brain metastases and survival evaluation in the SECOMBIT trial.mp4
Mini oral session – Melanoma and other skin tumours 1083MO – Brain metastases and survival evaluation in the SECOMBIT trial.pdf
Mini oral session – Melanoma and other skin tumours 1084MO – Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases.mp4
Mini oral session – Melanoma and other skin tumours 1084MO – Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases.pdf
Mini oral session – Melanoma and other skin tumours 1086MO – Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal.mp4
Mini oral session – Melanoma and other skin tumours 1086MO – Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal.pdf
Mini oral session – Melanoma and other skin tumours 1087MO – A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab.mp4
Mini oral session – Melanoma and other skin tumours 1087MO – A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab.pdf
Mini oral session – Melanoma and other skin tumours 1088MO – A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC) One-year follow-up.mp4
Mini oral session – Melanoma and other skin tumours 1088MO – A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC) One-year follow-up.pdf
Mini oral session – Melanoma and other skin tumours Invited Discussant 1083MO and 1084MO.mp4
Mini oral session – Melanoma and other skin tumours Invited Discussant 1083MO and 1084MO.pdf
Mini oral session – Melanoma and other skin tumours Invited Discussant 1087MO, 1088MO and LBA52.mp4
Mini oral session – Melanoma and other skin tumours Invited Discussant 1087MO, 1088MO and LBA52.pdf
Mini oral session – Melanoma and other skin tumours Invited Discussant LBA50, 1086MO and LBA51.mp4
Mini oral session – Melanoma and other skin tumours Invited Discussant LBA50, 1086MO and LBA51.pdf
Mini oral session – Melanoma and other skin tumours LBA50 – Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial.mp4
Mini oral session – Melanoma and other skin tumours LBA50 – Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial.pdf
Mini oral session – Melanoma and other skin tumours LBA51 – Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma.mp4
Mini oral session – Melanoma and other skin tumours LBA51 – Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma.pdf
Mini oral session – Melanoma and other skin tumours LBA52 – A randomized phase Ib II study of the selective small molecule AXL inhibitor bemcentinib.mp4
Mini oral session – Melanoma and other skin tumours LBA52 – A randomized phase Ib II study of the selective small molecule AXL inhibitor bemcentinib.pdf
Mini oral session – NETs and endocrine tumours 1183MO – Molecular characterization of rectal neuroendocrine tumors (NETs) with unfavorable.mp4
Mini oral session – NETs and endocrine tumours 1183MO – Molecular characterization of rectal neuroendocrine tumors (NETs) with unfavorable.pdf
Mini oral session – NETs and endocrine tumours 1184MO – Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3).mp4
Mini oral session – NETs and endocrine tumours 1184MO – Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3).pdf
Mini oral session – NETs and endocrine tumours 1185MO – Activity and safety of avelumab alone or in combination with cabozantinib in patients.mp4
Mini oral session – NETs and endocrine tumours 1185MO – Activity and safety of avelumab alone or in combination with cabozantinib in patients.pdf
Mini oral session – NETs and endocrine tumours 1186MO – A prospective phase II single-arm trial on neoadjuvant peptide receptor radionuclide therapy.mp4
Mini oral session – NETs and endocrine tumours 1186MO – A prospective phase II single-arm trial on neoadjuvant peptide receptor radionuclide therapy.pdf
Mini oral session – NETs and endocrine tumours 1187MO – Does the ENDOCAN-COMETE network improves the survival of adrenocortical carcinomas in France.mp4
Mini oral session – NETs and endocrine tumours 1187MO – Does the ENDOCAN-COMETE network improves the survival of adrenocortical carcinomas in France.pdf
Mini oral session – NETs and endocrine tumours 2211MO – Uncovering the mechanisms of persistent disease in RET-altered thyroid cancers.mp4
Mini oral session – NETs and endocrine tumours 2211MO – Uncovering the mechanisms of persistent disease in RET-altered thyroid cancers.pdf
Mini oral session – NETs and endocrine tumours 2212MO – Major secondary outcomes in the multicentre noninferiority randomised trial IoN.mp4
Mini oral session – NETs and endocrine tumours 2212MO – Major secondary outcomes in the multicentre noninferiority randomised trial IoN.pdf
Mini oral session – NETs and endocrine tumours 725MO – Phase I trial of the DLL3 CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours.mp4
Mini oral session – NETs and endocrine tumours 725MO – Phase I trial of the DLL3 CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours.pdf
Mini oral session – NETs and endocrine tumours Invited Discussant 1184MO, 1185MO and 725MO.mp4
Mini oral session – NETs and endocrine tumours Invited Discussant 1184MO, 1185MO and 725MO.pdf
Mini oral session – NETs and endocrine tumours Invited Discussant 1186MO, 2212MO and 1187MO.mp4
Mini oral session – NETs and endocrine tumours Invited Discussant 1186MO, 2212MO and 1187MO.pdf
Mini oral session – NETs and endocrine tumours Invited Discussant 2211MO and 1183MO.mp4
Mini oral session – NETs and endocrine tumours Invited Discussant 2211MO and 1183MO.pdf
Mini oral session – Policy and preventive strategies 1692MO – Is project Orbis successful The Swiss perspective.mp4
Mini oral session – Policy and preventive strategies 1692MO – Is project Orbis successful The Swiss perspective.pdf
Mini oral session – Policy and preventive strategies 1693MO – The high burden of long-term and late health-related problems among adolescent and young adult.mp4
Mini oral session – Policy and preventive strategies 1693MO – The high burden of long-term and late health-related problems among adolescent and young adult.pdf
Mini oral session – Policy and preventive strategies 1694MO – Socio-economic consequences among adolescent and young adult cancer patients.mp4
Mini oral session – Policy and preventive strategies 1694MO – Socio-economic consequences among adolescent and young adult cancer patients.pdf
Mini oral session – Policy and preventive strategies 1695MO – Cancer care during armed conflict- Factors associated with adult patient transfer for treatment abroad during the war in Ukraine.mp4
Mini oral session – Policy and preventive strategies 1695MO – Cancer care during armed conflict- Factors associated with adult patient transfer for treatment abroad during the war in Ukraine.pdf
Mini oral session – Policy and preventive strategies 1696MO – Partial orphan cancer drugs- FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending.mp4
Mini oral session – Policy and preventive strategies 1696MO – Partial orphan cancer drugs- FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending.pdf
Mini oral session – Policy and preventive strategies 1697MO – Spending on and beneficiaries of orphan cancer drugs for ultra-rare, rare, and common diseases.mp4
Mini oral session – Policy and preventive strategies 1697MO – Spending on and beneficiaries of orphan cancer drugs for ultra-rare, rare, and common diseases.pdf
Mini oral session – Policy and preventive strategies 1698MO – E-cigarette use among us ever-smoking cancer survivors and its implications on lung cancer screening.mp4
Mini oral session – Policy and preventive strategies 1698MO – E-cigarette use among us ever-smoking cancer survivors and its implications on lung cancer screening.pdf
Mini oral session – Policy and preventive strategies 1699MO – Intervening factors for participation and non-participation in colorectal cancer screening in Spain.mp4
Mini oral session – Policy and preventive strategies 1699MO – Intervening factors for participation and non-participation in colorectal cancer screening in Spain.pdf
Mini oral session – Policy and preventive strategies 1700MO – Knowledge of cancer risk factors and risk-reduction in 20 high- and middle-income countries.pdf
Mini oral session – Policy and preventive strategies 1759MO – Clinical breast examination for early diagnosis of breast cancer- An Egyptian nationwide study.mp4
Mini oral session – Policy and preventive strategies 1759MO – Clinical breast examination for early diagnosis of breast cancer- An Egyptian nationwide study.pdf
Mini oral session – Policy and preventive strategies Invited Discussant 1692MO, 1693MO, 1694MO and 1695MO.mp4
Mini oral session – Policy and preventive strategies Invited Discussant 1692MO, 1693MO, 1694MO and 1695MO.pdf
Mini oral session – Policy and preventive strategies Invited Discussant 1698MO, 1699MO and 1700MO.mp4
Mini oral session – Policy and preventive strategies Invited Discussant 1698MO, 1699MO and 1700MO.pdf
Mini oral session – Policy and preventive strategies Invited Discussant 1759MO, 1696MO and 1697MO.mp4
Mini oral session – Policy and preventive strategies Invited Discussant 1759MO, 1696MO and 1697MO.pdf
Mini oral session – Sarcoma 1914MO – The clinico-radiological outcome of desmoid type-fibromatosis after discontinuing the sorafenib.mp4
Mini oral session – Sarcoma 1914MO – The clinico-radiological outcome of desmoid type-fibromatosis after discontinuing the sorafenib.pdf
Mini oral session – Sarcoma 1915MO – Fear, anxiety and depression in gastrointestinal stromal tumor (GIST).mp4
Mini oral session – Sarcoma 1915MO – Fear, anxiety and depression in gastrointestinal stromal tumor (GIST).pdf
Mini oral session – Sarcoma 1916MO – A first-in-human phase I trial of NB003, a potent and selective KIT PDGFRa inhibitor.mp4
Mini oral session – Sarcoma 1916MO – A first-in-human phase I trial of NB003, a potent and selective KIT PDGFRa inhibitor.pdf
Mini oral session – Sarcoma 1917MO – CHAPTER-GIST-101- A phase I study of pimitespib combined with imatinib in patients.mp4
Mini oral session – Sarcoma 1917MO – CHAPTER-GIST-101- A phase I study of pimitespib combined with imatinib in patients.pdf
Mini oral session – Sarcoma 1918MO – Circulating tumor DNA in relation to tumor volume in gastro-intestinal stromal tumors.mp4
Mini oral session – Sarcoma 1918MO – Circulating tumor DNA in relation to tumor volume in gastro-intestinal stromal tumors.pdf
Mini oral session – Sarcoma 1919MO – Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma.mp4
Mini oral session – Sarcoma 1919MO – Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma.pdf
Mini oral session – Sarcoma 1920MO – Regomune- A phase II study of regorafenib + avelumab in solid tumors – Results of the advanced.mp4
Mini oral session – Sarcoma 1920MO – Regomune- A phase II study of regorafenib + avelumab in solid tumors – Results of the advanced.pdf
Mini oral session – Sarcoma 1921MO – Patterns of care, outcome and molecular landscape of PATZ1-rearranged sarcomas identifies.mp4
Mini oral session – Sarcoma 1921MO – Patterns of care, outcome and molecular landscape of PATZ1-rearranged sarcomas identifies.pdf
Mini oral session – Sarcoma Invited Discussant 1914MO and 1915MO.mp4
Mini oral session – Sarcoma Invited Discussant 1914MO and 1915MO.pdf
Mini oral session – Sarcoma Invited Discussant 1916MO, 1917MO and 1918MO.mp4
Mini oral session – Sarcoma Invited Discussant 1916MO, 1917MO and 1918MO.pdf
Mini oral session – Sarcoma Invited Discussant 1919MO, 1920MO and 1921MO.mp4
Mini oral session – Sarcoma Invited Discussant 1919MO, 1920MO and 1921MO.pdf
Mini oral session – Supportive and palliative care 1592MO – Anticancer therapy at the end-of-life- A cluster-randomized trial.mp4
Mini oral session – Supportive and palliative care 1592MO – Anticancer therapy at the end-of-life- A cluster-randomized trial.pdf
Mini oral session – Supportive and palliative care 1593MO – Combined early palliative care in patients with non small cell lung cancer.mp4
Mini oral session – Supportive and palliative care 1593MO – Combined early palliative care in patients with non small cell lung cancer.pdf
Mini oral session – Supportive and palliative care 1843MO – The effect of chronic psychological stress on the efficacy of first-line therapy of ICIs in advanced NSCLC (STRESS-LUNG-1 trial).mp4
Mini oral session – Supportive and palliative care 1843MO – The effect of chronic psychological stress on the efficacy of first-line therapy of ICIs in advanced NSCLC (STRESS-LUNG-1 trial).pdf
Mini oral session – Supportive and palliative care 1844MO – Association of peripheral blood leukocyte DNA methylation profiles with the development of depressive.mp4
Mini oral session – Supportive and palliative care 1844MO – Association of peripheral blood leukocyte DNA methylation profiles with the development of depressive.pdf
Mini oral session – Supportive and palliative care 2032MO – Correlation of safety and efficacy in atezolizumab therapy across indications.mp4
Mini oral session – Supportive and palliative care 2032MO – Correlation of safety and efficacy in atezolizumab therapy across indications.pdf
Mini oral session – Supportive and palliative care 2033MO – The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor.mp4
Mini oral session – Supportive and palliative care 2033MO – The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor.pdf
Mini oral session – Supportive and palliative care 2034MO – EAGER- A randomized, controlled, multicenter trial of electro-acupuncture in gastric cancer patients.mp4
Mini oral session – Supportive and palliative care 2034MO – EAGER- A randomized, controlled, multicenter trial of electro-acupuncture in gastric cancer patients.pdf
Mini oral session – Supportive and palliative care Invited Discussant 1592MO, 1593MO and 2034MO.mp4
Mini oral session – Supportive and palliative care Invited Discussant 1592MO, 1593MO and 2034MO.pdf
Mini oral session – Supportive and palliative care Invited Discussant 2032MO, 1843MO, 2033MO.mp4
Mini oral session – Supportive and palliative care Invited Discussant 2032MO, 1843MO, 2033MO.pdf
Mini oral session – Supportive and palliative care Invited Discussant LBA96, LBA97 and 1844MO.mp4
Mini oral session – Supportive and palliative care Invited Discussant LBA96, LBA97 and 1844MO.pdf
Mini oral session – Supportive and palliative care LBA96 – Roxadustat for chemotherapy-induced anemia in patients with non-myeloid malignancies.mp4
Mini oral session – Supportive and palliative care LBA96 – Roxadustat for chemotherapy-induced anemia in patients with non-myeloid malignancies.pdf
Mini oral session – Supportive and palliative care LBA97 – Olanzapine for the prevention of chemotherapy induced nausea vomiting in patients receiving.mp4
Mini oral session – Supportive and palliative care LBA97 – Olanzapine for the prevention of chemotherapy induced nausea vomiting in patients receiving.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive 1512MO – Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive 1512MO – Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive 1513MO – A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive 1513MO – A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive 945MO – AdvanTIG-206 Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive 945MO – AdvanTIG-206 Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive 94MO – Advanced extrahepatic cholangiocarcinoma- Post-hoc analysis of the ABC-01, -02 and -03 clinical trials.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive 94MO – Advanced extrahepatic cholangiocarcinoma- Post-hoc analysis of the ABC-01, -02 and -03 clinical trials.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive 95MO – Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive 95MO – Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant 945MO, 94MO and 95MO.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant 945MO, 94MO and 95MO.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA78 and 1512MO.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA78 and 1512MO.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA79, LBA80 and 1513MO.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA79, LBA80 and 1513MO.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA81 and LBA82.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA81 and LBA82.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA78 – Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA78 – Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA79 – GEMSTONE-303- Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA79 – GEMSTONE-303- Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA80 – Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA80 – Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA81 – Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA81 – Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line.pdf
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA82 – Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab.mp4
Mini oral session 1 – Gastrointestinal tumours, upper digestive LBA82 – Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab.pdf
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1262MO – Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely.mp4
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1262MO – Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely.pdf
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1263MO – The impact of PET-CT and brain MRI for metastasis detection among patients with T1-stage lung cancer.mp4
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1263MO – The impact of PET-CT and brain MRI for metastasis detection among patients with T1-stage lung cancer.pdf
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1988MO – Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell.mp4
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1988MO – Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell.pdf
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1989MO – Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC).mp4
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1989MO – Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC).pdf
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1990MO – Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC).mp4
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies 1990MO – Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC).pdf
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant 1262MO and 1263MO.mp4
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant 1262MO and 1263MO.pdf
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant 1988MO, 1989MO and 1990MO.mp4
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant 1988MO, 1989MO and 1990MO.pdf
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA99 and LBA93.mp4
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA99 and LBA93.pdf
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies LBA93 – EXTENTORCH- A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy.mp4
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies LBA93 – EXTENTORCH- A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy.pdf
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies LBA99 – First survival data from the NIPU trial- A randomised, open-label, phase II study evaluating.mp4
Mini oral session 1 – Non-metastatic NSCLC and other thoracic malignancies LBA99 – First survival data from the NIPU trial- A randomised, open-label, phase II study evaluating.pdf
Mini oral session 1 – NSCLC, metastatic 1312MO – Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab.mp4
Mini oral session 1 – NSCLC, metastatic 1312MO – Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab.pdf
Mini oral session 1 – NSCLC, metastatic 1313MO – Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patient.mp4
Mini oral session 1 – NSCLC, metastatic 1313MO – Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patient.pdf
Mini oral session 1 – NSCLC, metastatic 1314MO – TROPION-Lung05- Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer.mp4
Mini oral session 1 – NSCLC, metastatic 1314MO – TROPION-Lung05- Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer.pdf
Mini oral session 1 – NSCLC, metastatic 1315MO – Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive.mp4
Mini oral session 1 – NSCLC, metastatic 1315MO – Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive.pdf
Mini oral session 1 – NSCLC, metastatic 1316MO – BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer.mp4
Mini oral session 1 – NSCLC, metastatic 1316MO – BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer.pdf
Mini oral session 1 – NSCLC, metastatic Invited Discussant 1312MO and 1313MO.mp4
Mini oral session 1 – NSCLC, metastatic Invited Discussant 1312MO and 1313MO.pdf
Mini oral session 1 – NSCLC, metastatic Invited Discussant 1314MO, 1315MO and 1316MO.mp4
Mini oral session 1 – NSCLC, metastatic Invited Discussant 1314MO, 1315MO and 1316MO.pdf
Mini oral session 1 – NSCLC, metastatic Invited Discussant LBA68 and LBA69.mp4
Mini oral session 1 – NSCLC, metastatic Invited Discussant LBA68 and LBA69.pdf
Mini oral session 1 – NSCLC, metastatic Invited Discussant LBA70 and LBA71.mp4
Mini oral session 1 – NSCLC, metastatic Invited Discussant LBA70 and LBA71.pdf
Mini oral session 1 – NSCLC, metastatic LBA68 – FLAURA2- Safety and CNS outcomes of first-line (1L) osimertinib (osi) ñ chemotherapy (CTx) in EGFRm advanced NSCLC.mp4
Mini oral session 1 – NSCLC, metastatic LBA68 – FLAURA2- Safety and CNS outcomes of first-line (1L) osimertinib (osi) ñ chemotherapy (CTx) in EGFRm advanced NSCLC.pdf
Mini oral session 1 – NSCLC, metastatic LBA69 – Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation.mp4
Mini oral session 1 – NSCLC, metastatic LBA69 – Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation.pdf
Mini oral session 1 – NSCLC, metastatic LBA70 – OSIRAM-1- A multicenter, open label, randomized phase II study of osimertinib plus.mp4
Mini oral session 1 – NSCLC, metastatic LBA70 – OSIRAM-1- A multicenter, open label, randomized phase II study of osimertinib plus.pdf
Mini oral session 1 – NSCLC, metastatic LBA71 – A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab.mp4
Mini oral session 1 – NSCLC, metastatic LBA71 – A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab.pdf
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 1264MO – IMpower010- Exploratory analysis of disease-free survival (DFS) by TGFá cancer-associated fibroblast.mp4
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 1264MO – IMpower010- Exploratory analysis of disease-free survival (DFS) by TGFá cancer-associated fibroblast.pdf
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 1292MO – A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III.mp4
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 1292MO – A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III.pdf
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 1293MO – Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus.mp4
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 1293MO – Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus.pdf
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA57, 1264MO, LBA58 and LBA59.mp4
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA57, 1264MO, LBA58 and LBA59.pdf
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA61, 1292MO, LBA62 and 1293MO.mp4
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA61, 1292MO, LBA62 and 1293MO.pdf
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA57 – Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study- 3-y results by tumor PD-L1 expression.mp4
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA57 – Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study- 3-y results by tumor PD-L1 expression.pdf
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA58 – Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb).mp4
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA58 – Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb).pdf
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA59 – Associations of ctDNA clearance and pathological response with neoadjuvant treatment.mp4
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA59 – Associations of ctDNA clearance and pathological response with neoadjuvant treatment.pdf
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA61 – Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with.mp4
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA61 – Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with.pdf
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA62 – Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy.mp4
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies LBA62 – Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy.pdf
Mini oral session 2 – NSCLC, metastatic 1317MO – Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts).mp4
Mini oral session 2 – NSCLC, metastatic 1317MO – Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts).pdf
Mini oral session 2 – NSCLC, metastatic 1318MO – First-in-human study of ABBV-637, an EGFR-targeting BCL-XL-inhibiting antibody-drug conjugate.mp4
Mini oral session 2 – NSCLC, metastatic 1318MO – First-in-human study of ABBV-637, an EGFR-targeting BCL-XL-inhibiting antibody-drug conjugate.pdf
Mini oral session 2 – NSCLC, metastatic 1319MO – Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC- Results from HERTHENA-Lung01.mp4
Mini oral session 2 – NSCLC, metastatic 1319MO – Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC- Results from HERTHENA-Lung01.pdf
Mini oral session 2 – NSCLC, metastatic 1320MO – Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2.mp4
Mini oral session 2 – NSCLC, metastatic 1320MO – Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2.pdf
Mini oral session 2 – NSCLC, metastatic 1321MO – Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic.mp4
Mini oral session 2 – NSCLC, metastatic 1321MO – Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic.pdf
Mini oral session 2 – NSCLC, metastatic 1322MO – Insights into tumour dissemination and progression using longitudinal Imaging and ctDNA in the TRACERx lung cancer study.mp4
Mini oral session 2 – NSCLC, metastatic 1322MO – Insights into tumour dissemination and progression using longitudinal Imaging and ctDNA in the TRACERx lung cancer study.pdf
Mini oral session 2 – NSCLC, metastatic 1323MO – Immune evasion across space and time in patients with lung cancer enrolled in the PEACE autopsy study.mp4
Mini oral session 2 – NSCLC, metastatic 1323MO – Immune evasion across space and time in patients with lung cancer enrolled in the PEACE autopsy study.pdf
Mini oral session 2 – NSCLC, metastatic 1324MO – CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC- A LASER301 subset analysis.mp4
Mini oral session 2 – NSCLC, metastatic 1324MO – CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC- A LASER301 subset analysis.pdf
Mini oral session 2 – NSCLC, metastatic Invited Discussant 1317MO, 1318MO and 1320MO.mp4
Mini oral session 2 – NSCLC, metastatic Invited Discussant 1317MO, 1318MO and 1320MO.pdf
Mini oral session 2 – NSCLC, metastatic Invited Discussant 1319MO, 1321MO and 1324MO.mp4
Mini oral session 2 – NSCLC, metastatic Invited Discussant 1319MO, 1321MO and 1324MO.pdf
Mini oral session 2 – NSCLC, metastatic Invited Discussant 1322MO, LBA72 and 1323MO.mp4
Mini oral session 2 – NSCLC, metastatic Invited Discussant 1322MO, LBA72 and 1323MO.pdf
Mini oral session 2 – NSCLC, metastatic LBA72 – DARWIN II Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC.mp4
Mini oral session 2 – NSCLC, metastatic LBA72 – DARWIN II Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC.pdf
Mini oral session CNS tumours 502MO – Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma.mp4
Mini oral session CNS tumours 502MO – Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma.pdf
Mini oral session CNS tumours 503MO – Real-world clinical and genomic characterization of gliomas- Predictive and prognostic insights.mp4
Mini oral session CNS tumours 503MO – Real-world clinical and genomic characterization of gliomas- Predictive and prognostic insights.pdf
Mini oral session CNS tumours 504MO – Validation of a spectroscopic liquid biopsy for the earlier detection of brain cancer.mp4
Mini oral session CNS tumours 504MO – Validation of a spectroscopic liquid biopsy for the earlier detection of brain cancer.pdf
Mini oral session CNS tumours 505MO – A phase 0 Ib study of AZD1390 plus radiotherapy in recurrent glioblastoma patients.mp4
Mini oral session CNS tumours 505MO – A phase 0 Ib study of AZD1390 plus radiotherapy in recurrent glioblastoma patients.pdf
Mini oral session CNS tumours 506MO – A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR).mp4
Mini oral session CNS tumours 506MO – A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR).pdf
Mini oral session CNS tumours 507MO – REGOMA-OS- A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients.mp4
Mini oral session CNS tumours 507MO – REGOMA-OS- A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients.pdf
Mini oral session CNS tumours 508MO – Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition.mp4
Mini oral session CNS tumours 508MO – Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition.pdf
Mini oral session CNS tumours Invited Discussant 502MO, 503MO and 504MO.mp4
Mini oral session CNS tumours Invited Discussant 502MO, 503MO and 504MO.pdf
Mini oral session CNS tumours Invited Discussant 505MO and 506MO.mp4
Mini oral session CNS tumours Invited Discussant 505MO and 506MO.pdf
Mini oral session CNS tumours Invited Discussant 507MO and 508MO.mp4
Mini oral session CNS tumours Invited Discussant 507MO and 508MO.pdf
Mini oral session Developmental therapeutics 657MO – Recommended phase II dose (RP2D) selection and pharmacodynamic (PD).mp4
Mini oral session Developmental therapeutics 657MO – Recommended phase II dose (RP2D) selection and pharmacodynamic (PD).pdf
Mini oral session Developmental therapeutics 658MO – Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors.mp4
Mini oral session Developmental therapeutics 658MO – Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors.pdf
Mini oral session Developmental therapeutics 659MO – Preliminary results from a phase I II study of 9MW2821.mp4
Mini oral session Developmental therapeutics 659MO – Preliminary results from a phase I II study of 9MW2821.pdf
Mini oral session Developmental therapeutics 660MO – First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC.mp4
Mini oral session Developmental therapeutics 660MO – First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC.pdf
Mini oral session Developmental therapeutics 661MO – Anti-tumor activity of belvarafenib in combination with cobimetinib in patients.mp4
Mini oral session Developmental therapeutics 661MO – Anti-tumor activity of belvarafenib in combination with cobimetinib in patients.pdf
Mini oral session Developmental therapeutics 662MO – Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068.mp4
Mini oral session Developmental therapeutics 662MO – Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068.pdf
Mini oral session Developmental therapeutics Invited Discussant 656MO, 657MO, LBA34 and 658MO.mp4
Mini oral session Developmental therapeutics Invited Discussant 656MO, 657MO, LBA34 and 658MO.pdf
Mini oral session Developmental therapeutics Invited Discussant 659MO and 660MO.mp4
Mini oral session Developmental therapeutics Invited Discussant 659MO and 660MO.pdf
Mini oral session Developmental therapeutics Invited Discussant LBA35, 661MO and 662MO.mp4
Mini oral session Developmental therapeutics Invited Discussant LBA35, 661MO and 662MO.pdf
Mini oral session Developmental therapeutics LBA34 – Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors.mp4
Mini oral session Developmental therapeutics LBA34 – Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors.pdf
Mini oral session Developmental therapeutics LBA35 – BNT211-01- Interim results from a repeat dose escalation study of CLDN6 CAR-T cells.mp4
Mini oral session Developmental therapeutics LBA35 – BNT211-01- Interim results from a repeat dose escalation study of CLDN6 CAR-T cells.pdf
Mini oral session Developmental therapeutics The HER2-targeting ADC SHR-A1811 in HER2-expressing mutated.mp4
Mini oral session Developmental therapeutics The HER2-targeting ADC SHR-A1811 in HER2-expressing mutated.pdf
Molecular evolution of brain metastases and therapeutic implications Discussion led by Chair.mp4
Molecular evolution of brain metastases and therapeutic implications Discussion led by Chair.pdf
Molecular evolution of brain metastases and therapeutic implications Presentation by Expert.mp4
Molecular evolution of brain metastases and therapeutic implications Presentation by Expert.pdf
Molecular profiling of gynaecological cancers for therapeutic stratification Cervical cancer.mp4
Molecular profiling of gynaecological cancers for therapeutic stratification Cervical cancer.pdf
Molecular profiling of gynaecological cancers for therapeutic stratification Conclusions and perspectives.mp4
Molecular profiling of gynaecological cancers for therapeutic stratification Discussion.mp4
Molecular profiling of gynaecological cancers for therapeutic stratification Discussion.pdf
Molecular profiling of gynaecological cancers for therapeutic stratification Endometrial cancer.mp4
Molecular profiling of gynaecological cancers for therapeutic stratification Endometrial cancer.pdf
Molecular profiling of gynaecological cancers for therapeutic stratification Introduction and scientific background.mp4
Molecular profiling of gynaecological cancers for therapeutic stratification Introduction and scientific background.pdf
Molecular profiling of gynaecological cancers for therapeutic stratification Molecular profiling of gynaecological cancers A pathologist’s view.mp4
Molecular profiling of gynaecological cancers for therapeutic stratification Molecular profiling of gynaecological cancers A pathologist’s view.pdf
Molecular profiling of gynaecological cancers for therapeutic stratification Ovarian and rare gynaecological cancers.mp4
Molecular profiling of gynaecological cancers for therapeutic stratification Ovarian and rare gynaecological cancers.pdf
Molecular targets and related treatments Checkpoint inhibitors and Pi3K inhibitors.mp4
Molecular targets and related treatments Checkpoint inhibitors and Pi3K inhibitors.pdf
Molecular targets and related treatments Discussion.mp4
Molecular targets and related treatments Discussion.pdf
Molecular targets and related treatments How to interpret a genomic testing report.mp4
Molecular targets and related treatments How to interpret a genomic testing report.pdf
Molecular targets and related treatments PARP inhibition.mp4
Molecular targets and related treatments PARP inhibition.pdf
Molecular targets and related treatments PSMA targeting.mp4
Molecular targets and related treatments PSMA targeting.pdf
Molecular targets and related treatments Third generation AR targeting.mp4
Molecular targets and related treatments Third generation AR targeting.pdf
More intelligent trial design Conclusions and perspectives.mp4
More intelligent trial design Conclusions and perspectives.pdf
More intelligent trial design De-escalation trials.mp4
More intelligent trial design De-escalation trials.pdf
More intelligent trial design Discussion.mp4
More intelligent trial design Discussion.pdf
More intelligent trial design Introduction and scientific background.mp4
More intelligent trial design Introduction and scientific background.pdf
More intelligent trial design Multi-arm multi-stage (MAMS) trials.mp4
More intelligent trial design Multi-arm multi-stage (MAMS) trials.pdf
More intelligent trial design Pragmatic trials.mp4
More intelligent trial design Pragmatic trials.pdf
More intelligent trial design Trials in low-and middle-income countries (LMIC).mp4
More intelligent trial design Trials in low-and middle-income countries (LMIC).pdf
Neoadjuvant and adjuvant therapy in genitourinary cancers Discussion.mp4
Neoadjuvant and adjuvant therapy in genitourinary cancers Discussion.pdf
Neoadjuvant and adjuvant therapy in genitourinary cancers Global access considerations in systemic treatment of genitourinary cancers.mp4
Neoadjuvant and adjuvant therapy in genitourinary cancers Global access considerations in systemic treatment of genitourinary cancers.pdf
Neoadjuvant and adjuvant therapy in genitourinary cancers Interpretation of current peri-operative trial designs and endpoints.mp4
Neoadjuvant and adjuvant therapy in genitourinary cancers Interpretation of current peri-operative trial designs and endpoints.pdf
Neoadjuvant and adjuvant therapy in genitourinary cancers State-of-the-art in adjuvant treatment of renal cell carcinoma.mp4
Neoadjuvant and adjuvant therapy in genitourinary cancers State-of-the-art in adjuvant treatment of renal cell carcinoma.pdf
Neoadjuvant and adjuvant therapy in genitourinary cancers State-of-the-art in adjuvant treatment of urothelial cancer.mp4
Neoadjuvant and adjuvant therapy in genitourinary cancers State-of-the-art in adjuvant treatment of urothelial cancer.pdf
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Brain metastases- When radiation is (not!) indicated.mp4
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Brain metastases- When radiation is (not!) indicated.pdf
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Glioma beyond TMZ RT.mp4
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Glioma beyond TMZ RT.pdf
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Q&A and Discussion.mp4
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Supportive care- Antiepileptics, steroids and anticoagulation.mp4
Neuro-Oncology 101- All you need to know to take care of brain tumour patients Supportive care- Antiepileptics, steroids and anticoagulation.pdf
Neuro-Oncology 101- All you need to know to take care of brain tumour patients WHO classification simplified for the busy clinician.mp4
Neuro-Oncology 101- All you need to know to take care of brain tumour patients WHO classification simplified for the busy clinician.pdf
New approaches for technologies, therapies, and surgery Discussion.mp4
New approaches for technologies, therapies, and surgery Discussion.pdf
New approaches for technologies, therapies, and surgery How to decide which mutation to investigate and invest in.mp4
New approaches for technologies, therapies, and surgery How to decide which mutation to investigate and invest in.pdf
New approaches for technologies, therapies, and surgery Identification of new biomarkers in lung cancer.mp4
New approaches for technologies, therapies, and surgery Identification of new biomarkers in lung cancer.pdf
New approaches for technologies, therapies, and surgery Radiation therapies- How do proton beam therapy, stereotactic radiosurgery and gamma knife surgery treat cancer.mp4
New approaches for technologies, therapies, and surgery Radiation therapies- How do proton beam therapy, stereotactic radiosurgery and gamma knife surgery treat cancer.pdf
New approaches for technologies, therapies, and surgery Surgical therapies- What are the new robotic models and how do they support efficient processes in clinical settings.mp4
New approaches for technologies, therapies, and surgery Surgical therapies- What are the new robotic models and how do they support efficient processes in clinical settings.pdf
New mechanisms and drugs for the treatment of patients with sarcomas Conclusions and perspectives.mp4
New mechanisms and drugs for the treatment of patients with sarcomas Discussion.mp4
New mechanisms and drugs for the treatment of patients with sarcomas Discussion.pdf
New mechanisms and drugs for the treatment of patients with sarcomas Introduction and scientific background.mp4
New mechanisms and drugs for the treatment of patients with sarcomas Introduction and scientific background.pdf
New mechanisms and drugs for the treatment of patients with sarcomas Multi-facets of antiangiogenic agents.mp4
New mechanisms and drugs for the treatment of patients with sarcomas Multi-facets of antiangiogenic agents.pdf
New mechanisms and drugs for the treatment of patients with sarcomas Novel combinations.mp4
New mechanisms and drugs for the treatment of patients with sarcomas Novel combinations.pdf
New mechanisms and drugs for the treatment of patients with sarcomas Targeting proapoptotic pathways- MDM2 and beyond.mp4
New mechanisms and drugs for the treatment of patients with sarcomas Targeting proapoptotic pathways- MDM2 and beyond.pdf
New targets on the horizon Conclusions and perspectives.mp4
New targets on the horizon Conclusions and perspectives.pdf
New targets on the horizon Discussion.mp4
New targets on the horizon Discussion.pdf
New targets on the horizon Innovative novel delivery of immunotherapeutics.mp4
New targets on the horizon Innovative novel delivery of immunotherapeutics.pdf
New targets on the horizon Introduction and scientific background.mp4
New targets on the horizon Introduction and scientific background.pdf
New targets on the horizon Mutant specific inhibitors.mp4
New targets on the horizon Mutant specific inhibitors.pdf
New targets on the horizon Peptide-based cancer vaccines.mp4
New targets on the horizon Peptide-based cancer vaccines.pdf
New targets on the horizon POLTheta inhibitors and USP1 inhibitors for BRCA-deficient cancers.mp4
New targets on the horizon POLTheta inhibitors and USP1 inhibitors for BRCA-deficient cancers.pdf
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Conclusions and perspectives.mp4
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Discussion.mp4
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Discussion.pdf
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Drug sensitivity testing in blood cancer.mp4
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Drug sensitivity testing in blood cancer.pdf
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing How novel profiling methods impact trial design.mp4
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing How novel profiling methods impact trial design.pdf
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Introduction and scientific background.mp4
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Introduction and scientific background.pdf
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Liquid biopsy in lymphoma.mp4
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Liquid biopsy in lymphoma.pdf
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Multi-omic profiling in lymphoid neoplasms.mp4
Next generation diagnostics of blood cancer- An optimistic view on the future of cancer testing Multi-omic profiling in lymphoid neoplasms.pdf
Novel targets, therapies and toxicities in genitourinary cancers Advances in the molecular understanding of GU cancers- The next generation of therapeutic targets.mp4
Novel targets, therapies and toxicities in genitourinary cancers Advances in the molecular understanding of GU cancers- The next generation of therapeutic targets.pdf
Novel targets, therapies and toxicities in genitourinary cancers Antibody drug conjugates and FGFR-directed therapies- New toxicities.mp4
Novel targets, therapies and toxicities in genitourinary cancers Antibody drug conjugates and FGFR-directed therapies- New toxicities.pdf
Novel targets, therapies and toxicities in genitourinary cancers Conclusions and perspectives.mp4
Novel targets, therapies and toxicities in genitourinary cancers Conclusions and perspectives.pdf
Novel targets, therapies and toxicities in genitourinary cancers Discussion.mp4
Novel targets, therapies and toxicities in genitourinary cancers Discussion.pdf
Novel targets, therapies and toxicities in genitourinary cancers Introduction and scientific background.mp4
Novel targets, therapies and toxicities in genitourinary cancers Introduction and scientific background.pdf
Novel targets, therapies and toxicities in genitourinary cancers Prediction of toxicity in current systemic treatment of genitourinary cancers.mp4
Novel targets, therapies and toxicities in genitourinary cancers Prediction of toxicity in current systemic treatment of genitourinary cancers.pdf
Novel targets, therapies and toxicities in genitourinary cancers Screening new agents in “window of opportunity” neoadjuvant trials.mp4
Novel targets, therapies and toxicities in genitourinary cancers Screening new agents in “window of opportunity” neoadjuvant trials.pdf
Novocure GmbH – The evolving role of TTFields therapy in solid tumors Bringing change with TTFields therapy in ovarian cancer.mp4
Novocure GmbH – The evolving role of TTFields therapy in solid tumors Evolving role of TTFields therapy in NSCLC.mp4
Novocure GmbH – The evolving role of TTFields therapy in solid tumors Fireside chat.mp4
Novocure GmbH – The evolving role of TTFields therapy in solid tumors Practice changing experience of TTFields therapy in Glioblastoma.mp4
Novocure GmbH – The evolving role of TTFields therapy in solid tumors Welcome.mp4
Oncology drug trials- How can we bring true value for patients Challenges, pitfalls and the way forward- Investigator’s perspective.mp4
Oncology drug trials- How can we bring true value for patients Challenges, pitfalls and the way forward- Investigator’s perspective.pdf
Oncology drug trials- How can we bring true value for patients Clinical trials in oncology- What really matters to patients..mp4
Oncology drug trials- How can we bring true value for patients Clinical trials in oncology- What really matters to patients.pdf
Oncology drug trials- How can we bring true value for patients Q&A and Discussion.mp4
Oncology drug trials- How can we bring true value for patients Q&A and Discussion.pdf
Oncology drug trials- How can we bring true value for patients Walking the tightrope without losing sight of the patient.mp4
Oncology drug trials- How can we bring true value for patients Walking the tightrope without losing sight of the patient.pdf
Oncology drug trials- How can we bring true value for patients “Value” and what it really means for new cancer drugs.mp4
Oncology drug trials- How can we bring true value for patients “Value” and what it really means for new cancer drugs.pdf
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Conclusions and perspectives.mp4
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Discussion.mp4
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Discussion.pdf
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Duration of IO treatment.mp4
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Duration of IO treatment.pdf
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge How to overcome IO resistance- New approaches.mp4
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge How to overcome IO resistance- New approaches.pdf
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Immunotherapy re-challenge- Who, when and why.mp4
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Immunotherapy re-challenge- Who, when and why.pdf
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Introduction and scientific background.mp4
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge Introduction and scientific background.pdf
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge When and how to combine PD-1 PD-L1.mp4
Open questions in immunotherapy for advanced NSCLC- Duration of IO, combinations and rechallenge When and how to combine PD-1 PD-L1.pdf
Open questions in the management of mesothelioma Biomarker-selected therapy- Progress or delusion.mp4
Open questions in the management of mesothelioma Biomarker-selected therapy- Progress or delusion.pdf
Open questions in the management of mesothelioma Discussion.mp4
Open questions in the management of mesothelioma Discussion.pdf
Open questions in the management of mesothelioma Introduction and scientific background.mp4
Open questions in the management of mesothelioma Introduction and scientific background.pdf
Open questions in the management of mesothelioma Preoperative or postoperative radiation for mesothelioma.mp4
Open questions in the management of mesothelioma Preoperative or postoperative radiation for mesothelioma.pdf
Open questions in the management of mesothelioma What is the optimal first-line treatment.mp4
Open questions in the management of mesothelioma What is the optimal first-line treatment.pdf
Open questions in the management of mesothelioma When and when not to operate.mp4
Open questions in the management of mesothelioma When and when not to operate.pdf
Opening session Closure of the Opening Ceremony.mp4
Opening session Closure of the Opening Ceremony.pdf
Opening session ESMO Award 2023.mp4
Opening session ESMO Award 2023.pdf
Opening session ESMO Award for Translational Research 2023.mp4
Opening session ESMO Award for Translational Research 2023.pdf
Opening session ESMO Lifetime Achievement Award 2023.mp4
Opening session ESMO Lifetime Achievement Award 2023.pdf
Opening session ESMO Women for Oncology Award 2023.mp4
Opening session ESMO Women for Oncology Award 2023.pdf
Opening session Presentation of the ESMO awards 2023.mp4
Opening session Presentation of the ESMO awards 2023.pdf
Opening session Scientific Chair address.mp4
Opening session Scientific Chair address.pdf
Opening session Welcome and Presidential address.mp4
Opening session Welcome and Presidential address.pdf
Opening session World Health Organisation (WHO).mp4
Opening session World Health Organisation (WHO).pdf
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Discussion.mp4
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 HER2+ breast cancer.mp4
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 HER2+ breast cancer.pdf
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Introduction.mp4
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Introduction.pdf
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Luminal-like breast cancer.mp4
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Luminal-like breast cancer.pdf
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Triple-negative breast cancer.mp4
Optimal treatment sequence in metastatic breast cancer (mBC) in 2023 Triple-negative breast cancer.pdf
Optimising overall survival in advanced renal cancer Data from sequencing trials and new therapeutic targets.mp4
Optimising overall survival in advanced renal cancer Data from sequencing trials and new therapeutic targets.pdf
Optimising overall survival in advanced renal cancer Discussion.mp4
Optimising overall survival in advanced renal cancer Discussion.pdf
Optimising overall survival in advanced renal cancer Evolving frontline treatment paradigms.mp4
Optimising overall survival in advanced renal cancer Evolving frontline treatment paradigms.pdf
Optimising overall survival in advanced renal cancer What is the role of localised therapies in metastatic RCC.mp4
Optimising overall survival in advanced renal cancer What is the role of localised therapies in metastatic RCC.pdf
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Case Condition presentation.mp4
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Case Condition presentation.pdf
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Discussion.mp4
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Discussion.pdf
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Endoscopic management of obstructive jaundice- What clinicians should know.mp4
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Endoscopic management of obstructive jaundice- What clinicians should know.pdf
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Malignant ascites.mp4
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Malignant ascites.pdf
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Nutrition and exercise.mp4
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Nutrition and exercise.pdf
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Pain management and palliative care.mp4
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Pain management and palliative care.pdf
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Radiotherapy.mp4
Pancreatic cancer- Evidence based options to improve quality of life and extend survival Radiotherapy.pdf
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Contra.mp4
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Contra.pdf
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all First voting.mp4
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all First voting.pdf
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Perspective from the Chair.mp4
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Perspective from the Chair.pdf
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Pro.mp4
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Pro.pdf
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Second voting.mp4
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Second voting.pdf
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Welcome and “set the scene”.mp4
PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor- One approach for all Welcome and “set the scene”.pdf
People at the centre of cancer care Advocating for cancer care in Armenia.mp4
People at the centre of cancer care Advocating for cancer care in Armenia.pdf
People at the centre of cancer care Discussion.mp4
People at the centre of cancer care Patient satisfaction during treatment and after care.mp4
People at the centre of cancer care Patient satisfaction during treatment and after care.pdf
People at the centre of cancer care People at the centre.mp4
People at the centre of cancer care People at the centre.pdf
People at the centre of cancer care Personalised treatment- Reflections on CAR-T therapy.mp4
People at the centre of cancer care Personalised treatment- Reflections on CAR-T therapy.pdf
Pregnancy after breast cancer- Is it safe First voting.mp4
Pregnancy after breast cancer- Is it safe First voting.pdf
Pregnancy after breast cancer- Is it safe No.mp4
Pregnancy after breast cancer- Is it safe No.pdf
Pregnancy after breast cancer- Is it safe Perspective from the Chair.mp4
Pregnancy after breast cancer- Is it safe Perspective from the Chair.pdf
Pregnancy after breast cancer- Is it safe Second voting.mp4
Pregnancy after breast cancer- Is it safe Second voting.pdf
Pregnancy after breast cancer- Is it safe Welcome and “set the scene”.mp4
Pregnancy after breast cancer- Is it safe Welcome and “set the scene”.pdf
Pregnancy after breast cancer- Is it safe Yes.mp4
Pregnancy after breast cancer- Is it safe Yes.pdf
Presidential 1 Invited Discussant LBA1 and LBA2.mp4
Presidential 1 Invited Discussant LBA1 and LBA2.pdf
Presidential 1 Invited Discussant LBA3.mp4
Presidential 1 Invited Discussant LBA3.pdf
Presidential 1 Invited Discussant LBA4 and LBA5.mp4
Presidential 1 Invited Discussant LBA4 and LBA5.pdf
Presidential 1 LBA1 – CheckMate 77T- Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy.mp4
Presidential 1 LBA1 – CheckMate 77T- Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy.pdf
Presidential 1 LBA2 – ALINA- Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+.mp4
Presidential 1 LBA2 – ALINA- Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+.pdf
Presidential 1 LBA3 – Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase.mp4
Presidential 1 LBA3 – Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase.pdf
Presidential 1 LBA4 – Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC.mp4
Presidential 1 LBA4 – Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC.pdf
Presidential 1 LBA5 – Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20.mp4
Presidential 1 LBA5 – Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20.pdf
Presidential 2 Invited Discussant LBA10.mp4
Presidential 2 Invited Discussant LBA10.pdf
Presidential 2 Invited Discussant LBA6 and LBA7.mp4
Presidential 2 Invited Discussant LBA6 and LBA7.pdf
Presidential 2 Invited Discussant LBA8 and LBA9.mp4
Presidential 2 Invited Discussant LBA8 and LBA9.pdf
Presidential 2 LBA10 – Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated.mp4
Presidential 2 LBA10 – Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated.pdf
Presidential 2 LBA6 – EV-302 KEYNOTE-A39- Open-label, randomized phase III study of enfortumab vedotin in combination.mp4
Presidential 2 LBA6 – EV-302 KEYNOTE-A39- Open-label, randomized phase III study of enfortumab vedotin in combination.pdf
Presidential 2 LBA7 – Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated.mp4
Presidential 2 LBA7 – Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated.pdf
Presidential 2 LBA8 – A randomised phase III trial of induction chemotherapy followed by chemoradiation compared.mp4
Presidential 2 LBA8 – A randomised phase III trial of induction chemotherapy followed by chemoradiation compared.pdf
Presidential 2 LBA9 – innovaTV 301 ENGOT-cx12 GOG-3057- A global, randomized, open-label, phase III study of tisotumab.mp4
Presidential 2 LBA9 – innovaTV 301 ENGOT-cx12 GOG-3057- A global, randomized, open-label, phase III study of tisotumab.pdf
Presidential 2 Q&A.mp4
Presidential 3 Invited Discussant LBA11 and LBA12.mp4
Presidential 3 Invited Discussant LBA11 and LBA12.pdf
Presidential 3 Invited Discussant LBA13.mp4
Presidential 3 Invited Discussant LBA13.pdf
Presidential 3 Invited Discussant LBA14 and LBA15.mp4
Presidential 3 Invited Discussant LBA14 and LBA15.pdf
Presidential 3 LBA11 – Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic.mp4
Presidential 3 LBA11 – Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic.pdf
Presidential 3 LBA12 – Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced metastatic.mp4
Presidential 3 LBA12 – Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced metastatic.pdf
Presidential 3 LBA13 – Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore).mp4
Presidential 3 LBA13 – Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore).pdf
Presidential 3 LBA14 – Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated.mp4
Presidential 3 LBA14 – Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated.pdf
Presidential 3 LBA15 – Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated.mp4
Presidential 3 LBA15 – Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated.pdf
Presidential 3 Q&A.mp4
Proffered Paper session – Breast cancer, early stage Invited Discussant LBA17, LBA18 and LBA19.mp4
Proffered Paper session – Breast cancer, early stage Invited Discussant LBA17, LBA18 and LBA19.pdf
Proffered Paper session – Breast cancer, early stage Invited Discussant LBA20 and LBA21.mp4
Proffered Paper session – Breast cancer, early stage Invited Discussant LBA20 and LBA21.pdf
Proffered Paper session – Breast cancer, early stage LBA17 – Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer.mp4
Proffered Paper session – Breast cancer, early stage LBA17 – Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer.pdf
Proffered Paper session – Breast cancer, early stage LBA18 – Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage.mp4
Proffered Paper session – Breast cancer, early stage LBA18 – Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage.pdf
Proffered Paper session – Breast cancer, early stage LBA19 – Event-free survival (EFS) analysis of neoadjuvant taxane carboplatin with or without.mp4
Proffered Paper session – Breast cancer, early stage LBA19 – Event-free survival (EFS) analysis of neoadjuvant taxane carboplatin with or without.pdf
Proffered Paper session – Breast cancer, early stage LBA20 – A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy.mp4
Proffered Paper session – Breast cancer, early stage LBA20 – A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy.pdf
Proffered Paper session – Breast cancer, early stage LBA21 – KEYNOTE-756- Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo).mp4
Proffered Paper session – Breast cancer, early stage LBA21 – KEYNOTE-756- Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo).pdf
Proffered Paper session – Breast cancer, early stage Q&A 1.mp4
Proffered Paper session – Breast cancer, early stage Q&A 1.pdf
Proffered Paper session – Breast cancer, early stage Q&A 2.mp4
Proffered Paper session – Breast cancer, metastatic 376O – Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2.mp4
Proffered Paper session – Breast cancer, metastatic 376O – Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2.pdf
Proffered Paper session – Breast cancer, metastatic 377O – A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+).mp4
Proffered Paper session – Breast cancer, metastatic 377O – A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+).pdf
Proffered Paper session – Breast cancer, metastatic 378O – Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC).mp4
Proffered Paper session – Breast cancer, metastatic 378O – Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC).pdf
Proffered Paper session – Breast cancer, metastatic 381O – First-in-human phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors.mp4
Proffered Paper session – Breast cancer, metastatic 381O – First-in-human phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors.pdf
Proffered Paper session – Breast cancer, metastatic Invited Discussant 377O and 378O.mp4
Proffered Paper session – Breast cancer, metastatic Invited Discussant 377O and 378O.pdf
Proffered Paper session – Breast cancer, metastatic Invited Discussant 381O and 376O.mp4
Proffered Paper session – Breast cancer, metastatic Invited Discussant 381O and 376O.pdf
Proffered Paper session – Breast cancer, metastatic Q&A 1.mp4
Proffered Paper session – Breast cancer, metastatic Q&A 2.mp4
Proffered Paper session – CNS tumours 499O – A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric.mp4
Proffered Paper session – CNS tumours 499O – A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric.pdf
Proffered Paper session – CNS tumours 500O – Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT).mp4
Proffered Paper session – CNS tumours 500O – Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT).pdf
Proffered Paper session – CNS tumours 501O – Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed.mp4
Proffered Paper session – CNS tumours 501O – Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed.pdf
Proffered Paper session – CNS tumours Invited Discussant 498O.mp4
Proffered Paper session – CNS tumours Invited Discussant 498O.pdf
Proffered Paper session – CNS tumours Invited Discussant 499O, 500O and 501O.mp4
Proffered Paper session – CNS tumours Invited Discussant 499O, 500O and 501O.pdf
Proffered Paper session – CNS tumours Q&A 1.mp4
Proffered Paper session – CNS tumours Q&A 2.mp4
Proffered Paper session – CNS tumours Q&A 2.pdf
Proffered Paper session – Developmental therapeutics 652O – Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON).mp4
Proffered Paper session – Developmental therapeutics 652O – Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON).pdf
Proffered Paper session – Developmental therapeutics 653O – Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS.mp4
Proffered Paper session – Developmental therapeutics 653O – Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS.pdf
Proffered Paper session – Developmental therapeutics 654O – Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring.mp4
Proffered Paper session – Developmental therapeutics 654O – Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring.pdf
Proffered Paper session – Developmental therapeutics 655O – Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7.mp4
Proffered Paper session – Developmental therapeutics 655O – Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7.pdf
Proffered Paper session – Developmental therapeutics Invited Discussant 652O, 653O and LBA33.mp4
Proffered Paper session – Developmental therapeutics Invited Discussant 652O, 653O and LBA33.pdf
Proffered Paper session – Developmental therapeutics Invited Discussant 654O and 655O.mp4
Proffered Paper session – Developmental therapeutics Invited Discussant 654O and 655O.pdf
Proffered Paper session – Developmental therapeutics LBA33 – A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid.mp4
Proffered Paper session – Developmental therapeutics LBA33 – A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid.pdf
Proffered Paper session – Developmental therapeutics Q&A 1.mp4
Proffered Paper session – Developmental therapeutics Q&A 2.mp4
Proffered Paper session – Genitourinary tumours, prostate 1764O – Timing of radiotherapy (RT) after radical prostatectomy (RP)- Final results of RADICALS RT randomised controlled trial.mp4
Proffered Paper session – Genitourinary tumours, prostate 1764O – Timing of radiotherapy (RT) after radical prostatectomy (RP)- Final results of RADICALS RT randomised controlled trial.pdf
Proffered Paper session – Genitourinary tumours, prostate 1765O – Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune.mp4
Proffered Paper session – Genitourinary tumours, prostate 1765O – Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune.pdf
Proffered Paper session – Genitourinary tumours, prostate 1770O – Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for.mp4
Proffered Paper session – Genitourinary tumours, prostate 1770O – Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for.pdf
Proffered Paper session – Genitourinary tumours, prostate Invited Discussant 1764O and 1765O.mp4
Proffered Paper session – Genitourinary tumours, prostate Invited Discussant 1764O and 1765O.pdf
Proffered Paper session – Genitourinary tumours, prostate Invited Discussant LBA84 and 1770O.mp4
Proffered Paper session – Genitourinary tumours, prostate Invited Discussant LBA84 and 1770O.pdf
Proffered Paper session – Genitourinary tumours, prostate LBA84 – Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer.mp4
Proffered Paper session – Genitourinary tumours, prostate LBA84 – Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer.pdf
Proffered Paper session – Genitourinary tumours, prostate Q&A 1.mp4
Proffered Paper session – Genitourinary tumours, prostate Q&A 1.pdf
Proffered Paper session – Genitourinary tumours, prostate Q&A 2.mp4
Proffered Paper session – Genitourinary tumours, prostate Q&A 2.pdf
Proffered paper session – Haematological malignancies 822O – Activation of ?9ë2 T cells by ICT01 as a novel immunotherapeutic approach for relapsed refractory.mp4
Proffered paper session – Haematological malignancies 822O – Activation of ?9ë2 T cells by ICT01 as a novel immunotherapeutic approach for relapsed refractory.pdf
Proffered paper session – Haematological malignancies 823O – Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell.mp4
Proffered paper session – Haematological malignancies 823O – Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell.pdf
Proffered paper session – Haematological malignancies 824O – Treatment and survival in patients with localized primary ocular adnexal MALT lymphoma- A large bicentric cohort study.mp4
Proffered paper session – Haematological malignancies 824O – Treatment and survival in patients with localized primary ocular adnexal MALT lymphoma- A large bicentric cohort study.pdf
Proffered paper session – Haematological malignancies 825O – Genomic traits of therapeutic response to anti-PD-1 therapy in peripheral T cell lymphoma.mp4
Proffered paper session – Haematological malignancies 825O – Genomic traits of therapeutic response to anti-PD-1 therapy in peripheral T cell lymphoma.pdf
Proffered paper session – Haematological malignancies 826O – A single-arm, multicenter clinical study of radiotherapy combined with toripalimab in stage I II.mp4
Proffered paper session – Haematological malignancies 826O – A single-arm, multicenter clinical study of radiotherapy combined with toripalimab in stage I II.pdf
Proffered paper session – Haematological malignancies Invited Discussant 822O and 823O.mp4
Proffered paper session – Haematological malignancies Invited Discussant 822O and 823O.pdf
Proffered paper session – Haematological malignancies Invited Discussant 824O, 825O and 824O.mp4
Proffered paper session – Haematological malignancies Invited Discussant 824O, 825O and 824O.pdf
Proffered paper session – Haematological malignancies Q&A 1.mp4
Proffered paper session – Haematological malignancies Q&A 2.mp4
Proffered Paper session – Head and neck cancer 853O – OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases.mp4
Proffered Paper session – Head and neck cancer 853O – OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases.pdf
Proffered Paper session – Head and neck cancer 854O – INTERLINK-1- Phase III study of cetuximab (CTX) ñ monalizumab (M) in participants (pts) with.mp4
Proffered Paper session – Head and neck cancer 854O – INTERLINK-1- Phase III study of cetuximab (CTX) ñ monalizumab (M) in participants (pts) with.pdf
Proffered Paper session – Head and neck cancer 857O – MACH-EGFR- Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab).mp4
Proffered Paper session – Head and neck cancer 857O – MACH-EGFR- Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab).pdf
Proffered Paper session – Head and neck cancer 858O – Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic circulating tumor DNA (ctDNA).mp4
Proffered Paper session – Head and neck cancer 858O – Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic circulating tumor DNA (ctDNA).pdf
Proffered Paper session – Head and neck cancer Invited Discussant 853O and 857O.mp4
Proffered Paper session – Head and neck cancer Invited Discussant 853O and 857O.pdf
Proffered Paper session – Head and neck cancer Invited Discussant 854MO.mp4
Proffered Paper session – Head and neck cancer Invited Discussant 854MO.pdf
Proffered Paper session – Head and neck cancer Invited Discussant 858O.mp4
Proffered Paper session – Head and neck cancer Invited Discussant 858O.pdf
Proffered Paper session – Head and neck cancer Q&A 1.mp4
Proffered Paper session – Head and neck cancer Q&A 2.mp4
Proffered Paper session – Head and neck cancer Q&A 3.mp4
Proffered Paper session – Investigational immunotherapy 1016O – Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC.mp4
Proffered Paper session – Investigational immunotherapy 1016O – Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC.pdf
Proffered Paper session – Investigational immunotherapy 1017O – NTC-001- A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen.mp4
Proffered Paper session – Investigational immunotherapy 1017O – NTC-001- A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen.pdf
Proffered Paper session – Investigational immunotherapy 1018O – Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer.mp4
Proffered Paper session – Investigational immunotherapy 1018O – Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer.pdf
Proffered Paper session – Investigational immunotherapy 1019O – Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR).mp4
Proffered Paper session – Investigational immunotherapy 1019O – Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR).pdf
Proffered Paper session – Investigational immunotherapy Invited Discussant 1016O.mp4
Proffered Paper session – Investigational immunotherapy Invited Discussant 1016O.pdf
Proffered Paper session – Investigational immunotherapy Invited Discussant 1017O, 1018O and 1019O.mp4
Proffered Paper session – Investigational immunotherapy Invited Discussant 1017O, 1018O and 1019O.pdf
Proffered Paper session – Investigational immunotherapy Q&A 1.mp4
Proffered Paper session – Investigational immunotherapy Q&A 2.mp4
Proffered Paper session – Melanoma and other skin tumours 1081O – ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination.mp4
Proffered Paper session – Melanoma and other skin tumours 1081O – ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination.pdf
Proffered Paper session – Melanoma and other skin tumours 1082O – Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts).mp4
Proffered Paper session – Melanoma and other skin tumours 1082O – Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts).pdf
Proffered Paper session – Melanoma and other skin tumours 1085O – Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM).mp4
Proffered Paper session – Melanoma and other skin tumours 1085O – Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM).pdf
Proffered Paper session – Melanoma and other skin tumours Invited Discussant 1082O and 1085O.mp4
Proffered Paper session – Melanoma and other skin tumours Invited Discussant 1082O and 1085O.pdf
Proffered Paper session – Melanoma and other skin tumours Invited Discussant LBA48, LBA49 and 1081O.mp4
Proffered Paper session – Melanoma and other skin tumours Invited Discussant LBA48, LBA49 and 1081O.pdf
Proffered Paper session – Melanoma and other skin tumours LBA48 – Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab.mp4
Proffered Paper session – Melanoma and other skin tumours LBA48 – Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab.pdf
Proffered Paper session – Melanoma and other skin tumours LBA49 – mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk.mp4
Proffered Paper session – Melanoma and other skin tumours LBA49 – mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk.pdf
Proffered Paper session – Melanoma and other skin tumours Q&A 1.mp4
Proffered Paper session – Melanoma and other skin tumours Q&A 2.mp4
Proffered Paper session – NETs and endocrine tumours 1182O – Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well.mp4
Proffered Paper session – NETs and endocrine tumours 1182O – Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well.pdf
Proffered Paper session – NETs and endocrine tumours 723O – Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system.mp4
Proffered Paper session – NETs and endocrine tumours 723O – Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system.pdf
Proffered Paper session – NETs and endocrine tumours 724O – EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic.mp4
Proffered Paper session – NETs and endocrine tumours 724O – EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic.pdf
Proffered Paper session – NETs and endocrine tumours Invited Discussant 723O and LBA53.mp4
Proffered Paper session – NETs and endocrine tumours Invited Discussant 723O and LBA53.pdf
Proffered Paper session – NETs and endocrine tumours Invited Discussant LBA54, 1182O and 724O.mp4
Proffered Paper session – NETs and endocrine tumours Invited Discussant LBA54, 1182O and 724O.pdf
Proffered Paper session – NETs and endocrine tumours LBA53 – Alliance A021602- Phase III, double-blinded study of cabozantinib versus placebo for advanced.mp4
Proffered Paper session – NETs and endocrine tumours LBA53 – Alliance A021602- Phase III, double-blinded study of cabozantinib versus placebo for advanced.pdf
Proffered Paper session – NETs and endocrine tumours LBA54 – Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according.mp4
Proffered Paper session – NETs and endocrine tumours LBA54 – Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according.pdf
Proffered Paper session – NETs and endocrine tumours Q&A 1.mp4
Proffered Paper session – NETs and endocrine tumours Q&A 2.mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies 1261O – Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial.mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies 1261O – Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial.pdf
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies 1291O – Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients.mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies 1291O – Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients.pdf
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant 1261O and LBA56.mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant 1261O and LBA56.pdf
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA60 and 1291O.mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA60 and 1291O.pdf
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA98 and LBA92.mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Invited Discussant LBA98 and LBA92.pdf
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA56 – Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small.mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA56 – Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small.pdf
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA60 – Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant.mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA60 – Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant.pdf
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA92 – Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC).mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA92 – Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC).pdf
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA98 – Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic.mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies LBA98 – Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic.pdf
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Q&A 1.mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Q&A 1.pdf
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Q&A 2.mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Q&A 2.pdf
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Q&A 3.mp4
Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies Q&A 3.pdf
Proffered Paper session – NSCLC, metastatic Invited Discussant LBA63 and LBA64.mp4
Proffered Paper session – NSCLC, metastatic Invited Discussant LBA63 and LBA64.pdf
Proffered Paper session – NSCLC, metastatic Invited Discussant LBA65, LBA66 and LBA67.mp4
Proffered Paper session – NSCLC, metastatic Invited Discussant LBA65, LBA66 and LBA67.pdf
Proffered Paper session – NSCLC, metastatic LBA63 – SAPPHIRE- Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously.mp4
Proffered Paper session – NSCLC, metastatic LBA63 – SAPPHIRE- Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously.pdf
Proffered Paper session – NSCLC, metastatic LBA64 – Overall survival from a phase II randomised double-blind trial (PERLA) of dostarlimab (dostar).mp4
Proffered Paper session – NSCLC, metastatic LBA64 – Overall survival from a phase II randomised double-blind trial (PERLA) of dostarlimab (dostar).pdf
Proffered Paper session – NSCLC, metastatic LBA65 – KRYSTAL-7- Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-na‹ve.mp4
Proffered Paper session – NSCLC, metastatic LBA65 – KRYSTAL-7- Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-na‹ve.pdf
Proffered Paper session – NSCLC, metastatic LBA66 – Afatinib versus chemotherapy for treatment-na‹ve non-small cell lung cancer with a sensitizing.mp4
Proffered Paper session – NSCLC, metastatic LBA66 – Afatinib versus chemotherapy for treatment-na‹ve non-small cell lung cancer with a sensitizing.pdf
Proffered Paper session – NSCLC, metastatic LBA67 – A phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with.mp4
Proffered Paper session – NSCLC, metastatic LBA67 – A phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with.pdf
Proffered Paper session – NSCLC, metastatic Q&A 1.mp4
Proffered Paper session – NSCLC, metastatic Q&A 2.mp4
Proffered Paper session – Sarcoma 1913O – A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with.mp4
Proffered Paper session – Sarcoma 1913O – A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with.pdf
Proffered Paper session – Sarcoma Invited Discussant 1913O.mp4
Proffered Paper session – Sarcoma Invited Discussant 1913O.pdf
Proffered Paper session – Sarcoma Invited Discussant LBA89.mp4
Proffered Paper session – Sarcoma Invited Discussant LBA89.pdf
Proffered Paper session – Sarcoma Invited Discussant LBA90 and LBA91.mp4
Proffered Paper session – Sarcoma Invited Discussant LBA90 and LBA91.pdf
Proffered Paper session – Sarcoma LBA89 – Efficacy and safety findings from MANTRA- A global, randomized, multicenter, phase III study of the.mp4
Proffered Paper session – Sarcoma LBA89 – Efficacy and safety findings from MANTRA- A global, randomized, multicenter, phase III study of the.pdf
Proffered Paper session – Sarcoma LBA90 – A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with.mp4
Proffered Paper session – Sarcoma LBA90 – A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with.pdf
Proffered Paper session – Sarcoma LBA91 – TOMAS2- A randomized phase II study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib.mp4
Proffered Paper session – Sarcoma LBA91 – TOMAS2- A randomized phase II study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib.pdf
Proffered Paper session – Sarcoma Q&A 1.mp4
Proffered Paper session – Sarcoma Q&A 2.mp4
Proffered Paper session – Sarcoma Q&A 3.mp4
Proffered Paper session – Supportive and palliative care 2030O – Remote symptom monitoring with electronic patient-reported outcomes (ePROs) during treatment for.mp4
Proffered Paper session – Supportive and palliative care 2030O – Remote symptom monitoring with electronic patient-reported outcomes (ePROs) during treatment for.pdf
Proffered Paper session – Supportive and palliative care 2031O – Randomized trial of a telephone-based weight loss intervention in overweight and obese patients (pts).mp4
Proffered Paper session – Supportive and palliative care 2031O – Randomized trial of a telephone-based weight loss intervention in overweight and obese patients (pts).pdf
Proffered Paper session – Supportive and palliative care Invited Discussant 2030O and 2031O.mp4
Proffered Paper session – Supportive and palliative care Invited Discussant LBA94 and LBA95.mp4
Proffered Paper session – Supportive and palliative care Invited Discussant LBA94 and LBA95.pdf
Proffered Paper session – Supportive and palliative care LBA94 – Effects of short-term fasting on quality of life as an add-on option during chemotherapy.mp4
Proffered Paper session – Supportive and palliative care LBA94 – Effects of short-term fasting on quality of life as an add-on option during chemotherapy.pdf
Proffered Paper session – Supportive and palliative care LBA95 – Anamorelin and weight gain in patients with advanced non-small cell lung cancer (NSCLC) and cachexia.mp4
Proffered Paper session – Supportive and palliative care LBA95 – Anamorelin and weight gain in patients with advanced non-small cell lung cancer (NSCLC) and cachexia.pdf
Proffered Paper session – Supportive and palliative care Q&A 1.mp4
Proffered Paper session – Supportive and palliative care Q&A 1.pdf
Proffered Paper session – Supportive and palliative care Q&A 2.mp4
Proffered Paper session – Supportive and palliative care Q&A 2.pdf
Proffered Paper session 1 – Basic Science and Translational research 1206O – Clinical subtyping of cancer from blood based on comprehensive epigenomic profiling.mp4
Proffered Paper session 1 – Basic Science and Translational research 1206O – Clinical subtyping of cancer from blood based on comprehensive epigenomic profiling.pdf
Proffered Paper session 1 – Basic Science and Translational research 1207O – Beyond 100,000 genomes project- Whole genome sequencing for cancer patients within NHS Genomic Medicine Service.mp4
Proffered Paper session 1 – Basic Science and Translational research 1207O – Beyond 100,000 genomes project- Whole genome sequencing for cancer patients within NHS Genomic Medicine Service.pdf
Proffered Paper session 1 – Basic Science and Translational research 2231O – Pan-cancer assessment of the impact of intronic variants on cancer development and progression.mp4
Proffered Paper session 1 – Basic Science and Translational research 2231O – Pan-cancer assessment of the impact of intronic variants on cancer development and progression.pdf
Proffered Paper session 1 – Basic Science and Translational research Invited Discussant 1207O and 2231O.mp4
Proffered Paper session 1 – Basic Science and Translational research Invited Discussant 1207O and 2231O.pdf
Proffered Paper session 1 – Basic Science and Translational research Invited Discussant LBA55, 1206O and LBA16.mp4
Proffered Paper session 1 – Basic Science and Translational research Invited Discussant LBA55, 1206O and LBA16.pdf
Proffered Paper session 1 – Basic Science and Translational research LBA16 – Primary analysis of efficacy and safety in the CUPISCO trial- A randomised, global study of targeted.mp4
Proffered Paper session 1 – Basic Science and Translational research LBA16 – Primary analysis of efficacy and safety in the CUPISCO trial- A randomised, global study of targeted.pdf
Proffered Paper session 1 – Basic Science and Translational research LBA55 – An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer.mp4
Proffered Paper session 1 – Basic Science and Translational research LBA55 – An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer.pdf
Proffered Paper session 1 – Basic Science and Translational research Q&A 1.mp4
Proffered Paper session 1 – Basic Science and Translational research Q&A 2.mp4
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive 549O – Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC).mp4
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive 549O – Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC).pdf
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive 550O – Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC).mp4
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive 550O – Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC).pdf
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive 551O – Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras).mp4
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive 551O – Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras).pdf
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive Invited Discussant 549O, 550O and 551O.mp4
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive Invited Discussant 549O, 550O and 551O.pdf
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive Invited Discussant LBA25 and LBA26.mp4
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive Invited Discussant LBA25 and LBA26.pdf
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive LBA25 – Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course.mp4
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive LBA25 – Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course.pdf
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive LBA26 – Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with.mp4
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive LBA26 – Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with.pdf
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive Q&A 1.mp4
Proffered Paper session 1 – Gastrointestinal tumours, lower digestive Q&A 2.mp4
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive 1511O – Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal.mp4
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive 1511O – Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal.pdf
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Invited Discussant 1511O.mp4
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Invited Discussant 1511O.pdf
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA74 and LBA73.mp4
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA74 and LBA73.pdf
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA75.mp4
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Invited Discussant LBA75.pdf
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive LBA73 – Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin.mp4
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive LBA73 – Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin.pdf
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive LBA74 – Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy.mp4
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive LBA74 – Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy.pdf
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive LBA75 – Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal.mp4
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive LBA75 – Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal.pdf
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Q&A 1.mp4
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Q&A 2.mp4
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive Q&A 3.mp4
Proffered Paper session 1 – Genitourinary tumours, non-prostate 2359O – Phase III THOR study- Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients.mp4
Proffered Paper session 1 – Genitourinary tumours, non-prostate 2359O – Phase III THOR study- Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients.pdf
Proffered Paper session 1 – Genitourinary tumours, non-prostate 2360O – The double antibody drug conjugate (DAD) phase I trial- Sacituzumab govitecan (SG) plus enfortumab.mp4
Proffered Paper session 1 – Genitourinary tumours, non-prostate 2360O – The double antibody drug conjugate (DAD) phase I trial- Sacituzumab govitecan (SG) plus enfortumab.pdf
Proffered Paper session 1 – Genitourinary tumours, non-prostate Invited Discussant 2359O and LBA102.mp4
Proffered Paper session 1 – Genitourinary tumours, non-prostate Invited Discussant 2359O and LBA102.pdf
Proffered Paper session 1 – Genitourinary tumours, non-prostate Invited Discussant 2360O and LBA103.mp4
Proffered Paper session 1 – Genitourinary tumours, non-prostate Invited Discussant 2360O and LBA103.pdf
Proffered Paper session 1 – Genitourinary tumours, non-prostate LBA102 – THOR-2 cohort 1- Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts).mp4
Proffered Paper session 1 – Genitourinary tumours, non-prostate LBA102 – THOR-2 cohort 1- Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts).pdf
Proffered Paper session 1 – Genitourinary tumours, non-prostate LBA103 – ICRA- Efficacy of paclitaxel with tremelimumab +- durvalumab in metastatic urothelial carcinoma after.mp4
Proffered Paper session 1 – Genitourinary tumours, non-prostate LBA103 – ICRA- Efficacy of paclitaxel with tremelimumab +- durvalumab in metastatic urothelial carcinoma after.pdf
Proffered Paper session 1 – Genitourinary tumours, non-prostate Q&A 1.mp4
Proffered Paper session 1 – Genitourinary tumours, non-prostate Q&A 2.mp4
Proffered Paper session 1 – Gynaecological cancers Invited Discussant LBA36 and LBA37.mp4
Proffered Paper session 1 – Gynaecological cancers Invited Discussant LBA36 and LBA37.pdf
Proffered Paper session 1 – Gynaecological cancers Invited Discussant LBA38.mp4
Proffered Paper session 1 – Gynaecological cancers Invited Discussant LBA38.pdf
Proffered Paper session 1 – Gynaecological cancers LBA36 – Efficacy and safety of senaparib as maintenance treatment in patients with newly.mp4
Proffered Paper session 1 – Gynaecological cancers LBA36 – Efficacy and safety of senaparib as maintenance treatment in patients with newly.pdf
Proffered Paper session 1 – Gynaecological cancers LBA37 – Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for.mp4
Proffered Paper session 1 – Gynaecological cancers LBA37 – Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for.pdf
Proffered Paper session 1 – Gynaecological cancers LBA38 – Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer.mp4
Proffered Paper session 1 – Gynaecological cancers LBA38 – Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer.pdf
Proffered Paper session 1 – Gynaecological cancers Q&A 1.mp4
Proffered Paper session 1 – Gynaecological cancers Q&A 1.pdf
Proffered Paper session 1 – Gynaecological cancers Q&A 2.mp4
Proffered Paper session 1 – Gynaecological cancers Q&A 2.pdf
Proffered Paper session 2 – Basic Science and Translational research 131O – A composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort.mp4
Proffered Paper session 2 – Basic Science and Translational research 131O – A composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort.pdf
Proffered Paper session 2 – Basic Science and Translational research 1O – CircIGF1R_0001 mediates platinum resistance in ovarian cancer that sensitive to PARP inhibitors via.mp4
Proffered Paper session 2 – Basic Science and Translational research 1O – CircIGF1R_0001 mediates platinum resistance in ovarian cancer that sensitive to PARP inhibitors via.pdf
Proffered Paper session 2 – Basic Science and Translational research 2232O – Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer.mp4
Proffered Paper session 2 – Basic Science and Translational research 2232O – Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer.pdf
Proffered Paper session 2 – Basic Science and Translational research 2O – PD-1 defines a distinct, functional, tissue-adapted state in V-delta-1+ T cells with implications for cancer immunotherapy.mp4
Proffered Paper session 2 – Basic Science and Translational research 2O – PD-1 defines a distinct, functional, tissue-adapted state in V-delta-1+ T cells with implications for cancer immunotherapy.pdf
Proffered Paper session 2 – Basic Science and Translational research 3O – IGSF8 is an innate immune checkpoint and cancer immunotherapy target.mp4
Proffered Paper session 2 – Basic Science and Translational research 3O – IGSF8 is an innate immune checkpoint and cancer immunotherapy target.pdf
Proffered Paper session 2 – Basic Science and Translational research Invited Discussant 131O and 1O.mp4
Proffered Paper session 2 – Basic Science and Translational research Invited Discussant 131O and 1O.pdf
Proffered Paper session 2 – Basic Science and Translational research Invited Discussant 2232O, 2O and 3O.mp4
Proffered Paper session 2 – Basic Science and Translational research Invited Discussant 2232O, 2O and 3O.pdf
Proffered Paper session 2 – Basic Science and Translational research Q&A 1.mp4
Proffered Paper session 2 – Basic Science and Translational research Q&A 2.mp4
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive 552O – FOxTROT- Results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant.mp4
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive 552O – FOxTROT- Results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant.pdf
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive 553O – Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III.mp4
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive 553O – Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III.pdf
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive Invited Discussant 552O and LBA27.mp4
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive Invited Discussant 552O and LBA27.pdf
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive Invited Discussant 553O, LBA28 and LBA29.mp4
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive Invited Discussant 553O, LBA28 and LBA29.pdf
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive LBA27 – First-line systemic treatment in patients with initially unresectable colorectal cancer liver.mp4
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive LBA27 – First-line systemic treatment in patients with initially unresectable colorectal cancer liver.pdf
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive LBA28 – The PEGASUS trial- Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.mp4
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive LBA28 – The PEGASUS trial- Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.pdf
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive LBA29 – Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT)- An international, phase III.mp4
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive LBA29 – Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT)- An international, phase III.pdf
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive Q&A 1.mp4
Proffered Paper session 2 – Gastrointestinal tumours, lower digestive Q&A 2.mp4
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive 1616O – Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or.mp4
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive 1616O – Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or.pdf
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive Invited Discussant 1616O and LBA83.mp4
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive Invited Discussant 1616O and LBA83.pdf
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive Invited Discussant LBA76 and LBA77.mp4
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive Invited Discussant LBA76 and LBA77.pdf
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive LBA76 – The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus.mp4
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive LBA76 – The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus.pdf
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive LBA77 – 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative.mp4
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive LBA77 – 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative.pdf
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive LBA83 – Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based.mp4
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive LBA83 – Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based.pdf
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive Q&A 1.mp4
Proffered Paper session 2 – Gastrointestinal tumours, upper digestive Q&A 2.mp4
Proffered Paper session 2 – Genitourinary tumours, non-prostate 1881O – Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC- Results of the.mp4
Proffered Paper session 2 – Genitourinary tumours, non-prostate 1881O – Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC- Results of the.pdf
Proffered Paper session 2 – Genitourinary tumours, non-prostate 1882O – RENOTORCH- Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced.mp4
Proffered Paper session 2 – Genitourinary tumours, non-prostate 1882O – RENOTORCH- Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced.pdf
Proffered Paper session 2 – Genitourinary tumours, non-prostate Invited Discussant 1882O.mp4
Proffered Paper session 2 – Genitourinary tumours, non-prostate Invited Discussant 1882O.pdf
Proffered Paper session 2 – Genitourinary tumours, non-prostate Invited Discussant LBA87, LBA88 and 1881O.mp4
Proffered Paper session 2 – Genitourinary tumours, non-prostate Invited Discussant LBA87, LBA88 and 1881O.pdf
Proffered Paper session 2 – Genitourinary tumours, non-prostate LBA87 – Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell.mp4
Proffered Paper session 2 – Genitourinary tumours, non-prostate LBA87 – Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell.pdf
Proffered Paper session 2 – Genitourinary tumours, non-prostate LBA88 – Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal.mp4
Proffered Paper session 2 – Genitourinary tumours, non-prostate LBA88 – Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal.pdf
Proffered Paper session 2 – Genitourinary tumours, non-prostate Q&A 1.mp4
Proffered Paper session 2 – Genitourinary tumours, non-prostate Q&A 2.mp4
Proffered Paper session 2 – Gynaecological cancers Invited Discussant LBA40.mp4
Proffered Paper session 2 – Gynaecological cancers Invited Discussant LBA40.pdf
Proffered Paper session 2 – Gynaecological cancers Invited Discussant LBA41 and LBA42.mp4
Proffered Paper session 2 – Gynaecological cancers Invited Discussant LBA41 and LBA42.pdf
Proffered Paper session 2 – Gynaecological cancers LBA40 – Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with.mp4
Proffered Paper session 2 – Gynaecological cancers LBA40 – Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with.pdf
Proffered Paper session 2 – Gynaecological cancers LBA41 – Durvalumab (durva) plus carboplatin paclitaxel (CP) followed by maintenance (mtx) durva ñ olaparib.mp4
Proffered Paper session 2 – Gynaecological cancers LBA41 – Durvalumab (durva) plus carboplatin paclitaxel (CP) followed by maintenance (mtx) durva ñ olaparib.pdf
Proffered Paper session 2 – Gynaecological cancers Q&A 1.mp4
Proffered Paper session 2 – Gynaecological cancers Q&A 2.mp4
Proffered paper session Policy and preventive strategies 1687O – PRIMCAT- A novel approach to informing health technology assessment decision making in Australia.mp4
Proffered paper session Policy and preventive strategies 1687O – PRIMCAT- A novel approach to informing health technology assessment decision making in Australia.pdf
Proffered paper session Policy and preventive strategies 1688O – Informative censoring of surrogate end-point data in FDA-approved cancer drugs.mp4
Proffered paper session Policy and preventive strategies 1688O – Informative censoring of surrogate end-point data in FDA-approved cancer drugs.pdf
Proffered paper session Policy and preventive strategies 1689O – Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in.mp4
Proffered paper session Policy and preventive strategies 1689O – Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in.pdf
Proffered paper session Policy and preventive strategies 1690O – Impact of the SARS-CoV-2 outbreak on the initial clinical presentation of new solid cancer.mp4
Proffered paper session Policy and preventive strategies 1690O – Impact of the SARS-CoV-2 outbreak on the initial clinical presentation of new solid cancer.pdf
Proffered paper session Policy and preventive strategies 1691O – Trends in new patient consultations during the COVID-19 pandemic at a comprehensive cancer centre.mp4
Proffered paper session Policy and preventive strategies 1691O – Trends in new patient consultations during the COVID-19 pandemic at a comprehensive cancer centre.pdf
Proffered paper session Policy and preventive strategies Invited Discussant 1687O, 1688O and 1689O.mp4
Proffered paper session Policy and preventive strategies Invited Discussant 1687O, 1688O and 1689O.pdf
Proffered paper session Policy and preventive strategies Invited Discussant 1690O and 1691O.mp4
Proffered paper session Policy and preventive strategies Invited Discussant 1690O and 1691O.pdf
Proffered paper session Policy and preventive strategies Q&A 1.mp4
Proffered paper session Policy and preventive strategies Q&A 2.mp4
Protein degrading cancer drugs- The promises of the new generation Bifunctional small molecules that mediate the degradation of extracellular proteins.mp4
Protein degrading cancer drugs- The promises of the new generation Bifunctional small molecules that mediate the degradation of extracellular proteins.pdf
Protein degrading cancer drugs- The promises of the new generation Conclusions and perspectives.mp4
Protein degrading cancer drugs- The promises of the new generation Degrading cancer targets on the cell surface (SureTACs).mp4
Protein degrading cancer drugs- The promises of the new generation Degrading oncogenic transcription factors.mp4
Protein degrading cancer drugs- The promises of the new generation Degrading oncogenic transcription factors.pdf
Protein degrading cancer drugs- The promises of the new generation Discussion.mp4
Protein degrading cancer drugs- The promises of the new generation Discussion.pdf
Protein degrading cancer drugs- The promises of the new generation Introduction and scientific background.mp4
Rectal cancer with oligometastatic disease Case condition presentation.mp4
Rectal cancer with oligometastatic disease Case condition presentation.pdf
Rectal cancer with oligometastatic disease Discussion.mp4
Rectal cancer with oligometastatic disease Discussion.pdf
Rectal cancer with oligometastatic disease How to perform an accurate staging.mp4
Rectal cancer with oligometastatic disease How to perform an accurate staging.pdf
Rectal cancer with oligometastatic disease Options for the choice of the systemic therapy.mp4
Rectal cancer with oligometastatic disease Options for the choice of the systemic therapy.pdf
Rectal cancer with oligometastatic disease Radiotherapy and timing.mp4
Rectal cancer with oligometastatic disease Radiotherapy and timing.pdf
Rectal cancer with oligometastatic disease Timing and modality of surgical intervention.mp4
Rectal cancer with oligometastatic disease Timing and modality of surgical intervention.pdf
Relieving complex suffering in women with advanced cervical cancer Discussion.mp4
Relieving complex suffering in women with advanced cervical cancer Discussion.pdf
Relieving complex suffering in women with advanced cervical cancer Nausea and vomiting in advanced cervical cancer.mp4
Relieving complex suffering in women with advanced cervical cancer Nausea and vomiting in advanced cervical cancer.pdf
Relieving complex suffering in women with advanced cervical cancer Presentation of case condition.mp4
Relieving complex suffering in women with advanced cervical cancer Presentation of case condition.pdf
Relieving complex suffering in women with advanced cervical cancer Refractory pain.mp4
Relieving complex suffering in women with advanced cervical cancer Refractory pain.pdf
Relieving complex suffering in women with advanced cervical cancer Ureteral and bowel obstruction, haemorrhage- A surgical perspective.mp4
Relieving complex suffering in women with advanced cervical cancer Ureteral and bowel obstruction, haemorrhage- A surgical perspective.pdf
Scientific Congress Highlights 1 Basic science & translational research.mp4
Scientific Congress Highlights 1 Basic science & translational research.pdf
Scientific Congress Highlights 1 Breast cancer, early stage.mp4
Scientific Congress Highlights 1 Breast cancer, early stage.pdf
Scientific Congress Highlights 1 Breast cancer, metastatic.mp4
Scientific Congress Highlights 1 Breast cancer, metastatic.pdf
Scientific Congress Highlights 1 CNS tumours.mp4
Scientific Congress Highlights 1 CNS tumours.pdf
Scientific Congress Highlights 1 Developmental therapeutics.mp4
Scientific Congress Highlights 1 Developmental therapeutics.pdf
Scientific Congress Highlights 1 GU non-prostate.mp4
Scientific Congress Highlights 1 GU non-prostate.pdf
Scientific Congress Highlights 1 GU prostate.mp4
Scientific Congress Highlights 1 GU prostate.pdf
Scientific Congress Highlights 1 Gynaecological cancers.mp4
Scientific Congress Highlights 1 Gynaecological cancers.pdf
Scientific Congress Highlights 1 Investigational immunotherapy.mp4
Scientific Congress Highlights 1 Investigational immunotherapy.pdf
Scientific Congress Highlights 1 Policy and preventive strategies.mp4
Scientific Congress Highlights 1 Policy and preventive strategies.pdf
Scientific Congress Highlights 2 GI, lower digestive.mp4
Scientific Congress Highlights 2 GI, lower digestive.pdf
Scientific Congress Highlights 2 GI, upper digestive- Gastroesophageal.mp4
Scientific Congress Highlights 2 GI, upper digestive- Gastroesophageal.pdf
Scientific Congress Highlights 2 GI, upper digestive- HPB.mp4
Scientific Congress Highlights 2 GI, upper digestive- HPB.pdf
Scientific Congress Highlights 2 Haematological malignancies.mp4
Scientific Congress Highlights 2 Haematological malignancies.pdf
Scientific Congress Highlights 2 Head and neck cancer.mp4
Scientific Congress Highlights 2 Head and neck cancer.pdf
Scientific Congress Highlights 2 Melanoma and other skin tumours.mp4
Scientific Congress Highlights 2 Melanoma and other skin tumours.pdf
Scientific Congress Highlights 2 NETs and endocrine tumours.mp4
Scientific Congress Highlights 2 NETs and endocrine tumours.pdf
Scientific Congress Highlights 2 Non-metastatic NSCLC and other thoracic malignancies.mp4
Scientific Congress Highlights 2 Non-metastatic NSCLC and other thoracic malignancies.pdf
Scientific Congress Highlights 2 NSCLC, metastatic.mp4
Scientific Congress Highlights 2 NSCLC, metastatic.pdf
Scientific Congress Highlights 2 Sarcoma.mp4
Scientific Congress Highlights 2 Sarcoma.pdf
Scientific Congress Highlights 2 Supportive and palliative care.mp4
Scientific Congress Highlights 2 Supportive and palliative care.pdf
Seagen – ADCs’ Potential Across Tumors ADC Technologies in Oncology.mp4
Seagen – ADCs’ Potential Across Tumors Advances in ADCs for Head and Neck Cancer.mp4
Seagen – ADCs’ Potential Across Tumors Closing Remarks.mp4
Seagen – ADCs’ Potential Across Tumors Emerging ADCs in Non-Small Cell Lung Cancer.mp4
Seagen – ADCs’ Potential Across Tumors Future Directions for ADCs in Urothelial Cancer.mp4
Seagen – ADCs’ Potential Across Tumors Panel Discussion and Audience Q&A.mp4
Seagen – ADCs’ Potential Across Tumors Welcome and Introduction.mp4
Seagen – Case by Case- Strategic Sequencing Considerations Charting the Course- Navigating the Landscape From Real-world Evidence to Future Studies.mp4
Seagen – Case by Case- Strategic Sequencing Considerations Closing Remarks.mp4
Seagen – Case by Case- Strategic Sequencing Considerations Decision-making in 3L Following T-DXd Progression (Case-based discussion).mp4
Seagen – Case by Case- Strategic Sequencing Considerations Decision-making in 3L Progression With CNS Involvement (Case-based discussion).mp4
Seagen – Case by Case- Strategic Sequencing Considerations Embracing Change- Uncovering Challenges and Opportunities in the Changing Treatment Landscape of HER2+ MBC.mp4
Seagen – Case by Case- Strategic Sequencing Considerations Q&A.mp4
Seagen – Case by Case- Strategic Sequencing Considerations Welcome and Introductions.mp4
Seagen – HER2-Targeted Therapies in mCRC Closing Remarks.mp4
Seagen – HER2-Targeted Therapies in mCRC Exploring New Opportunities to Improve Outcomes in Patients with HER2+ mCRC.mp4
Seagen – HER2-Targeted Therapies in mCRC HER2 as an Actionable Target in HER2+ mCRC.mp4
Seagen – HER2-Targeted Therapies in mCRC Panel Discussion and Interactive Q&A.mp4
Seagen – HER2-Targeted Therapies in mCRC The Role of HER2 Testing in mCRC.mp4
Seagen – HER2-Targeted Therapies in mCRC Welcome and Introduction.mp4
Servier – A journey through IDH1mutated Cholangiocarcinoma CCA diagnosis- current practice and challenges.mp4
Servier – A journey through IDH1mutated Cholangiocarcinoma Conclusion.mp4
Servier – A journey through IDH1mutated Cholangiocarcinoma Introducing a patient case with IDH1 mutated CCA.mp4
Servier – A journey through IDH1mutated Cholangiocarcinoma Introduction.mp4
Servier – A journey through IDH1mutated Cholangiocarcinoma Molecular profiling in CCA- where do we stand..mp4
Servier – A journey through IDH1mutated Cholangiocarcinoma Panel discussion Q&A.mp4
Servier – A journey through IDH1mutated Cholangiocarcinoma Treatment landscape in CCA and future perspectives.mp4
Servier – Are brain cancer patients finally able to Connecting the dots- Understanding recent clinical evidence in the framework of previous studies and current practice.mp4
Servier – Are brain cancer patients finally able to IDH Mutated Glioma- A Decade’s journey from bench to bedside.mp4
Servier – Are brain cancer patients finally able to Introduction- The Sword of Damocles hanging over each patient.mp4
Servier – Are brain cancer patients finally able to Navigating the paradigm shift- Thriving in the new era glioma care.mp4
Servier – Are brain cancer patients finally able to The evolving paradigm for clinical management of glioma.mp4
Servier – Shining the light on colorectal cancer- Advancing treatment strategies in mCRC Conclusion.mp4
Servier – Shining the light on colorectal cancer- Advancing treatment strategies in mCRC Introduction.mp4
Servier – Shining the light on colorectal cancer- Advancing treatment strategies in mCRC New approaches in treating patients with mCRC.mp4
Servier – Shining the light on colorectal cancer- Advancing treatment strategies in mCRC Patient cases in mCRC and panel discussion.mp4
Servier – Shining the light on colorectal cancer- Advancing treatment strategies in mCRC Redefining the meaning of later lines of therapy.mp4
Tertiary lymphoid structures- The control centre of immune responses against tumors Discussion led by Chair.mp4
Tertiary lymphoid structures- The control centre of immune responses against tumors Discussion led by Chair.pdf
Tertiary lymphoid structures- The control centre of immune responses against tumors Presentation by Expert.mp4
Tertiary lymphoid structures- The control centre of immune responses against tumors Presentation by Expert.pdf
The hallmarks of cancer in 2023 Introduction by the Chair.mp4
The hallmarks of cancer in 2023 Introduction by the Chair.pdf
The hallmarks of cancer in 2023 The hallmarks of cancer in 2023.mp4
The hallmarks of cancer in 2023 The hallmarks of cancer in 2023.pdf
The importance of secondary prevention Cancer screening, another ground of health equity.mp4
The importance of secondary prevention Cancer screening, another ground of health equity.pdf
The importance of secondary prevention Discussion.mp4
The importance of secondary prevention Discussion.pdf
The importance of secondary prevention Improving early diagnosis through screening programme guidelines- The case of lung cancer.mp4
The importance of secondary prevention Improving early diagnosis through screening programme guidelines- The case of lung cancer.pdf
The importance of secondary prevention The case of colon cancer.mp4
The importance of secondary prevention The case of colon cancer.pdf
The importance of secondary prevention The case of dental screening programmes.mp4
The importance of secondary prevention The case of dental screening programmes.pdf
The importance of secondary prevention The importance of harmonizing screening programmes across different levels of healthcare systems- Europe, national, regional.mp4
The importance of secondary prevention The importance of harmonizing screening programmes across different levels of healthcare systems- Europe, national, regional.pdf
The importance to address the caregivers needs Cancer patient groups and their help to support caregivers- Guide for healthcare professionals.mp4
The importance to address the caregivers needs Cancer patient groups and their help to support caregivers- Guide for healthcare professionals.pdf
The importance to address the caregivers needs Caregiver Carer Who are they.mp4
The importance to address the caregivers needs Caregiver Carer Who are they.pdf
The importance to address the caregivers needs Caregivers after patient end of life- The caregivers’ role continues.as do their needs!.mp4
The importance to address the caregivers needs Caregivers after patient end of life- The caregivers’ role continues.as do their needs!.pdf
The importance to address the caregivers needs Caregivers’ needs along the patient journey- What do nurses need to know..mp4
The importance to address the caregivers needs Caregivers’ needs along the patient journey- What do nurses need to know..pdf
The importance to address the caregivers needs Caregivers’ needs along the patient journey- What do oncologists need to know..mp4
The importance to address the caregivers needs Conclusion.mp4
The importance to address the caregivers needs Discussion.mp4
The importance to address the caregivers needs Discussion.pdf
The positive sentinel lymph node- What does it mean for treatment A medical oncologist’s perspective.mp4
The positive sentinel lymph node- What does it mean for treatment A medical oncologist’s perspective.pdf
The positive sentinel lymph node- What does it mean for treatment A radiation oncologist’s perspective.mp4
The positive sentinel lymph node- What does it mean for treatment A radiation oncologist’s perspective.pdf
The positive sentinel lymph node- What does it mean for treatment A surgeon’s perspective.mp4
The positive sentinel lymph node- What does it mean for treatment A surgeon’s perspective.pdf
The positive sentinel lymph node- What does it mean for treatment Discussion.mp4
The positive sentinel lymph node- What does it mean for treatment Discussion.pdf
Therapeutic view on tumour immune microenvironment- It’s TIME How tumour-draining lymph nodes inform the content of the TME and vice versa.mp4
Therapeutic view on tumour immune microenvironment- It’s TIME How tumour-draining lymph nodes inform the content of the TME and vice versa.pdf
Therapeutic view on tumour immune microenvironment- It’s TIME Immune suppressive cell populations in TME.mp4
Therapeutic view on tumour immune microenvironment- It’s TIME Immune suppressive cell populations in TME.pdf
Therapeutic view on tumour immune microenvironment- It’s TIME Modulating TME to overcome primary and acquired resistance.mp4
Therapeutic view on tumour immune microenvironment- It’s TIME Modulating TME to overcome primary and acquired resistance.pdf
Therapeutic view on tumour immune microenvironment- It’s TIME Q&A and Discussion.mp4
Therapeutic view on tumour immune microenvironment- It’s TIME Q&A and Discussion.pdf
Transnational cancer policies EBCP and implementation plans at the EU level.mp4
Transnational cancer policies EBCP and implementation plans at the EU level.pdf
Transnational cancer policies Q&A and Discussion.mp4
Transnational cancer policies Q&A and Discussion.pdf
Transnational cancer policies The joint development of policies through Joint Actions as policy projects, and the arising EU guide for National Cancer Control Programmes.mp4
Transnational cancer policies The joint development of policies through Joint Actions as policy projects, and the arising EU guide for National Cancer Control Programmes.pdf
Transnational cancer policies The Youth Cancer Europe’s perspective.mp4
Transnational cancer policies The Youth Cancer Europe’s perspective.pdf
Transnational cancer policies WHO IARC national cancer control plan tool and case studies.mp4
Transnational cancer policies WHO IARC national cancer control plan tool and case studies.pdf
Unravelling choices for adjuvant endocrine therapy Beyond chemo and endocrine therapy.mp4
Unravelling choices for adjuvant endocrine therapy Beyond chemo and endocrine therapy.pdf
Unravelling choices for adjuvant endocrine therapy ER positive breast cancer- What endocrine therapy is needed in menopausal patients.mp4
Unravelling choices for adjuvant endocrine therapy ER positive breast cancer- What endocrine therapy is needed in menopausal patients.pdf
Unravelling choices for adjuvant endocrine therapy Q&A and Discussion.mp4
Unravelling choices for adjuvant endocrine therapy Q&A and Discussion.pdf
Unravelling choices for adjuvant endocrine therapy Risk assessment stratification.mp4
Unravelling choices for adjuvant endocrine therapy Risk assessment stratification.pdf
Upper GI cancers- From bench to bedside Conclusions and perspectives.mp4
Upper GI cancers- From bench to bedside ctDNA- From theory to clinical translation.mp4
Upper GI cancers- From bench to bedside ctDNA- From theory to clinical translation.pdf
Upper GI cancers- From bench to bedside Discussion.mp4
Upper GI cancers- From bench to bedside Discussion.pdf
Upper GI cancers- From bench to bedside Evolving diagnostics in gastroesophageal cancer.mp4
Upper GI cancers- From bench to bedside Evolving diagnostics in gastroesophageal cancer.pdf
Upper GI cancers- From bench to bedside Heterogeneity, evolution, and outcomes in gastroesophageal cancer.mp4
Upper GI cancers- From bench to bedside Heterogeneity, evolution, and outcomes in gastroesophageal cancer.pdf
Upper GI cancers- From bench to bedside Introduction and scientific background.mp4
Upper GI cancers- From bench to bedside Introduction and scientific background.pdf
Upper GI cancers- From bench to bedside New directions in pancreas cancer.mp4
Upper GI cancers- From bench to bedside New directions in pancreas cancer.pdf
What is the optimal therapeutic approach following Discussion.mp4
What is the optimal therapeutic approach following Discussion.pdf
What is the optimal therapeutic approach following Novel treatment options for PARPi resistant ovarian cancer.mp4
What is the optimal therapeutic approach following Novel treatment options for PARPi resistant ovarian cancer.pdf
What is the optimal therapeutic approach following Presentation of case condition.mp4
What is the optimal therapeutic approach following Presentation of case condition.pdf
What is the optimal therapeutic approach following Systemic treatment options following progression on PARPi.mp4
What is the optimal therapeutic approach following Systemic treatment options following progression on PARPi.pdf
What is the optimal therapeutic approach following The role of surgery.mp4
What is the optimal therapeutic approach following The role of surgery.pdf
What is the optimal therapeutic approach following Understanding and overcoming resistance to PARP inhibitors- What is the way forward.mp4
What is the optimal therapeutic approach following Understanding and overcoming resistance to PARP inhibitors- What is the way forward.pdf
What’s the future in melanoma therapy Bispecific T-Cell engagers (TCE) and fusion protein carriers- Ready for prime-time in melanoma..mp4
What’s the future in melanoma therapy Bispecific T-Cell engagers (TCE) and fusion protein carriers- Ready for prime-time in melanoma..pdf
What’s the future in melanoma therapy Clinical data, NGS, (x)-omics et al.- What is the ideal mixture to identify and overcome primary resistance to immune-checkpoint inhibitors.mp4
What’s the future in melanoma therapy Clinical data, NGS, (x)-omics et al.- What is the ideal mixture to identify and overcome primary resistance to immune-checkpoint inhibitors.pdf
What’s the future in melanoma therapy Conclusions and perspectives.mp4
What’s the future in melanoma therapy Conclusions and perspectives.pdf
What’s the future in melanoma therapy Discussion.mp4
What’s the future in melanoma therapy Discussion.pdf
What’s the future in melanoma therapy Introduction and scientific background.mp4
What’s the future in melanoma therapy Introduction and scientific background.pdf
What’s the future in melanoma therapy Revisiting old friends New clinical developments of MEKi BRAFi NRASi combinations.mp4
What’s the future in melanoma therapy Revisiting old friends New clinical developments of MEKi BRAFi NRASi combinations.pdf
When and from where is tumour DNA sequencing needed for patients with metastatic breast cancer (mBC) Discussion led by Chair.mp4
When and from where is tumour DNA sequencing needed for patients with metastatic breast cancer (mBC) Discussion led by Chair.pdf
When and from where is tumour DNA sequencing needed for patients with metastatic breast cancer (mBC) Presentation by Expert.mp4
When and from where is tumour DNA sequencing needed for patients with metastatic breast cancer (mBC) Presentation by Expert.pdf
When can we cure patients with metastatic sarcoma Discussion led by Chair.mp4
When can we cure patients with metastatic sarcoma Introduction.mp4
When can we cure patients with metastatic sarcoma Introduction.pdf
When can we cure patients with metastatic sarcoma Presentation by Expert.mp4
When can we cure patients with metastatic sarcoma Presentation by Expert.pdf
When does targeted therapy outperform immunotherapy in patients with advanced melanoma Discussion led by Chair.mp4
When does targeted therapy outperform immunotherapy in patients with advanced melanoma Presentation by Expert.mp4
When does targeted therapy outperform immunotherapy in patients with advanced melanoma Presentation by Expert.pdf
When to stop systemic anticancer treatment in patients with advanced malignancy Discussion led by Chair.mp4
When to stop systemic anticancer treatment in patients with advanced malignancy Discussion led by Chair.pdf
When to stop systemic anticancer treatment in patients with advanced malignancy Presentation by Expert.mp4
When to stop systemic anticancer treatment in patients with advanced malignancy Presentation by Expert.pdf
Women for Oncology – How is the progress towards gender equity. 10 years of ESMO W4O advocating for the cause 10 years of ESMO W4O advocating for gender equity.mp4
Women for Oncology – How is the progress towards gender equity. 10 years of ESMO W4O advocating for the cause 10 years of ESMO W4O advocating for gender equity.pdf
Women for Oncology – How is the progress towards gender equity. 10 years of ESMO W4O advocating for the cause Live discussion, Q&A and wrap-up.mp4
Women for Oncology – How is the progress towards gender equity. 10 years of ESMO W4O advocating for the cause Welcome.mp4
Women for Oncology – How is the progress towards gender equity. 10 years of ESMO W4O advocating for the cause Welcome.pdf
YO Boxing session Discussion led by Chairs 1.mp4
YO Boxing session Discussion led by Chairs 1.pdf
YO Boxing session Discussion led by Chairs 2.mp4
YO Boxing session Discussion led by Chairs 2.pdf
YO Boxing session Do you need a basic science rotation for your career in oncology. No.mp4
YO Boxing session Do you need a basic science rotation for your career in oncology. No.pdf
YO Boxing session Do you need a basic science rotation for your career in oncology. Yes.mp4
YO Boxing session Do you need a basic science rotation for your career in oncology. Yes.pdf
YO Boxing session Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours – No.mp4
YO Boxing session Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours – No.pdf
YO Boxing session Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours – Yes.mp4
YO Boxing session Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours – Yes.pdf
YO Brunch 1- Caring for the LGBTQ+ cancer patient Discussion led by Chair.mp4
YO Brunch 1- Caring for the LGBTQ+ cancer patient Discussion led by Chair.pdf
YO Brunch 1- Caring for the LGBTQ+ cancer patient.mp4
YO Brunch 1- Caring for the LGBTQ+ cancer patient.pdf
YO Brunch 2- How to tell a compelling story in scientific articles and presentations Discussion led by Chair.mp4
YO Brunch 2- How to tell a compelling story in scientific articles and presentations Discussion led by Chair.pdf
YO Brunch 2- How to tell a compelling story in scientific articles and presentations.mp4
YO Brunch 2- How to tell a compelling story in scientific articles and presentations.pdf
YO Brunch 3- Establishing successful global research collaborations and network Discussion led by Chair.pdf
YO Brunch 3- Establishing successful global research collaborations and network.mp4
YO Brunch 3- Establishing successful global research collaborations and network.pdf
YO Clinical Case Discussion sessions Table 2- Integration of liquid biopsy in decision making in the management of patients with colon cancer.pdf
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Awards- Presentation of the 2023 Fellows and Best Exam.mp4
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Awards- Presentation of the 2023 Fellows and Best Exam.pdf
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Best Fellowship Project.mp4
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Best Fellowship Project.pdf
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Best Publication from a Fellowship.mp4
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Best Publication from a Fellowship.pdf
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Conclusions.mp4
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Conclusions.pdf
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Introduction to the ESMO Fellowship Programme.mp4
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Introduction to the ESMO Fellowship Programme.pdf
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Practical tips from a former fellow.mp4
YO Fellowship Session- Fellowships in Europe- Educational opportunities for young oncologists Practical tips from a former fellow.pdf
YO Forum- Preparing future-proof (young) oncologists Discussion.mp4
YO Forum- Preparing future-proof (young) oncologists Discussion.pdf
YO Forum- Preparing future-proof (young) oncologists Empowerment and resilience- A toolbox to foster your well-being and personal development.mp4
YO Forum- Preparing future-proof (young) oncologists Empowerment and resilience- A toolbox to foster your well-being and personal development.pdf
YO Forum- Preparing future-proof (young) oncologists How to put together a great CV and make a standout application.mp4
YO Forum- Preparing future-proof (young) oncologists How to put together a great CV and make a standout application.pdf
YO Forum- Preparing future-proof (young) oncologists How to write a successful research grant protocol.mp4
YO Forum- Preparing future-proof (young) oncologists How to write a successful research grant protocol.pdf
YO Forum- Preparing future-proof (young) oncologists The dos and don’ts of research project management.mp4
YO Forum- Preparing future-proof (young) oncologists The dos and don’ts of research project management.pdf
YO Masterclass- Tackling new challenges facing young investigators Bridging the gap between basic science and clinical research.mp4
YO Masterclass- Tackling new challenges facing young investigators Bridging the gap between basic science and clinical research.pdf
YO Masterclass- Tackling new challenges facing young investigators Discussion 1.mp4
YO Masterclass- Tackling new challenges facing young investigators Discussion 1.pdf
YO Masterclass- Tackling new challenges facing young investigators Discussion 2.mp4
YO Masterclass- Tackling new challenges facing young investigators Discussion 2.pdf
YO Masterclass- Tackling new challenges facing young investigators Discussion 3.mp4
YO Masterclass- Tackling new challenges facing young investigators Discussion 3.pdf
YO Masterclass- Tackling new challenges facing young investigators Discussion 4.mp4
YO Masterclass- Tackling new challenges facing young investigators Discussion 4.pdf
YO Masterclass- Tackling new challenges facing young investigators Interpreting clinical trial data- How to understand subgroup analyses.mp4
YO Masterclass- Tackling new challenges facing young investigators Interpreting clinical trial data- How to understand subgroup analyses.pdf
YO Masterclass- Tackling new challenges facing young investigators Investigator-initiated trials- From design to activation.mp4
YO Masterclass- Tackling new challenges facing young investigators Investigator-initiated trials- From design to activation.pdf
YO Masterclass- Tackling new challenges facing young investigators Preprints from medRxiv and bioRxiv- Should I trust them.mp4
YO Masterclass- Tackling new challenges facing young investigators Preprints from medRxiv and bioRxiv- Should I trust them.pdf